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CHAPTER 1: 
GENERAL INTRODUCTION  
8  
BREAST CANCER  
Breast cancer is as old as history itself, the first description of breast cancer was found on 
the Edwin Smith papyrus from 1600 BCE.(1) Before the 20th century it was considered an 
unspeakable disease. Mostly as a result of the hard work of female laymen advocates 
people and doctors became more aware of the disease and treatment options were 
developed.(1) Nowadays breast cancer patients are united in patient associations, there is a 
breast cancer awareness month, and major advances in treatments have been made.  
Breast cancer is a form of cancer that arises from breast tissue. Most breast cancers 
originate from glandular tissue (adenocarcinoma). All cancers start off as a single cell, as the 
cell divides and multiplies the new cells form a tumor. Initially the tumor is confined to a 
natural compartment; this is called an in situ carcinoma. In breast cancer these are mostly 
ductal carcinoma in situ (DCIS), or less commonly lobular carcinoma in situ (LCIS). As the 
tumor grows and develops, it may break through the basement membrane, then it is called 
invasive disease (Figure 1).(2) It is not certain if in situ carcinoma is an obligatory precursor 
of invasive cancer. With many diagnoses of breast cancer, only invasive disease is found, 
without evidence of in situ carcinoma. The size of the tumor and its relationship to 
surrounding tissues, possible lymph node involvement and distant metastases determine its 
stage.  
 
Figure 1. Different stages of breast cancer, in situ carcinoma and invasive carcinoma. 
Breast cancer is most commonly classified using the TNM classification (Table 1). T stands 
for tumor, N for lymph nodes, and M for metastases. Invasive cancer (T1 to T4) can spread 
via lymph nodes or via the bloodstream (hematogenic). Lymph node metastases manifest 
first in the first draining lymph node (sentinel node). If there are lymph node metastases, 
the disease is node positive. Hematogenic spread occurs in lungs, pleura, brain, skin, bones, 
liver, adrenals or peritoneum (metastatic disease). Disease with distant metastases is 
considered incurable.  
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Table 1. TNM classification in breast cancer.(3) 
Stage     
DCIS 
 
Ductal carcinoma in situ  
T1 
 
Tumor 2 cm or less in greatest dimension 
 
T1a 0,1 cm or more and less than 0,5 cm in greatest dimension 
 
T1b 0,5 cm or more and less than 1 cm in greatest dimension  
 
T1c 1 cm or more and less than 2 cm in greatest dimension  
T2 
 
2 cm or more and less than 5 cm in greatest dimension  
T3 
 
5 cm or more in greatest dimension  
T4 
 
Tumor of any size with direct extension to chest wall and/or to skin 
(ulceration or skin nodules) 
N0  No regional lymph node metastasis 
N1  Metastasis in movable ipsilateral level I, II axillary lymph node(s) 
N2 
 
Metastasis in ipsilateral level I,II axillary lymph node(s) that are clinically 
fixed, or in ipsilateral internal mammary lymph node(s) in the absence of 
axillary lymph node metastasis 
N3 
 
Metastasis in ipsilateral infraclavicular (level III axillary) lymph node(s) with 
or without level I, II axillary lymph node involvement or internal mammary 
lymph node involvement. 
M0  No distant metastasis 
M1  Distant metastasis 
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TREATMENT  
Treatment of DCIS usually consists of a local excision followed by radiation therapy. 
Complete mastectomy is considered for large tumors, or with multi-centricity of disease. 
Staging of axillary lymph nodes is only indicated if women are younger than 55, if the 
mammogram shows a mass, if the histopathology is suspect of invasive disease, or if 
histopathology shows an intermediate or poorly differentiated DCIS.(4)  
In the treatment of small invasive disease local excision is possible if a cosmetically 
acceptable result is expected and if proper loco-regional tumor control can be obtained. In 
all other cases treatment consists of mastectomy. Local excision is usually followed by 
radiation therapy. For small invasive disease, the axillary lymph nodes are evaluated. 
Dissemination does not need to be examined, unless per-operative findings or 
postoperative histopathology shows a higher disease stage.(4) Adjuvant systemic therapy is 
considered for all patients with positive lymph nodes and patients with unfavorable 
characteristics (young age, negative receptors, or large tumors). Neo-adjuvant systemic 
therapy (given before surgery) is considered for locally advanced disease.(4)  
SURVIVAL 
In recent decades in most developed countries the mortality rate of breast cancer has been 
declining, despite increasing incidence.(5) In the Netherlands 5-year survival has increased 
from 77% in cancers diagnosed between 1989 and 1993 to 87% in cancers diagnosed 
between 2008-2012.(5)  
The increased survival is probably a combined result of advancements in treatment and 
early detection. Trials studying the use of adjuvant chemotherapy were conducted since 
1995. A review in 2005 showed a reduction in breast cancer death by about 35% for first 
generation adjuvant chemotherapy regimens. Since then breast cancer mortality reduction 
has increased further with 20% for second generation regimens and again with 20% with 
third generation regimens.(6)  
Some of the improved survival may be attributable to the fact that more breast cancer will 
be detected at an earlier stage, the period of time between diagnosis and death becomes 
inevitably longer. Relative survival is expected to be better. However, also the absolute 
number of breast cancer deaths has reduced from 3,365 in 1989 to 3,014 in 2014.(5) 
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SCREENING TRIALS AND UK INDEPENDENT PANEL REVIEW 
In 1948 Jacob Gershon-Cohen demonstrated the feasibility of detecting occult carcinomas 
with X-ray. Fourteen years later a large study was conducted by Egan et al. in which two-
view mammograms were read and the readers were able to distinguish the benign 
conditions from the malignant conditions without clinical examination.(1) 
Between 1963 and 1991 the following randomized trials were conducted to evaluate 
mammography screening: New York Health Insurance Plan (HIP), Malmö I and II, Swedish 
two county trial (Kopparberg and Östergötland), Canada I and II, Stockholm, Göteborg, UK 
age trial, and Edinburgh. These trials compared women invited to screening to women not 
invited to screening. Most of the trials found that among the women invited for screening, 
fewer women died of breast cancer. Treatments as well as screening methods have 
improved since the trials. Therefore the effect of screening can be different nowadays.  
Because there has been a lot of debate on the benefits of screening, an independent 
research panel has been established in the UK in 2013 performing an extensive review of 
the evidence for benefits and harms of breast cancer screening. They found that for 10,000 
women invited to screening from age 50 for 20 years 43 breast cancer deaths will be 
averted.(7)  
More recently the International Agency for Research on Cancer assessed the cancer-
preventative and adverse effects of different screening methods. They found there is 
sufficient evidence that mammography screening reduces breast cancer mortality for 
women aged 50-74 years, and this reduction outweighs the risk of radiation-induced breast 
cancer. They also found sufficient evidence that mammography screening induces 
overdiagnosis.(8)  
EFFECT EVALUATION OTHER THAN TRIALS 
To evaluate the effect of screening, several case-control studies have been conducted. Case-
control studies compare the number of women who died of breast cancer to the number of 
women who did not die from breast cancer with regards to exposure to screening. Otto et al 
found that participating in breast cancer screening reduces the risk of dying of breast cancer 
with 49%.(9)  
Cohort studies examine the risk of breast cancer death in a cohort of women exposed to 
screening, compared to a cohort not exposed to screening. Cohorts can be historical, if the 
cohorts are defined by a difference in the time at which both cohorts were exposed to 
screening.(10) Cohorts can also be geographical, if a certain county or district has been 
exposed to screening, and the other (possibly neighboring) cohort has not been exposed to 
screening. (11) Kalager compared historical groups and found an overdiagnosis rate of 15-
25%.(10) Autier compared neighboring countries, that had implemented mass breast cancer 
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screening at a different time and suggested that screening did not play a direct part in the 
reductions in breast cancer mortality.(11) The difficulty with historical and geographical 
cohorts is the introduction of bias. Historical cohorts suffer from bias because treatments, 
screening strategies and overall survival change over time. Geographical cohorts suffer from 
bias because neighboring counties or countries can have differences in the accessibility of 
health care, or the use of opportunistic screening.  
SCREENING IN THE NETHERLANDS 
After a successful initial pilot mammography screening program in Utrecht and Nijmegen 
starting in 1974, screening was gradually implemented between 1989 and 1997.(12) Every 
woman aged 50-69 years old receives an invitation for screening every other year. The 
invitation is accompanied by an information flyer, which contains information on the harms 
and benefits of screening and emphasizes the voluntary nature of the program. In 1998 the 
program was extended to include women aged 70-74.  
All examinations are read by two radiologists. If there is a difference in assessment, the two 
readers can confer with one and other to reach consensus, or call in a third party for 
arbitration. The radiologists that reports the latest assessment, decides. 
The program made a transition from screening with film screen mammography to digital 
mammography between 2004 and 2009. Since 2009 all screening examinations are digital. 
Digital mammography screening has a higher recall rate, resulting in a higher detection rate, 
particularly for DCIS and small invasive carcinoma. The positive predictive value of a recall is 
lower for digital mammography. One major advantage of digital mammography screening is 
that it is easier to compare the images to previous screens, and that the work-flow on the 
computer is much easier than it was with old-fashioned mammograms, which had to be 
hanged on the lightbox before evaluation.  
Initially all women had a two-view examination (cranial caudal and mediolateral oblique) at 
first screening, and only a one-view mammogram (mediolateral oblique) at every 
subsequent screening, unless the technician saw a need to perform a second view. Reasons 
for performing a second view mammography included: an abnormality not seen on the 
previous examination, technical difficulties that might impair interpretation, or patients 
with specific symptoms. A study on two-view mammography in 2012 found that routine 
two-view mammography at subsequent screenings may modestly increase cancer detection 
at an earlier stage, with limited additional screening costs.(13) After 2010 all women 
routinely had a two-view mammography at all screening examinations.  
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BREAST CANCER INCIDENCE IN THE NETHERLANDS 
Breast cancer incidence in women aged 50-55 has risen steeply in the Netherlands since the 
introduction of population-based screening in 1990. This steep increase is the result of the 
first screening rounds when many prevalent breast cancers were detected. After the initial 
steep increase, the increase became much less steep (Figure 2a).(5) In women aged 70-75 
we see that breast cancer incidence peaks in 1999, immediately after the program was 
expanded in 1998. The breast cancer incidence in women aged 75-80 decreases after the 
expansion of the program, because most tumors detected at this age have now been 
diagnosed in the age group 70-75. DCIS incidence increased with the introduction of 
screening in women aged 50-55 in 1990, and with the expansion of the program in 1998 in 
women aged 70-75. DCIS incidence gradually increases in women of all ages and women 
aged 75-80 (Figure 2b).    
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A 
  
B 
 
Figure 2. A: Breast cancer incidence per 100,000 women in the Netherlands from 1989 (the 
last year before population-based screening was introduced) to 2014 (the most recent year 
with complete data) by age group. B: DCIS incidence per 100,000 women in the Netherlands 
from 1989 (the last year before population-based screening was introduced) to 2014 (the 
most recent year with complete data) by age group.  
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BREAST CANCER MORTALITY IN THE NETHERLANDS 
Breast cancer mortality in women over 50 has been declining since the early 1990’s (Figure 
3).(5) This is the result of both population-based screening and the introduction of adjuvant 
therapy; chemo therapy and hormonal therapy.(14)  
 
Figure 3. Breast cancer mortality per 100,000 women in the Netherlands from 1989 (the last 
year before population-based screening was introduced) to 2013 (the most recent year with 
complete data) by age group. 
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NORWAY 
The Norwegian Breast Cancer Screening Program (NBCSP) has been gradually introduced 
between 1996 and 2005. The NBCSP has been the topic of a fierce debate on the benefits 
and harms of a population-based screening program for breast cancer.(10, 15) For this 
reason, and because the program has been implemented a decade later than the Dutch 
program, we applied to participate in the recent evaluation of the NBCSP that was 
conducted by the Research council of Norway.(16)  
BREAST CANCER INCIDENCE IN NORWAY 
In Norway breast cancer incidence in women aged 50-54 has risen spectacularly since 1995 
(Figure 4).(17) This is remarkable, since population screening was gradually introduced in 
Norway between 1996 and 2005.(18) Breast cancer incidence in women aged 70-74 declines 
in 1999 because these women are no longer screened, and the tumors that would have 
been detected at this age, have been detected earlier by screening. 
 
Figure 4. Invasive breast cancer incidence in Norway per 100,000 women from 1989 to 
2013, by age group.  
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BREAST CANCER MORTALITY IN NORWAY 
Breast cancer mortality in Norway has been declining in women aged 55-80 from the early 
1990’s. (Figure 5).(17) This decline occurred prior to the introduction of population-based 
screening. This is probably the result of adjuvant therapy, greater awareness, and the use of 
(opportunistic) screening.  
 
Figure 5. Breast cancer mortality in Norway per 100,000 women from 1989 to 2013, by age 
group.  
SCREENING IN NORWAY 
In Norway, population-based screening was gradually introduced between 1996 and 
2005.(18) Compared to other Nordic European countries this is relatively late. Sweden 
started in 1986, Finland in 1987, and Denmark in 1991.(19) All women aged 50-70 years old 
are invited to mammography screening every other year. All women routinely have a two-
view mammogram. All examinations are read by two radiologists. The mammogram is taken 
in a mobile unit, or in a dedicated stationary unit.(16) Because Norway is a vast country with 
low population density, distances to a screening unit are larger than in the Netherlands, and 
travel costs contribute considerably to the cost of screening.(20)  
DISADVANTAGES OF SCREENING 
The aim of population-based screening for cancer is to reduce the cancer specific mortality. 
Screening prevents cancer specific mortality by detecting cancer early; at a stage the disease 
can still be cured. The disadvantage of early detection is that screening also detects disease 
that would never have become apparent if a woman was never exposed to screening. This is 
called overdiagnosis. (21) Overdiagnosis occurs when a woman dies of other causes than 
breast cancer prior to the time when the disease would have become manifest. This can be 
the result of an untimely death, or because the disease in itself has an indolent character. 
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DCIS, or small invasive cancer may grow very slowly, or DCIS may even never become 
invasive disease. Overdiagnosis is the major cause of harm in population-based screening. 
Because it is impossible to know on an individual level which diagnosed disease is 
overdiagnosis, all women with a diagnosis of breast cancer will be treated accordingly. Thus 
overdiagnosis leads to overtreatment. The treatment of an overdiagnosed disease cannot 
contribute to life years gained, since the patient will die of other causes, regardless of the 
breast cancer diagnosis.  
CALCULATION OF OVERDIAGNOSIS 
Breast cancer incidence in women of the screening age is higher than in women not 
exposed to screening. This is the result of early diagnosis. After women reach the upper age 
limit for screening, breast cancer incidence should drop, since cancers that would have 
occurred in women of this age, were already detected by screening earlier in life and were 
already treated. The higher incidence in women of the screening age is called excess 
incidence. The lower incidence in older women is called deficit.  
The easiest way to estimate overdiagnosis is to subtract the deficit incidence (after the 
upper age limit of screening has been reached) from the excess incidence (in women of the 
screening age). For a population this can be done by subtracting the incidence without 
screening in women of all ages from the incidence with screening in women of all ages 
(Figure 6).  
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Figure 6. Theoretical breast cancer incidence per 100,000 women in women of all ages 
without screening and with screening by age. Graphical depiction of the excess incidence 
and the deficit, these are the areas between the curves.  
With regards to the definition of overdiagnosis the UK Independent Review Panel proposed 
two definitions: 
1. from a population perspective: the number of excess diagnoses minus the number of 
deficit diagnoses divided by the total number of diagnoses in invited women of all ages. 
2. from an individual perspective: the number of excess diagnoses minus the number of 
deficit diagnoses divided by the total number of diagnoses in invited women of the 
screening age.  
They estimate that overdiagnosis rate for a population invited to screening is about 11%, 
and for an individual invited to screening is about 19%. These estimates are based on data 
from the trials performed in the 1980’s.  
We used the definitions of overdiagnosis put forward by the UK Independent Review Panel 
throughout the thesis to allow comparability.  
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METHODS TO ESTIMATE OVERDIAGNOSIS 
To calculate overdiagnosis we need an estimate of the cancer incidence in the absence of 
screening. Because population-based screening is now implemented in most countries, 
these data can no longer be observed. Women choosing not to participate in population-
based screening are not a reliable control group since their decision not to participate can 
be correlated with their breast cancer risk.(22)  
There are several methods to estimate incidence rate in the absence of screening. Some 
authors have used breast cancer incidence prior to the introduction of screening.(10, 15) 
Comparing this incidence to the current breast cancer incidence may introduce bias. The 
underlying background incidence of breast cancer may very well be different today than it 
was twenty or even ten years ago.  
Another method is to use a model. An age period cohort model studies a population and 
mathematically derives the individual effect of age of the patients, period of study, and 
birth-cohort.(23) The aim is to eradicate bias as a result of age, period or cohort. A 
microsimulation model such as the MIcro-simulation SCreening ANalysis (MISCAN) models 
the individual life histories of all women in a population.(24) 
MISCAN 
The Micro-simulation SCreening ANalysis (MISCAN) model generates life histories of all 
women in a fictional population. The model predicts the onset of cancer, the detection of 
cancer, and the time and cause of death. Cause of death can be breast cancer, or other 
causes. A screening scenario can be superimposed on these life histories and may alter the 
time of detection of cancer, and the cause and time of death. All of the parameters can be 
calculated in a situation with screening, and in a situation without screening. The model can 
be calibrated to mimic different populations and different screening strategies. 
Population composition is based on demographic data on population composition (number 
of women of a certain age). The microsimulation model calculates the complete life history 
for each individual woman in the model. Each woman is given a date of birth, a date of 
death, and a cause of death, based on national statistical data. The probability of having an 
onset of breast cancer is determined by the incidence of breast cancer in the population of 
interest, prior to the introduction of screening (i.e. in the Netherlands 1989). 
The progression of cancer is modelled using a semi-Markov process. After the onset of 
breast cancer a woman has preclinical pre-invasive disease. Preclinical pre-invasive disease 
can progress to preclinical invasive disease (progression from pre-invasive disease to 
invasive disease, not clinically manifest), clinical pre-invasive disease (if it becomes clinically 
manifest disease), or it may regress back to normal. The possibility of spontaneous 
regression has been shown in vitro, and there are case-reports on spontaneous 
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regression.(25, 26) In the situation with screening, preclinical disease can now become 
screen-detected (Figure 7).  
 
 
Figure 7. Progression of disease in the MISCAN model. DCIS: ductal carcinoma in situ.  
The time between transitions cannot directly be observed. These durations, in the diagram 
in the gray area, are estimated based on stage distribution in a situation with screening. 
The model is recalibrated regularly. Baseline onset is modelled on incidence rates prior to 
the introduction of screening. For the Dutch model an annual percentage change of 1.4% is 
modelled to account for increasing background incidence. In the Norwegian model an 
additional risk factor was introduced to account for the steep increase in breast cancer 
incidence. The sensitivity of the screening program is determined by the number of interval 
cancers within two years since the last screening examination. Stage specific breast cancer 
mortality and improvement of survival modeled using several international sources.(27, 28)  
The model can calculate every event and every interval, for example number of breast 
cancers detected, number of (breast cancer) deaths, and number of invitations and screens, 
and stage distribution, all by age and calendar year. All output can be generated for a 
situation with screening, and for a situation without screening for the same population. 
With this output we can calculate the number of breast cancer deaths prevented by 
screening, the life years gained, overdiagnosis, etc.  
With the output data we can calculate overdiagnosis is two ways. The model can directly 
provide output on women who have a screen-detected cancer which would never have 
been detected in the situation without screening, because her death would occur prior to 
the diagnosis of breast cancer in the situation without screening. Or we can calculate the 
number of breast cancer diagnoses in women of all ages in a situation without screening 
and subtract that from the number of breast cancer diagnoses in women of all ages in a 
situation with screening (Figure 6). 
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COST-EFFECTIVENESS ANALYSIS 
A cost-effectiveness analysis is performed to determine if a health intervention is cost-
effective. In a cost-effectiveness analysis the benefits of the intervention is compared to the 
costs of the intervention.(29) In the case of breast cancer screening the intervention is the 
screening program.  
Benefits are measured in life years gained after adjusting for loss in quality of life (QALYs). 
The benefits of breast cancer screening are avoided breast cancer deaths, resulting in life 
years gained. These life years gained however are not all lived in good health. Diagnosis and 
treatment bear down on the quality of life. Utilities are measures to quantify the loss of 
quality of life. Utilities have a quantity and duration (Table 2). If an intervention reduces the 
quality of life by 15% for the duration of one half year the utility for that year is 
0.5*0.85=0.43. Multiplying the life years gained by the utilities results in the QALYs gained.  
To determine what is cost-effective, several measures can be used. The NICE guideline from 
2013 advocates 20,000 GBP-30,000 GBP per QALY gained, which is 23,978 to 35,967 EUR 
(exchange rate July 14th 2016).(30) This threshold is gradually expanding. The World Health 
Organization uses a threshold of three times the gross domestic product (GDP) per capita to 
estimate cost-effectiveness.  
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Table 2. Durations and utilities for breast cancer screening and treatment, from Haes et 
al.(31)  
Health stage Duration  Utility 
      
Screening 0.0192 0.9940 
Diagnostic phase  0.0962 0.8950 
      
Initial surgery 0.1667 0.1330 
Initial radiotherapy 0.1667 0.1970 
Initial chemotherapy 0.5000 0.2830 
Initial hormonal therapy 2.0000 0.1800 
      
Disease free 2m-1y mastectomy 0.8333 0.1560 
Disease free 2m-1y breast conserving 0.8333 0.0860 
      
Disease free >1y mastectomy † 1.0000 0.0530 
Disease free >1y breast conserving † 1.0000 0.0400 
      
Terminal illness 0.0833 0.7120 
      
Palliative therapy + chemotherapy 0.3333 0.4690 
Palliative therapy + radiotherapy 0.0833 0.4190 
Palliative therapy + surgical therapy 0.0962 0.3830 
Palliative therapy + hormonal therapy 1.1667 0.3370 
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RESEARCH QUESTIONS AND OUTLINE OF THIS THESIS: 
The aim of the thesis is to evaluate overdiagnosis in breast cancer screening in well-
established national screening programs. To achieve this we addressed the following 
research questions: 
The detection of DCIS seems to be associated with a higher risk of overdiagnosis. What is 
the impact of the transition to digital mammography on the amount of DCIS diagnosed with 
screening (Chapter 2)? 
Overdiagnosis is a well debated issue in breast cancer screening, but not in screening for 
cervical cancer screening. Is there overdiagnosis in cervical cancer screening, and how does 
this relate to the overdiagnosis rate in breast cancer screening (Chapter 3)? 
What is the impact of DCIS on overdiagnosis estimates in breast cancer screening (Chapter 
4)? 
Is the Norwegian Breast Cancer Screening Program generating overdiagnosis, and at what 
level (Chapter 5)? 
Is the NBCSP effective in reducing breast cancer mortality despite the occurrence of 
overdiagnosis (Chapter 6)? 
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ABSTRACT  
PURPOSE: To critically evaluate and confirm previous results regarding the diagnostic 
accuracy of digital mammography screening (DM), compared to screen-film mammography 
(SFM) in the whole Dutch screening program, in the period 2004-2010, during which a full 
transition from SFM to DM was made. 
MATERIALS AND METHODS: 1.5 million DM and 4.6 million SFM were read in the 
Dutch national breast-cancer screening program in the period 2004-2010. We evaluated 
recall rate, detection rate, positive predictive value and tumor-size distribution for younger 
and older women, for first time participants and women having a timely subsequent screen. 
We compared DM screens read by radiologists reading DM and SFM (DM-group) to SFM 
screens read by these radiologists (SFM-group) and to SFM screens read by radiologists 
reading only SFM (SFMonly-group). 
RESULTS: Recall rate was 2.0 %(95% C.I.: 2.0; 2.1) in the DM-group, compared to 1.6% 
(95% C.I.: 1.6; 1.6) in the SFM-group and 1.6% (95% C.I.: 1.5; 1.6) in the SFMonly-group. The 
overall detection rates were 5.9/1,000 screens (95% C.I.: 5.7; 6.0) in the DM-group, 
5.1/1,000 screens (95% C.I.: 5.0; 5.2) in the SFM-group and 5.0/1,000 screens (95% C.I.: 5.0; 
5.1) in the SFMonly-group. Detection rate rose most markedly in younger women (age 49-
54) from 4.0 / 1,000 screens to 5.1 / 1,000 screens (p-value <0.001). PPV in DM rose from 
18.4% (95% C.I.: 14.6; 23.1) in 2004 to 32.5% (95% C.I.: 31.7; 33.2) in 2010. Detection rate 
rose in SFM-group from 5.0/ 1,000 screens (95% C.I.: 4.7; 5.3) in 2004 to 5.5/ 1,000 screens 
(95% C.I.: 5.2; 5.7) in2010. Detection rate in DM-group rose mostly due to DCIS detection 
especially in younger women/ first screens. The proportion of T1a tumors was significantly 
higher in DM-group; otherwise size distribution did not change significantly for invasive 
carcinoma. Recall rates were variable between different screening regions. 
CONCLUSION: In accordance to previous, smaller, studies, we can confirm that DM has a 
higher detection rate compared to SFM, at the cost of a higher recall rate and lower PPV. 
More DCIS and a higher fraction of very small tumors were detected with DM, which has 
positive consequences for the stage shift as a result of mass screening.  
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INTRODUCTION 
The independent UK Panel on Breast Cancer Screening recently published their review1. 
They state that in light of the current debate on breast cancer screening the benefits 
outweigh the harms. This panel based their decisions on data from screen-film 
mammography (SFM), some of which from decades ago. The consequences of a transition 
of the program to digital mammography (DM) were not yet fully elucidated. 
The Dutch screening program was implemented in 1990. All targeted women aged 50-75 
receive an invitation for screening mammography, free of charge, every other year. The 
attendance rate is approximately 80%. A feasibility study was carried out between 2003 and 
2007 to ascertain whether it was feasible to convert to digital mammography in the 
screening program2. Since June 2010 all mammography screening in the Netherlands is 
performed digitally. In the recent past five studies were performed in the Netherlands, 
based on data of the feasibility study or from a single region2-5. These studies all found a 
higher recall rate, higher detection rate and lower PPV. Decision making in service screening 
in Europe is based mainly on population based data. Sometimes in depth information can 
only be manually extracted because it is not readily available in national data. The 
disadvantage of this is a lack of power. Since we observe considerable regional differences 
we wondered how a very large, national data set would relate to national and international 
communications on differences between SFM and DM.  
All over Europe and elsewhere studies were conducted on the impact of a transition to 
digital mammography screening2-12. All studies found that the diagnostic precision of DM 
was at least similar to that of SFM, however some found a higher recall rate and lower 
positive predictive value (PPV)4-6, where others found a similar or higher PPV2,3,7-11. No clear 
cut results on invasive stages/ DCIS were published. The differences in published outcomes 
may be explained by sample size and study design. 
We retrospectively used the annual monitoring parameters in more than 1.5 million DM and 
4.6 million SFM to assess performance during the transition from SFM to DM. As our study 
covers all screening examinations performed within the nation-wide breast cancer screening 
program and therefore has a larger external validity, also it enables us to compare 
differences between regions. 
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MATERIALS AND METHODS  
CASE SELECTION 
All women aged 50 to 75 (corresponding with ages 49-74 at the beginning of a calendar 
year) receive a personal invitation biennially for mammography screening. By participating 
in the program, women automatically consent to the use of their data to evaluate and 
improve the program. Information about the use of data is provided in a flyer accompanying 
the invitation letter. If a woman does not want the screening organization to use her data 
for this purpose, she can return the signed corresponding form to the screening 
organization. Only a minor fraction (0.01%) used this possibility13.  
We retrospectively evaluated the aggregated data over the years 2004-2010 from the 
regional screening organizations, which is delivered to us annually for the purpose of 
monitoring the nation-wide program. We had information on age of the women invited and 
attending, screening round and screening results, whether the examinations were digital or 
screen-film, and if radiologists were reading DM (always in combination with SFM at some 
point in time), SFM (in this case in combination with DM at some point in time), or only SFM 
(a group that diminished to zero in 2010).  
In 2007 the roll out of digital screening was initiated nationwide, one screening unit at a 
time. Because several screening units are attached to one radiologists’ group (so-called 
reading unit), this gradual roll out resulted in reading units reading both DM and SFM at a 
given time.  
This gave us the opportunity to analyze our data by type of reading unit that evaluated the 
screens; 
1. DM read by a reading unit reading both SFM and DM, we will refer to this group as 
DM-group. 
2. SFM read by a reading unit reading both SFM and DM, we will refer to this group as 
SFM-group. 
3. SFM read by a reading unit reading only SFM, we will refer to this group as SFMonly-
group. 
We performed subgroup analyses on women attending their first screening examinations 
aged 49-51, on women attending subsequent screens performed within the appropriate 
screening interval of 2.5 years (we will refer to these as timely subsequent screens) aged 50-
74, on younger women aged 49-54, and on older women aged 55-74 for first and 
subsequent screens together. 
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Our main outcome measures were recall rate (the number of women recalled for clinical 
assessment, based on suspicion of malignancy and inconclusive results per 1,000 women 
screened), detection rate (the number of women diagnosed with breast cancer as a result of 
screening per 1,000 women screened), PPV (the percentage of recalled women diagnosed 
with breast cancer), and stage distribution of screen detected breast cancers (based on size 
and invasion).Because detection rate overall increased, stage distribution was expressed by 
the proportion of all detected tumors to indicate differences in stage shift, rather than 
increased detection.  
The data contained information on the reading unit (reading SFM, DM or both), on the 
number of women initially or subsequently screened, on the interval period between 
screens, and on the number of recalls and screen-detected breast cancers. From the 
6,370,556 screens performed between 2004 and 2010, we excluded women older than 74, 
because they represent very small numbers (n= 7,548), women who had their first screen at 
an age older than 51 years (n= 90,665), and women with a subsequent screen after a 
screening interval of more than 2.5 years (n= 264,761). The latter two groups were expected 
to have a higher detection rate, dependent on age-specific incidence and the average 
screening interval.13 After exclusion 6,007,582 screens were left for analysis.  
SCREENING RADIOLOGISTS 
A Dutch screening radiologist has to be certified for screening in the national service 
screening program. This can be achieved by participating in an eight days training in the 
National Training and Reference Center (NETC) in Nijmegen. The mean reading volume is 
13,000 screens per year with a range from 3,000 to 60,000. Increasing numbers of screening 
organisations are now routinely performing two view mammographies. In 2010 93% of all 
screens were performed with two view mammography. 
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DATA ANALYSIS 
We retrospectively analyzed the aggregated data for the DM and SFM screens for the 
following outcome measures: recall rate, detection rate, positive predictive value, and 
tumor size distribution of screen-detected carcinomas. Each screening examination is one 
event, regardless of the number of mammography views, lesions or malignancies.  
During the study period 2004-2010, we compared outcome measures and trends between 
the SFM-group, DM-group, and SFMonly-group and between first screens, timely 
subsequent screens, and first screens and timely subsequent screens together. Additionally 
we stratified results by age-group, 49-54 and 55-74.  
Because the detection of DCIS rose markedly we decided to analyse the proportion of 
disease stages in invasive breast cancer separately from the DCIS. The proportion of DCIS is 
of the total number of screen detected breast cancer, the proportions of T1a, T1b, T1c and 
T2+ are of the sum of all invasive cancers (explicitely not including DCIS).  
SPREAD OF OUTCOMES BY REGION 
We also looked at the spread of outcomes between different regions. During the study 
period, the Netherlands had nine different screening regions. They were allocated letters A 
through I. Each screening region contained a variable number of reading units. The results 
by region were divided in DM-group and SFM-group, for the SFMonly- group we did not 
have data per region, and by women aged 49-54 and women aged 55-74. 
STATISTICAL ANALYSIS 
All rates have been age-adjusted by direct standardization using the Dutch female 
population in 2000 as a reference population. We used linear regression to test for 
differences in proportions between DM and SFM and we stratified by age. P values less than 
0.05 were considered significant. All regression analyses were done using R. 
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RESULTS 
In total 6,007,582 screens were included for analysis. Of these 1,452,508 (24%) were DM, 
1,460,344 (24%) SFM in the SFM-group, and 3,094,730 (52%) SFM in the SFMonly-group 
(Table 1). There was no difference between the groups regarding age and the distribution of 
first and subsequent screens. In 2010 there were no more reading units reading only SFM.  
Table 1. Descriptive statistics. The percentage indicated in screening round is the percentage 
of all screens in that group, the percentage indicated in the number of screens is the 
percentage of a group of all screens in that year. Timely screen= a subsequent screen within 
2.5 years since the previous screen. DM= digital mammography, SFM= screen-film 
mammography. DM-group= DM-screens read by radiologists reading both SFM and DM, 
SFM-group= SFM-screens read by radiologists reading both SFM and DM, SFMonly-group= 
SFM screens read by radiologists reading only SFM. 
  DM SFM SFMonly 
  N= 1,452,508 N= 1,460,344 N= 3,094,730 
              
  μ μ μ 
Mean age 59.69 59.62 59.58 
              
  N % N % N % 
Screening round             
First screen 164,652 11 165,225 11 351,892 11 
Timely subsequent 
screen 1,287,856 89 1,295,119 89 2,742,838 89 
              
Number of screens             
2004 9,342 1 177,180 21 643,998 78 
2005 33,087 4 161,015 19 643,541 77 
2006 39,494 5 153,337 18 640,800 77 
2007 62,744 7 175,429 20 621,628 72 
2008 87,055 10 364,710 42 419,069 48 
2009 364,041 42 375,360 43 125,694 15 
2010 856,745 94 53,313 6 n.a. n.a. 
              
2004-2010 1,452,508 24 1,460,344 24 3,094,730 52 
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OVERALL 
With regard to the overall results of the three different groups of reading units, across the 
years the DM-group had a significantly higher recall rate of 2.0% (95% C.I. 2.0; 2.1) than 
both the SFM-group with 1.6% (95% C.I. 1.6; 1.6), and the SFMonly-group with 1.6% (95% 
C.I. 1.5; 1.6) (Table 2). This was also true for detection rate (5.9/1,000 screens in DM-group 
(95% C.I. 5.7; 6.0), vs. 5.1 (95% C.I 5.0; 5.2), and 5.0 (95% C.I. 4.9; 5.1) in SFM-group and 
SFMonly-group respectively). PPV was significantly lower in DM-group at 31.2% (95% C.I. 
30.6; 31.7) compared to 34.4% (95% C.I. 33.8; 35.0), and 34.2% (95% C.I. 33.7; 34.6) in SFM-
group and SFMonly-group respectively.  
TRENDS 
In the DM-group the recall rate dropped rapidly from 3.41,000% (95% C.I. 3.1; 3.8) in 2004 
to 2.01,000% (95% C.I. 2.0; 2.0) in 2010, and the detection rate dropped from 6.5/ 1,000 
screens (95% C.I. 5.1; 8.4) in 2004 to 5.9/ 1,000 screens (95% C.I. 5.7; 6.1) in 2010 after an 
initial increase in the pilot, stabilizing at a lower level (Figure 1a and 1b), the resulting PPV 
rose accordingly from 18.5% (95% C.I. 14.6; 23.1) in 2004 to 32.5% (95% C.I 31.7; 33.2)  in 
2010 and also stabilized, but at a higher level (Figure 1c). In the SFM-group recall rate and 
detection rate rose up to and including 2009 (recall rate went from 1.5 /1,000 (95% C.I.: 1.4; 
1.6) in 2004 to 1.7 /1,000 (95% C.I. : 1.7; 1.8), detection rate went from 5.0 /1,000 (95% C.I.: 
4.7; 5.3) to 5.5 (95% C.I.: 5.3; 5.8)), resulting in an overall unaltered PPV (35.1% (95% C.I.: 
33.9; 36.3) in 2009). In 2010, all three parameters dropped, probably as a result of smaller 
numbers of screening examinations (see Table 1). Finally, in the SFMonly-group recall rate 
increased, from 1.3% (95% C.I. 1.3; 1.3) in 2004 to 1.8% (95% C.I. 1.8; 1.9) in 2009, but 
detection rate did not improve, thus PPV decreased over time (from 37.9% (95% C.I.: 36.8; 
38.9) in 2004 to 29.4% (95% C.I.: 27.6; 31.4) in 2009).  
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Figure 1. Recall rate per 1,000 screens (1a), detection rate per 1,000 screens (1b) and 
positive predictive value at screening (PPV, %) (1c), development over time. DM= digital 
mammography, SFM= screen-film mammography. DM-group= DM-screens read by 
radiologists reading both SFM and DM, SFM-group= SFM-screens read by radiologists 
reading both SFM and DM, SFMonly-group= SFM screens read by radiologists reading only 
FSM.  
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SUBGROUP ANALYSIS BY AGE AND BY SCREENING ROUND 
We stratified the analysis by age (younger women, 49-54 years, and older women, 55-74 
years), and by screening round (first screens in women aged 49-51 years, and timely 
subsequent screens in all ages).  
RECALL RATE 
In all subgroup analyses recall rate was significantly higher in the DM-group than in the 
other groups, with the exception of timely subsequent screens (Table 2). The biggest 
difference (p-value <0.001) was found in first screens with a recall rate for DM-group of 
4.6%  compared to 3.3%  in SFM-group and 3.2% in SFMonly-group (Table 2).  
DETECTION RATE 
Detection rate was significantly higher (p-value< 0.001) for DM-group in all subgroup 
analyzes (Table 2). This was the most pronounced in younger women (5.1/1,000 vs. 
4.0/1,000 in SFM-group and 4.1/1,000 in SFMonly-group), and in first screens (7.0/1,000 in 
DM-group vs. 5.5/1,000 in SFM-group and 5.6/1,000 in SFMonly-group).  
PPV 
PPV was significantly lower in DM-group than in the other groups in all subgroup analyzes, 
except in younger women (Table 2). This difference (p-value < 0.001) was largest in older 
women (35.7% in DM-group, vs. 40.1% in SFM-group, and 39.4% in SFMonly-group), and in 
subsequent screens (p-value < 0.001) (30.6% in DM-group, vs. 33.5% in SFM-group, and 
33.4% in SFMonly-group). 
 
 
 
  
Table 2. Overall results and results by subgroup: women aged 49-54, women aged 55-74, first screens and timely subsequent screens. P-values 
less than 0.05 are considered significant and indicated in bold. DM= digital mammography screen, SFM= screen-film mammography screen, 
DM-group= DM-screens read by radiologists reading both SFM and DM, SFM-group= SFM-screens read by radiologists reading both SFM and 
DM, SFMonly-group= SFM screens read by radiologists reading only SFM. PPV= positive predictive value. 
    Screens Recalls 
Recall rate 
(%) 
P-
value Cancers 
Detection 
rate/ 1,000 
screens 
P-
value PPV 
P-
value 
                    
                      
Overall DM-group 1,452,508 29,363 2.0   8,474 5.9   31.2%   
  SFM-group 1,460,344 22,799 1.6 <0.001 7,382 5.1 <0.001 34.4% <0.001 
  SFMonly-group 3,094,730 47,683 1.6 <0.001 15,407 5.0 <0.001 34.2% <0.001 
49-54 years (first 
screens 49-51 years, 
timely subsequent 
screens 50-74 years) 
DM-group 429,692 11,973 2.7   2,247 5.1   21.4%   
SFM-group 434,064 8,882 2.0 <0.001 1,773 4.0 <0.001 22.1% 0.23 
  SFMonly-group 932,129 18,369 1.9 <0.001 3,835 4.1 <0.001 23.0% <0.001 
55-74 years (timely 
subsequent screens) DM-group 1,022,816 17,390 1.7   6,227 6.2   35.7%   
  SFM-group 1,026,280 13,917 1.4 <0.001 5,609 5.6 <0.001 40.1% <0.001 
  SFMonly-group 2,162,601 29,314 1.4 <0.001 11,572 5.5 <0.001 39.4% <0.001 
First screen (49-51 
years) DM-group 164,652 7,422 4.6   1,103 7.0   15.2%   
  SFM-group 165,225 5,359 3.3 <0.001 880 5.5 <0.001 16.5% 0.05 
  SFMonly-group 351,892 10,773 3.2 <0.001 1,862 5.6 <0.001 17.6% <0.001 
Timely subsequent 
screen (50-74 years) DM-group 1,287,856 21,941 1.6   7,371 5.3   30.6%   
  SFM-group 1,295,119 17,440 1.3 <0.001 6,502 4.6 <0.001 33.5% <0.001 
  SFMonly-group 2,742,838 36,910 1.7 <0.001 13,545 4.6 <0.001 33.4% <0.001 
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STAGE DISTRIBUTION 
In both subgroup analyses significantly more DCIS (p-value < 0.001) were detected in DM-
group (Figure 2): in first screens 24.5% vs. 19.7% in SFM-group, and 18.2% in SFMonly-
group21.5% in DM-group vs. 15.6% in SFM-group, and 14.8% in SFMonly-group; in younger 
women 25.9% in DM-group vs. 19.5% in SFM-group and 19.1% in SFMonly-group; and in 
older women 19.3% in DM-group vs. 14.5% in SFM-group, and 13.2% in SFMonly-group.  
 
Figure 2. Proportion of DCIS (%, with 95% confidence interval) of all screen-detected cancers 
by subgroup for younger and older women and first and timely subsequent screen. DM= 
digital mammography screen, SFM= screen-film mammography screen, DM-group= DM-
screens read by radiologists reading both SFM and DM, SFM-group= SFM-screens read by 
radiologists reading both SFM and DM, SFMonly-group= SFM screens read by radiologists 
reading only SFM. 
The analysis of the invasive cancers was done separately from DCIS, to avoid the large 
increase in DCIS to affect the proportions of invasive carcinomas. T1a was found significantly 
more frequently in DM-group in both age-groups (7.2% of invasive tumors in younger 
women vs. 5.3% in SFM-group (p-value= 0.02), and 5.6% in SFMonly-group (p-value= 0.04), 
and 6.9% in older women vs. 4.7% in SFM-group (p-value < 0.001), and 5.0% in SFMonly-
group(p-value < 0.001)), as well as in subsequent screens (4.4% in DM, vs 6.9% in SFM and 
5.7% in SFMonly, p-value < 0.001) (Table 3). 
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Table 3. Tumor size distribution of invasive tumors by subgroup, including unclassified tumors (not shown). P-values less than 0.05 are 
considered significant. N= number of cases, %= age adjusted proportion of that size of all detected breast cancers (without the tumors with 
unknown stage and size), 95% C.I.= 95% confidence interval, DM= digital mammography, SFM= screen-film mammography. DM-group= DM-
screens read by radiologists reading both SFM and DM, SFM-group= SFM-screens read by radiologists reading both SFM and DM, SFMonly-
group= SFM screens read by radiologists reading only SFM.  T1a= tumor with a diameter up to 0.5 cm, T1b= tumor with a diameter from 0.6 cm  
up to 1.0 cm, T1c= tumor with a diameter from 1.1 cm  up to 2.0 cm, T2+= any tumor with a diameter larger than 2.0 cm. 
  Women aged 49-54 Women aged 55-74  First screen Timely subsequent 
screen 
  N % P-value N % P-value  N % P-
value 
N % P-value 
T1a DM-group 120 7.2%  346 6.9%   60 7.1%  406 4.4%  
 SFM-group 74 5.3% 0.02 224 4.7% <0.001  36 4.1% 0.0126 262 6.9% <0.001 
 SFMonly-
group 
174 5.6% 0.04 506 5.0% <0.001  81 6.4% 0.5184 599 5.7% <0.001 
T1b DM-group 302 17.9%  1,272 25.0%   133 16.0%  1,441 21.9%  
 SFM-group 286 20.2% 0.08 1,109 22.8% 0.014  129 18.4% 0.215 1,266 22.6% 0.38 
 SFMonly-
group 
582 18.7% 0.56 2,278 22.4% <0.001  269 17.7% 0.3 2,591 19.8% <0.001 
T1c DM-group 827 50.0%  2,417 47.8%   393 48.0%  2,851 46.8%  
 SFM-group 708 50.0% 0.87 2,441 50.8% 0.004  342 48.1% 0.97 2,807 47.1% 0.67 
 SFMonly-
group 
1,526 49.4% 0.6 5,263 52.2% <0.001  727 47.4% 0.78 6,062 49.6% <0.001 
T2+ DM-group 362 21.8%  866 17.5%   191 25.2%  1,037 16.8%  
 SFM-group 308 21.3% 0.64 916 19.0% 0.04  171 23.5% 0.44 1,053 17.9% 0.13 
 SFMonly-
group 
703 22.6% 0.53 1,829 18.4% 0.23  364 23.8% 0.45 2,168 18.0% 0.04 
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In older women, DM detected significantly more T1b tumors (25.0%) than both the SFM-
group (22.8%, p-value < 0.014) and SFMonly-group (22.4% p-value < 0.001).  
In younger women, and by stratifying by screening round, no significant differences in the 
proportion of T1b, T1c and T2+ were found.  
As a consequence significantly less T1c and T2+ tumors were found in DM-group in older 
women: 47.8% T1c tumors in DM-groupvs. in SFM-group (50.8%, p-value = 0.004), and   
SFMonly-group (52.2%, p-value < 0.001), and 17.5% T2+ vs. 19.0% in SFM-group (p-value = 
0.04). In the timely subsequent screens the difference in proportion of T2+ tumors was 
significantly lower for DM, 16.8% in DM-group, vs. 18.0% in SFMonly-group (p-value = 0.04). 
The number of screen detected breast cancers with a positive node status did not differ 
significantly between the groups (data not shown).  
VARIATION BETWEEN REGIONS 
We evaluated the results by screening region, the largest spread is found in recall rate, with 
less variation in detection rate, resulting in varying PPV (Table 4). The spread is given in 
overall numbers for the entire study period. When looking at the range of variation over the 
years of the study period we did not find evidence for convergence (data not shown).  
Table 4. Point estimates and range of variation in regions in recall rate, detection rate and 
PPV between regions.  DM= digital mammography, SFM= screen-film mammography. DM-
group= DM-screens read by radiologists reading both SFM and DM, SFM-group= SFM-
screens read by radiologists reading both SFM and DM. PPV= positive predictive value. 
  
DM-group 
  
FSM-group 
  
  National 
Range of 
variation National 
Range of 
variation 
Women aged 49-54         
          
Recall rate (%) 2.7 1.7-3.3 2.0 1.3-3.0 
Detection rate (%) 5.1 4.4-6.2 4.0 3.4-4.8 
PPV (%) 21.4 16.8-29.9 22.1 15.0-30.8 
          
Women aged 55-74         
          
Recall rate (%) 1.7 1.2-2.0 1.4 1.1-1.6 
Detection rate (%) 6.2 5.5-6.7 5.6 5.0-6.4 
PPV (%) 35.7 30.5-47.5 40.1 30.8-54.0 
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DISCUSSION 
In this study, we were able to confirm the higher detection rate for DM at the cost of a 
higher recall rate, and a slightly lower positive predictive value of recall. But most 
importantly we found a significant difference in the detection of DCIS and T1a tumors.   
After an initial increase, the recall rate declined in the years following first introduction of 
DM. This is in line with the objective of the Netherlands Expert and Training Centre for 
Breast cancer screening (NETCB), advising to aim for an overall recall rate of approximately 
20 per 1,000 screens. The NETCB offered one day specialist training courses for the reading 
radiologists on reading DM to obtain this objective.  
The recall rate in the Dutch program has stabilized at 20/1,000 screens. In an international 
perspective, this is still relatively low14. Incidence rates of invasive breast cancer in the 
Netherlands (both screen detected and clinically detected) remained stable throughout the 
study period (270-400/100,000 women, dependent on age), incidence rates of DCIS 
increased steadily with the expansion of DM within the country (from 40-45/100,000 
women to 55-68/100,000 women, dependent on age)15.  
When we place the recall rate in the perspective of long term performance data of the 
Dutch program we see that there has been a pre-existing trend towards higher recall rates 
since the second half of the 1990s. This trend does not appear to be strongly affected by the 
introduction of digital screening13. We confirmed the results of the earlier studies with 
regards to recall rate, detection rate and PPV2,3,5,7. We did not have the data to determine 
the grade of DCIS detected with DM. However we found a significantly higher detection rate 
of small invasive tumors7.   
In the perspective of the European literature on the subject, with 152,515 DM being the 
largest reported study, we can confirm previous results with regard to diagnostic precision. 
We found that PPV is slightly lower in DM, but steadily increases over time. This must be 
due to a learning curve with better understanding of the findings on DM. Compared to 
different countries the recall rate is relatively low in the Netherlands, with a high PPV (Table 
5)6,8-11,16-18.  
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Table 5. Summary of some European research on performance of digital mammography, 
compared to screen-film mammography. SFM= the number of film screen examinations 
analyzed, DM= the number of digital screen examinations analyzed. RR=recall rate, DR= 
detection rate, PPV= positive predictive value, FP= false positive rate. 
Author Reference Year Country Study Population 
RR 
(%) 
DR 
(%) 
PPV 
(%) 
FP 
(%) 
Ongeval 16 2010 Belgium DM 11,355 2.1 0.59 34.9   
SFM 23,325 1.58 0.64 30.76   
Domingo 12 2011 Spain DM 71,647 6.1 0.43 7.0   
SFM 171,191 8.0 0.45 6.0   
Sala 17 2009 Spain DM 6,074 4.2 0.4   3.8 
SFM 12,958 5.5 0.4   5.1 
Vinnicombe 10 2009 Great Britain DM 88,478 4.79 0.68 14.3   
SFM 31,720 4.43 0.65 14.6   
Hambly 9 2009 Republic of 
Ireland 
DM 35,204 4.0 6.3 15.7   
SFM 153,619 3.1 5.2 16.7   
del Turco 11 2007 Italy DM 14,385 4.56 0.72 15.9   
SFM 14,385 3.96 0.58 14.7   
Skaane 18 2004 Norway DM 6,997 3.8 0.59 21.6   
SFM 17,911 2.5 0.41 22.1   
Vigeland 8 2007 Norway DM 18,239 4.09 0.77 18.5   
SFM 324,763 4.16 0.65 15.1   
Our results   2013 The 
Netherlands 
DM 1,452,508 2.0 0.59 31.2   
SFM 1,460,344 1.6 0.51 34.4   
 
Despite the fact that the radiologists in SFM-group and SFMonly-group did not change 
technique, there is an obviously increasing trend in recall rate and detection rate. This was 
in part intentional policy communicated during audits and onsite visits by the NETCB, as a 
result of the optimization study carried out in 2004 and perhaps also influenced by the recall 
rates in DM2.  
The sharpest increase was found in the proportion of DCIS detected. This immediately 
triggers the concern of overdiagnosis, as often raised by those opposing screening. Since 
this issue can only be elucidated by very long term evaluations of mortality reduction, at this 
moment only modeling studies can be used to predict the impact of DM on overdiagnosis 
rate. The clinical consequences of higher DCIS detection rates have been explored by de 
Gelder et al. in 201119. She used the data of the feasibility study from 2004 to 2006 and a 
statistical model to predict the mortality reduction and overdiagnosis rate. The current 
increase in DCIS is still in line with the data used in their paper (1.2/1,000 screens) and does 
not alter their conclusion that increased detection of DCIS by DM reduces breast cancer 
mortality by a further 4.4% at a 21% increased overdiagnosis rate. 
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The increase in the amount of detected DCIS is stronger in younger women and in first 
screens (aged 50-51). This confirms the previous result of Pisano et al. in the US that the 
detection rate is more strongly affected by DM in younger women12. In oncology DCIS is still 
considered a serious condition and should be treated. 20 
The increase in the number of DCIS detected is rather steep. Possibly this is due to a first 
pass effect. This means that outcomes will be most strongly affected directly after the 
introduction of a new technology or method, comparable to a prevalence screen. The 
number of DCIS might stabilize at a lower level in the upcoming years. 
As a result of higher DCIS detection rates, we expect the detection rates of more advanced 
tumors to decline in the upcoming years, although we do expect part of the DCIS to 
represent overdiagnosis19,21. A recent study of the type of DCIS in the pilot phase showed no 
shift towards low grade DCIS, but significantly more high grade DCIS in subsequent screens7.  
We also found significantly more T1a tumors in DM-group. Detection of invasive breast 
cancer in an early stage may be beneficiary for the results of screening on mortality 
reduction, dependent on the grade of the tumors detected. We have no information on 
grade, but Nederend et al. found that DM finds more low and intermediate grade tumors5. 
The effect of an increased detection rate on interval cancer rate needs to be awaited. 
A wide range of variance exists when looking at regions separately. All regions perform 
within the internationally set standards. We found no evidence for convergence over time; 
this is in line with our expectations as multiple parameters vary (reading radiologists, 
changes in equipment etc.).  
With the introduction of DM many screening organizations were stimulated to perform two 
view examinations, not only at initial screen, but also at regular follow up screen. In 2010 
93% of all participants were examined using a two view examination. This change in policy 
may also have influenced the performance rates of the screening program22. 
In summary, we can confirm earlier results on DM screening in terms of diagnostic accuracy 
and can add that DM detects a significantly higher amount of DCIS and small invasive 
tumors. The effects of this additional stage shift on mortality reduction will have to be 
awaited. The performance of the Dutch screening program in international perspective is 
good, with a low recall rate and a high detection rate.  
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ABSTRACT 
BACKGROUND: Early detection of cancer prevents cancer deaths if an effective 
treatment is available for the early stage at detection. A drawback of mass screening is 
overdiagnosis. The potential harm of overdiagnosis depends on its frequency and the 
consequences of diagnosis and treatment. There is much debate on the topic of 
overdiagnosis in screening for breast cancer, but less so on overdiagnosis in screening for 
cervical cancer.  
MATERIALS AND METHODS: We estimated overdiagnosis rates by microsimulation 
for breast cancer screening and for cervical cancer screening, using a cohort run of women 
born in 1982 with lifelong follow-up. Overdiagnosis estimates were made analogous to two 
definitions formed by the UK 2012 breast screening review. Pre-invasive disease was 
included in both definitions.  
RESULTS: Screening prevented 921 cervical cancers (-55%); and 378 cervical cancer 
deaths (-59%) and 169 (-1.3%) breast cancer cases and 970 breast cancer deaths (-21%). 
Cervical cancer overdiagnosis rate was 74.8%, when including pre-invasive disease. Breast 
cancer overdiagnosis rate was estimated at 2.5%, when including pre-invasive disease. For 
women of all ages in breast cancer screening, an excess of 207 diagnoses/100,000 women 
was found with screening, compared to an excess of 3,999 diagnoses/100,000 women in 
cervical cancer screening. 
CONCLUSION: For breast cancer, the frequency of overdiagnosis in screening is relatively 
low, but consequences are evident. For cervical cancer, the frequency of overdiagnosis in 
screening is high, because of detection of pre-invasive disease, but the consequences per 
case are relatively small due to less invasive treatment. This illustrates that it is necessary to 
present overdiagnosis in relation to disease stage and consequences.  
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INTRODUCTION 
The purpose of cancer screening is to prevent cancer death by detecting a cancerous lesion 
early, and for some cancers pre-cancerous lesions, when treatment is still a viable option 
and more effective, or cancer may be prevented altogether.(1) Screening advances the 
diagnosis of disease to an earlier age, resulting in a higher incidence just after the initiation 
of screening. After the upper age limit of screening, the incidence rate will drop.(2)  
Breast cancer screening detects invasive breast cancer and ductal carcinoma in situ (DCIS), 
which are both considered a cancer diagnosis.(3, 4) The number of breast cancer diagnoses 
has increased since the introduction of screening, due to both lead time and changes in 
underlying risk. In a mature cervical cancer screening program, the screen-detection of 
invasive cancer is rare due to the higher frequency of detection of precursor lesions, thus 
altering the natural history of those lesions that are progressive. Screening for cervical 
cancer mostly detects cervical intra-epithelial neoplasia (CIN). CIN is not regarded as a 
cancer diagnosis. The incidence rate of cervical cancer had been decreasing prior to the 
introduction of screening and has continued to decrease due to screening.(5, 6) To the 
degree that a colorectal cancer screening program focuses on the detection of 
adenomatous polyps and cancer, incidence also is expected to decline along with mortality 
after screening is introduced.(6)  
A downside of early detection is the possibility of detecting abnormalities that would never 
have become clinically apparent in the absence of screening.(7) This may occur because 
abnormalities spontaneously regress, as is described for cervical cancer,(8-10) or that they 
remain indolent, as is described for breast cancer.(11, 12) Although there is little evidence 
to support the possibility of regression of breast cancer, it has been shown in vitro.(13) The 
detection of such an abnormality is called overdiagnosis, and most overdiagnoses lead to 
overtreatment. Overdiagnosis has been the topic of a fierce debate in breast cancer 
screening.(7) In cervical cancer screening, overdiagnosis is usually quantified as a lack of 
specificity for clinically significant disease. 
The impact of overdiagnosis depends on its frequency and its consequences. In breast 
cancer screening, the overdiagnosis rate is relatively low,(7, 14, 15) in cervical cancer 
screening the overdiagnosis rate as such is usually not established. The consequence of 
overdiagnosis is unnecessary treatment which is inherently harmful. The consequences of 
overdiagnosis in breast cancer screening are more severe than those in overdiagnosed non-
progressive CIN in cervical cancer screening. For an individual patient the name of the 
disease carries weight as well.  
We aimed to exemplify the impact of overdiagnosis by comparing these two screening 
programs, which have been implemented for several decades in the Netherlands; for 
cervical cancer since 1985 for women aged 30-60 every five years, and for breast cancer 
since 1990 for women aged 50-74 every two years.(16, 17) 
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Estimates of the measure of overdiagnosis in breast cancer screening in literature vary from 
4-54%.(7, 14, 18-20) The proper estimate of overdiagnosis has been the topic of many 
debates and the cause of many misunderstandings. We chose to use the definitions put 
forward by the UK independent review panel.(21)  
This is the first simulation study aiming to compare different screening programs by 
addressing the potential amount and composition of overdiagnosed cases in the same 
overdiagnosis framework. 
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MATERIALS AND METHODS 
The MISCAN model is a microsimulation model. This means the model simulates all 
individual life histories in a population. We have a model for breast cancer screening 
(MISCAN-Breast) and a model for cervical cancer screening (MISCAN-Cervix).(7, 22) In order 
to obtain a representative population, the models are fitted with a birth table and a life 
table. Each life history has its own probability of developing a (pre-) cancerous lesion. In 
MISCAN-Breast this probability is determined by fitting the model parameters: hazard, 
onset, and incidence, to data on incidence without screening from the Netherlands Cancer 
Registry. In MISCAN-Cervix the model is fitted to incidence data from Dutch Cancer Registry 
Database and data on detection from PALGA/PALEBA.(23),(24) From each state the disease 
may progress to the next stage by a semi-Markov progression model (Figure 1). In MISCAN-
Breast screening is implemented in the model using data on gradual roll-out, attendance 
rate and re-attendance rate in the Dutch screening program. Sensitivity, stage distribution, 
distribution of sojourn-time were estimated by fitting these parameters to data on 
incidence and stage distribution with screening (1991-2010) and without screening (1990). 
MISCAN-Breast assumes a 1.4% annual percentage change in underlying incidence.(25) 
Mortality reduction in the breast cancer model is based on the results of the Swedish 
trials.(26) The mortality reduction in the cervical cancer model is based on observational 
data, provided by the Dutch Cancer Registry and PALGA in the years 1998-2007.  
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Figure 1. Progression in the MISCAN model. Every woman starts at the top left, where she 
has no cancer. From there she may progress through the different stages of cancer. If the 
cancer is detected by screening, the woman moves to the bottom of the graph (screen-
detected). If the cancer is clinically detected she moves to the far right of the graph 
(clinically detected).  
The impact of screening on an individual life history is illustrated by Figure 2, in which there 
are five different women, and each has a scenario without (A) and with (B) screening. The 
black areas are the negative effects of screening (life years with lower quality due to 
diagnosis and treatment), and dark grey areas are the positive effects of screening (healthy 
life years gained). Woman number 1 will benefit from screening. In situation 1A, there is no 
mass screening. She will have an onset of cancer; this cancer will grow and develop up to 
the point when she develops symptoms. The cancer will be clinically diagnosed and she will 
die from this cancer. In situation 1B, there is mass screening. The woman will have the same 
onset and the same preclinical disease phase, but now mass screening will detect her cancer 
before she develops symptoms. Therefore the disease is in a less advanced state and 
treatment is successful. She has gained life-years and will die of other causes than cancer. 
Woman number 2 does not benefit from screening. Like woman number 1, she has an onset 
of cancer, followed by a preclinical disease phase. This phase however, would extend 
beyond her lifespan. She will never be diagnosed with cancer in the situation without 
screening (2A). In the situation with screening (2B) the cancer will be detected by screening 
and she will be treated accordingly. She will still die at the same time, but now she has lost 
several quality-adjusted-life-years (QALY) due to the fact that she had a cancer diagnosed. 
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Woman number 3 develops a pre-invasive disease that will progress to a clinically detected 
cancer, but she will not die from this cancer (3A). She will also not gain any life-years by 
screening (3B). Woman number 4 has a type of cancer with an obvious pre-invasive 
precursor state (i.e. CIN in cervical cancer). In this case the preclinical phase is divided into 
two phases, one with preclinical pre-invasive disease and one with preclinical cancer. The 
preclinical-pre-invasive state will progress to preclinical cancer, which becomes clinically 
detected and leads to cancer-related death in the situation without screening (4A). When 
this woman is screened (4B) while her disease is in the pre-invasive phase and her condition 
is detected, she may be cured completely and thus cancer was prevented, she benefits from 
screening. Woman number 5 does not benefit from screening; she has a preclinical-pre-
invasive disease that will not progress, or may even regress back to normal without 
screening (5A). Screening (5B) will give her a diagnosis of pre-invasive disease, but she will 
not gain any life-years. 
                                                        
 
 
 
Figure 2. Life histories of women affected differently by screening. The numbers indicate different women, each of them having a life history 
without screening (A) and with screening (B). LY= life-years. Black areas represent negative effects of screening (overdiagnosis), dark grey areas 
represent the positive effects of screening (life years gained). 
1A
1B
Screening Diagnosis
2A
2B
Screening Diagnosis
3A
3B
Screening Diagnosis
4A
4B
5A
5B Healthy Preclinical-Pre-invasive LY with precancerous Healthy
Birth Onset Screening Diagnosis Treatment Other causes related death
Other causes related death
Healthy Preclinical-Pre-invasive Healthy
Birth Onset Regression/ no progression Other causes related death
Birth Onset Screening Diagnosis Treatment Cancer related death prevented
Healthy Preclinical-Pre-invasive LY with precancerous Healthy LY gained
Healthy Preclinical-Pre-invasive Preclinical cancer Ly with cancer
Birth Onset Progression Clinical Diagnosis Cancer related death
Healthy Preclinical cancer Extra LY with cancer LY with cancer
Birth Onset No clinical diagnosis Other causes related death
Healthy Preclinical cancer LY with cancer
Birth Onset Clinical Diagnosis Other causes related death
Healthy Preclinical cancer Extra LY with cancer LY with cancer
Birth Onset Other causes related death
Clinical Diagnosis
Healthy Preclinical cancer Extra LY with cancer LY with cancer LY gained
Birth Onset No clinical diagnosis Cancer related death prevented Other causes related death
Healthy Preclinical cancer
Birth Onset Other causes related death
Healthy Preclinical cancer LY with cancer
Birth Onset Clinical Diagnosis Cancer related death
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MISCAN-breast assumes a regression rate of 2%, and a progression rate of 11%, for 
DCIS.(27) MISCAN-Cervix has six different disease paths, five assume regression, and 
assumes progression from onset to invasive disease. Each woman has an age-dependent 
probability of ending up in one of the disease paths.  
We performed a cohort run using our breast cancer model and cervical cancer model. The 
cohort consisted of 10,000,000 women, all born in 1982. The year 1982 was chosen so all 
women were 30 years and invited for cervical cancer screening in 2012, the most recent 
year with complete data. The number of simulated women alive in 2012 was also chosen as 
the denominator to convert raw data to rates. Between 2012 and 2032 (the year all women 
are invited to breast cancer screening for the first time) approximately 2% of the simulated 
women die of all-cause mortality (including cancer). Follow-up was completed for ages 30-
100 years. Output measures were: number of diagnoses during entire follow-up in the 
situation without screening and in the situation with screening, and the number of 
diagnoses during the screening ages in the situation without screening and in the situation 
with screening. All results are presented per 100,000 women aged 30 in 2012 and stratified 
by pre-cancer (DCIS for breast cancer and CIN grades I, II and III for cervical cancer) and 
invasive cancer.  
To estimate overdiagnosis we used the definitions set forward by the UK Independent 
review panel, which are: 1. “from the population perspective, the proportion of all cancers 
ever diagnosed in women invited to screening that are overdiagnosed”, and 2. “from the 
perspective of a woman invited to screening, the probability that a cancer diagnosed during 
the screening period represents overdiagnosis”.(21) To be able to address all diagnoses in 
the program, we extend the definitions above to include pre-invasive lesions, such as CIN I, 
II and III. 
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These definitions translate into the following calculations:  
1. From the population perspective: Number of extra diagnoses with screening/Total 
number of diagnoses in a population with screening. For the purpose of comparison we 
used ages 30-100 years. No significant amount of cancers occurs before the age of 30.  
2. From an individual perspective: Number of extra diagnoses with screening/Total number 
of diagnoses in women of screening age. For breast cancer screening this age range is 49-75 
years. For cervical cancer screening this age range is 29-60 years, but we used 29-64 years 
because the diagnostic process in cervical cancer screening may take some time due to 
follow-up. This definition corresponds to the risk of having an overdiagnosed cancer in the 
lifetime of screening.  
The number of extra diagnoses with screening is the difference between the total number 
of diagnoses in women aged 0-100 without screening and the total number of diagnoses in 
women aged 0-100 with screening. When we consider overdiagnosis, we included pre-
invasive disease. If we had not included pre-invasive disease, overdiagnosis measures would 
not have applied. 
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RESULTS 
All results are given per 100,000 women aged 30 in 2012. The model predicted 1,669 
cervical neoplasia diagnoses (Table 1) and 13,210 breast cancer diagnoses per 100,000 
women without screening (Table 2). Screening added 3,999 cervical neoplasia diagnoses and 
207 breast cancer diagnoses. The extra cervical cancer diagnoses were 4,920 extra CIN 
lesions, which cannot be clinically detected, and 921 (-55.2%) fewer cervical cancer 
diagnoses. The extra breast cancer diagnoses were the result of 376 extra DCIS diagnoses 
(+61.7%), and a 169 less invasive cancers (-1.3%). We stratified the number by CIN grade, 
because impact and treatment options differ for each grade. 
From a population perspective, the breast cancer overdiagnosis rate estimate was 1.5%. 
Cervical cancer overdiagnosis rate estimates from a population perspective varied from 
70.6%, when including all CIN and invasive diagnoses to 50.0%, when including only CIN III 
and invasive disease. From the individual perspective, the breast cancer overdiagnosis rate 
estimate was 2.5%. Cervical cancer overdiagnosis rate estimates from this perspective 
varied from 74.8%, when including all CIN and invasive diagnoses, to 55.4%, when including 
only CIN III and cervical cancer (Table 3).  
For women aged 30-100 we predicted 266 cervical cancer deaths with screening and  644 
without screening , a mortality reduction of 59%. For women aged 30-100 we predicted 
3,668 breast cancer deaths with screening and  4,637 without screening , a mortality 
reduction of 21%. 
 
 
 
Table 1. Cervical cancer. Number of cases by stage and overdiagnosis rate per 100,000 women aged 30 years in 2012. CIN= cervical intra 
epithelial hyperplasia. 
  
No 
screening With screening 
    Both clinically and screendetected Screendetected  
Clinically 
detected 
Diagnoses during entire life         
(Ages 30-100 years)         
CIN I 0 1,138 1,138 0 
CIN II 0 1,189 1,189 0 
CIN III 0 2,593 2,593 0 
Cervical cancer 1,669 748 117 632 
          
Total  1,669 5,668 5,037 632 
Diagnoses during screening         
(Ages 30-64 years)         
CIN I 0 1,138 1,138 0 
CIN II 0 1,189 1,189 0 
CIN III 0 2,593 2,593 0 
Cervical cancer 1,138 424 117 307 
          
Total  1,138 5,344 5,037 307 
Cervical cancer deaths (Ages 30-
100) 644 266     
Mortality reduction   59%     
 
 
 
Table 2. Breast cancer. Number of cases by stage and overdiagnosis rate per 100,000 women aged 30 years in 2012. DCIS= ductal carcinoma in 
situ.  
 
  
No 
screening With screening 
    Both clinically and screendetected Screendetected  
Clinically 
detected 
Diagnoses during entire life         
(Ages 30-100 years)         
          
DCIS 610 985 531 454 
Breast cancer 12,600 12,432 3,523 8,908 
          
Total  13,210 13,417 4,055 9,362 
          
Diagnoses during screening         
(Ages 49-75 years)         
          
DCIS 364 746 531 215 
Breast cancer 7,286 7,447 3,523 3,924 
          
Total  7,650 8,194 4,055 4,139 
Breast cancer deaths (Ages 
30-100) 
              
4,637                                                     3,668      
Mortality reduction   21%     
 
 
Table 3. Overdiagnosis in Cervical cancer and Breast cancer. Number of cases by stage and overdiagnosis rate per 100,000 
women aged 30 years in 2012. Excess diagnoses were calculated by subtracting all diagnoses in women aged 30-100 in the 
situation without screening from all diagnoses in women aged 30-100 in the situation with screening. Lifetime diagnoses are 
all diagnoses in women aged 30-100. Screening age diagnoses are all diagnoses in women aged 30-64 for cervical cancer, and 
in women aged 49-75 for breast cancer. CIN= cervical intra epithelial hyperplasia. DCIS= ductal carcinoma in situ. 
                
Population perspective   Individual perspective   
 Overdiagnosis rate = 
  Excess diagnoses   
 Overdiagnosis 
rate= 
  Excess diagnoses   
  
Lifetime diagnoses   
  
Screening age 
diagnoses   
                
CIN I+II+III+cervical 
cancer   70.6%     74.8%   
CIN II+III+cervical 
cancer   63.2%     68.0%   
CIN III+cervical cancer   50.0%     55.4%   
DCIS + breast cancer   1.5%     2.5%   
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DISCUSSION 
Our comparison of the burden of breast cancer screening to that of cervical cancer 
screening shows that screening prevents cancer specific mortality, but  when also including 
the detection of pre-invasive lesions in this equation, both types of screening also generate 
overdiagnosis. 
The burden of overdiagnosis depends on its frequency and its consequences. Although the 
overdiagnosis frequency is high in cervical cancer screening relative to breast cancer 
screening, the impact is limited because treatment is minimally invasive. For CIN I most 
often no treatment is necessary, and for CIN II or III a loop excision or conisation may be 
done in an out-patient setting.(28) These procedures have relatively limited risks, and no 
apparent cosmetic impact. However, cold knife conisation and large loop excision may be 
associated with preterm delivery, low birth weight, caesarean section and preterm rupture 
of the membranes in future pregnancies.(29-31) For breast cancer screening, the frequency 
is low relative to cervical cancer screening, but the impact is higher due to more invasive 
treatment. The treatment of DCIS is lumpectomy or even mastectomy, in some cases 
followed by radiation therapy.(32, 33) The risks of these treatments include (rare) standard 
operation risks (haemorrhage or infection), and the risk of generalized anaesthesia. 
Additionally the cosmetic result of these procedures has significant impact.(33) The 
perception of the individual also needs to be taken into account. The information provided 
with each diagnosis, whether it is cancer or pre-invasive disease is crucial to the impact of 
this event.  
The decision to count a diagnosis as overdiagnosis has to be related to its severity, 
treatment warranted, and on the impact of the information provided at diagnosis.  
Our estimates for overdiagnosis of breast cancer were different from those previously 
published using the MISCAN model. This is a direct result of using cohort runs instead of 
simulating a realistic population. If we run our model with a population aged 0-100, we 
obtain an overdiagnosis rate directly comparable to that of De Gelder et al.(7) This rate is: 
from a population perspective, for all diagnoses 4.6%; and from an individual perspective, 
for all diagnoses 8.1%.(7, 14, 18-20) For cervical cancer no comparable numbers were 
published.  
Our analysis for cervical cancer screening was performed on the current situation (i.e. 
primary conventional cytology testing with cytology triage) in the Netherlands. However, 
over the last years most laboratories have added a test to detect human papillomavirus 
(HPV) infections in the triage phase which slightly increases CIN I and CIN II detection.(34) In 
addition, most laboratories processing primary screening tests have switched from using 
conventional cytology to liquid-based cytology tests SurePath and ThinPrep. Rozemeijer et 
al. showed that CIN2+ detection rates increased by using SurePath, while they were 
64 
 
unaffected by using ThinPrep. this means that overdiagnosis rates are probably somewhat 
higher in the current Dutch situation than estimated in our study. Also, it is expected that 
from 2016 onwards, cervical cancer screening will be further modified in the Dutch program 
in 2016. Primary cytology will then be replaced by primary HPV screening with cytology 
triage. Furthermore, women will be invited for screening 5 times in their lifetime.(35) On the 
one hand there is a risk of increasing overdiagnosis by detecting disease at yet an earlier 
stage, on the other hand overdiagnosis may decrease due to less screening examinations in 
a life time.  
Screening practices for breast and cervical cancer vary widely between countries. For 
example the United States do not have a national screening programme, though the 
recently updated American Cancer Society guideline for mammography screening 
recommends annual screening for women aged 45-54 and biennial screening after 55.(36) 
Cervical cancer screening in the US is carried out by many practitioners with shorter 
intervals than guidelines indicate, despite the recommendation made by the United States 
Preventive Services Task Force (USPSTF).(37, 38)  Although the affordable Care Act now ties 
coverage to the USPSTF recommendations, more doctors follow the American Cancer 
Society (ACS) guidelines in breast cancer screening than the USPSTF recommendations. The 
NHS Breast cancer screening program in the UK invites women aged 50-70 every three years 
and is currently extending to include women aged 47-73. (39).In cervical cancer screening in 
the United States the guidelines are similar to those in the Netherlands.(40, 41) In another 
example the cervical cancer screening program of Finland is comparable to that of the 
Netherlands (but with considerably more opportunistic screening), while in the UK, Sweden 
and Denmark women are screened 12 and 13 times a lifetime starting at the ages of 25, 23 
and 23, respectively.(42-44) Therefore our estimates may be different in other countries. 
Overdiagnosis estimates are expected to increase for both screening programs with 
increasing number of screening examinations and with a younger age at first screening. 
Every early diagnosis can lead to overdiagnosis, because other cause mortality may occur 
before the benefits of early treatment are realized. This is most likely in older women, but it 
may also occur in younger women, especially with indolent disease In fact more non-
progressive CIN is found in younger women than in older women. (45) 
Looking towards the future, if we were to analyse the data for colorectal cancer screening 
we would expect results in between those of breast cancer and cervical cancer screening, 
depending on the screening test being used. Faecal occult blood tests, especially the older 
guaiac tests but also the newer e.g. immunochemical tests, have a lower sensitivity for 
early, pre-invasive disease than endoscopy. The most sensitive test will find more pre-
invasive disease, which will need less invasive treatment but also more often would not 
have developed into clinical disease, so the frequency of overdiagnosis would be high but 
the per case consequences would be low.  
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As more types of cancer will become eligible for screening, we hope that in the future 
balanced reports will elucidate the impact of any cancer screening on the advanced cancer 
rate and disease specific mortality while also publishing the properly estimated extent of 
overdiagnosis. 
LIMITATIONS OF THE STUDY 
In order to compare the two programs, which offer screening at different ages, we 
performed a cohort run. Although this results in a lifetime estimate of harms and benefits, it 
remains hypothetical as the homogeneity of a cohort never resembles a real population. 
Mathematical modelling requires assumptions made in the model on natural history of 
cancer. The mean duration of sojourn time and the probability of progression are 
interchangeable in the model, the assumptions used have influenced the overdiagnosis 
estimate. (46)  
We have extended the definition of overdiagnosis somewhat by including precursor lesions 
that commonly are not judged to be cancers. This is not the case so much with DCIS of the 
breast, but precursor lesions of the cervix have not commonly been included in discussions 
of overdiagnosis, nor have adenomas. In the case of each, the fraction of overdiagnosis will 
be harder to estimate because you would need to estimate the fraction of treated lesions 
that were progressive, something that is quite uncertain. 
CONCLUSION 
We have compared the burden of screening for two of the population screening programs 
for cancer currently in use in the Netherlands. For breast cancer, overdiagnosis estimates 
are relatively low, but the consequences for overdiagnosed women are significant. For the 
program overall these consequences however are quite small. For cervical cancer, 
overdiagnosis estimates of pre-invasive disease are high, but the consequences are 
relatively small due to less invasive treatment. Informing women about the potential harms 
of screening should include the consequences of finding the different lesions, invasive or 
pre-invasive.  
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ABSTRACT 
INTRODUCTION: The incidence of ductal carcinoma in situ (DCIS) has rapidly increased 
over time. The malignant potential of DCIS is dependent on its differentiation grade.  
MATERIALS AND METHODS: Our aim is to determine the distribution of different 
grades of DCIS among women screened in the mass-screening program, and women not 
screened in the mass screening program and to estimate the amount of overdiagnosis by 
grade of DCIS. We retrospectively included a population-based sample of 4,232 women with 
a diagnosis of DCIS in the years 2007-2009 from the Nationwide network and registry of 
histopathology and cytopathology in the Netherlands. Excluded were women with 
concurrent invasive breast cancer, lobular carcinoma in situ and no DCIS, women recently 
treated for invasive breast cancer, no grade mentioned in the record, inconclusive record on 
invasion, and prevalent DCIS. The screening status was obtained via the screening 
organizations. The distribution of grades was incorporated in the well-established and 
validated microsimulation model MISCAN. 
RESULTS: Overall, 17.7% of DCIS were low-grade, 31.4% intermediate-grade, and 50.9% 
high-grade. This distribution did not differ by screening status, but did vary by age. Older 
women were more likely to have low-grade DCIS than younger women. Overdiagnosis as a 
proportion of all cancers in women of the screening age was 61% for low-grade, 57% for 
intermediate-grade, 45% for high-grade DCIS. For women age 50-60 years with a high-grade 
DCIS this overdiagnosis rate was 21-29%, compared to 50-66% in women age 60-75 years 
with high-grade DCIS.  
CONCLUSION: Amongst the rapidly increasing numbers of DCIS diagnosed each year is a 
significant number of overdiagnosed cases. Tailoring treatment to the probability of 
progression is the next step to preventing overtreatment. The basis of this tailoring could be 
DCIS grade and age. 
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INTRODUCTION 
Ductal carcinoma in situ (DCIS) is a “neoplastic proliferation of cells within the ductal-lobular 
structures of the breast that has not penetrated the myoepithelial-basement membrane 
interface”.(1) Before the introduction of mammography screening, DCIS was rarely 
diagnosed. In 1989, 366 women in the Netherlands were diagnosed with DCIS. In 2003, 
more than 10 years after the introduction of mass-screening, 1,171 women had a DCIS 
diagnosed. With the introduction of digital screening this figure rose to 2,046 women in 
2011, and most recently to 2,406 in 2014.(2)  
The extent to which DCIS represents overdiagnosis has been extensively debated in relation 
to organised screening programmes.(3-6) Overdiagnosis is defined as a lesion diagnosed by 
screening in an asymptomatic woman that would not have been detected during the 
woman’s lifetime in the absence of screening.(4) To predict the probability of a DCIS to 
progress to invasive carcinoma, six different grading systems were proposed, based on 
morphology or molecular profile.(7) All of these classify DCIS into three categories of 
malignant potential: Low (I), intermediate (II), or high (III). The grade of DCIS is correlated 
with the risk of progression, as well as with the grade of concurrent invasive carcinoma.(8-
13) The transition from low-grade DCIS to high-grade DCIS or to high-grade invasive 
carcinoma is deemed unlikely.(8-10, 12) 
The grade distribution of DCIS has been studied in mostly small series,(6, 14-18) or only 
included screen-detected cases (Table 1). (19) More insight in this distribution based on 
larger numbers in both screened and non-screened populations is of paramount importance 
and may improve our estimates of overdiagnosis. 
The aim of this study was to establish the distribution of different grades of DCIS in different 
subgroups based on mass-screening status and age group, and to estimate the 
overdiagnosis rate for each grade and age group specifically.  
  
Table 1. Grade distribution by detection mode and sample size compared to previous studies on DCIS grade distribution. 
  Screendetected Symptomatic Not specified 
  
DCIS 
grade 1 
DCIS 
grade 2 
DCIS 
grade 3   
DCIS 
grade 1 
DCIS 
grade 2 
DCIS 
grade 3   
DCIS 
grade 1 
DCIS 
grade 2 
DCIS 
grade 3   
  % % % N % % % N % % % N 
This study 16 32 52 1430 19 28 54 263         
                          
Evans 2001 13 18 69 222 16 23 61 151 - - - - 
Kessar 2002 23 23 54 98 19 19 62 52 - - - - 
Meijnen 2005 22 31 47 87 26 24 49 293 - - - - 
De Roos 2007 7 44 53 54 30 45 25 20 - - - - 
Sorum 2010 - - - - - - - - 23 23 53 2403 
Bluekens 2012 15 32 54 853 - - - - - - - - 
Weigel 2015 18 39 42 898 - - - - - - - - 
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MATERIALS AND METHODS 
PATIENT SELECTION 
We obtained 17,744 excerpts from 12,301 women with DCIS from the years 2007, 2008 and 
2009 from the ‘Nationwide network and registry of histopathology and cytopathology in the 
Netherlands’ (PALGA). PALGA is a national database containing the excerpts and coded 
diagnoses of all pathological and cytological examinations performed in the 
Netherlands.(20) The mass-screening status of these women was established by linking the 
database to the databases of the screening organizations by an independent third party, 
with permission of the screening organizations. Our database contained anonymized 
records of mass-screening status (positive, negative, year of last mass-screening and 
number of mass-screening examinations), age, year of diagnosis, and a short summary of 
the conclusion of the original pathology report.  
From the 12,301 women, we excluded those who also had a concurrent invasive breast 
cancer (ipsilateral or contralateral, N=7,089), those who had a lobular carcinoma in situ and 
no DCIS (N=6), those who turned out after excision biopsy or ablation not to have any 
malignancy (N=131), those who had recently been treated for invasive breast cancer 
(N=247), those who had no grade mentioned in the excerpt (N=17), those who had an 
inconclusive excerpt on invasion or otherwise (N=242), and women who had a prevalent 
DCIS, rather than a new diagnosis in the study period (N=354). We excluded contralateral 
disease because our model does not include bilateral disease.  
DCIS DETECTED BY MASS-SCREENING 
DCIS were assumed to be ‘detected by mass-screening’ when a woman had had a positive 
screening examination in between 2007 and 2009. Women who had participated in the 
screening program, and did not have any positive screens, but who did have a DCIS 
diagnosis in 2007, 2008, or 2009 were assumed to have an interval-DCIS. The number of 
interval-DCIS increased across the study period due to the cumulative effect of interval-DCIS 
diagnosed in women screened in the previous year (2007) or in the two previous years 
(2007 and 2008). Interval-DCIS were rare in 2007 because of the low frequency of interval 
carcinoma’s within the same calendar year in which the screening examination took place. 
In 2008 interval-DCIS were diagnosed in women screened in 2007 or 2008, and in 2009 
interval-DCIS were diagnosed in women screened in 2007, 2008 or 2009. 
Women who were not known to the screening organizations may have been under clinical 
surveillance because of high familial risk, frequent (benign) breast anomalies, or because of 
personal preference. Diagnoses in this group may be the result of screening, but are not the 
result of the mass-screening program. Therefore we cannot conclude that DCIS not detected 
by mass-screening, were not detected by screening. To compare the distribution of DCIS 
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detected by mass-screening to DCIS not detected by mass-screening, we, therefore, chose 
to compare the DCIS detected by mass-screening to the interval-DCIS.  
GRADING OF DCIS 
In line with the Dutch guidelines, the classification by Holland et al. is almost exclusively 
used.(21) At the start of the mass-screening program in the early 1990’s, pathologists were 
instructed on how to uniformly classify each DCIS.  
DCIS grade was determined using the information in the short summary of the pathology 
report by description, i.e. high, moderate, or low differentiation; low, intermediate, or high 
malignancy potential; or grade I, II, or III. If the summary contained more than one grade 
this case was graded according to the highest grade mentioned. If there was a discrepancy 
between grades in different specimens of the same patient, the grade was based on the 
most representative specimen, i.e. resection is more representative than biopsy, but biopsy 
is more representative than cytology. 
STATISTICAL ANALYSIS 
Proportions of DCIS grades were calculated by year, age group, and screening status. We 
compared these proportions between screening groups using the Pearson chi-square test. 
Multivariate analyses on age groups were performed with a logistic regression model. The 
statistically significant parameters were identified by the introduction of variables in a 
stepwise manner. All calculations were performed using SPSS 20.  
MODELLING APPROACH 
The MISCAN model is a microsimulation model that simulates the individual life histories of 
women.(22) The probability of each woman to have an onset of breast cancer is determined 
by calibrating the model to the incidence rate in 1989 (the year before screening was 
introduced), adjusted with an annual percentage change of 1.4% to account for the rising 
background breast cancer incidence.(23) The natural history of breast cancer is modelled as 
a Markov-like progression through the successive pre-clinical stages of the disease. Details 
of the model have been described previously.(4) For this analysis we added the three DCIS 
grades to the model, using the age-dependent grade distribution found in this study (Figure 
1).  
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Figure 1. Schematic drawing of the extended MISCAN model. Transition possibilities are 
indicated with arrows. All diseases within the grey area are preclinical disease, after 
diagnosis they are either clinically detected or detected by mass-screening. DCIS= Ductal 
Carcinoma In Situ, T1a= tumour with a diameter up to 5 mm, T1b= tumour with a diameter 
from 5 mm up to 10 mm, T1c= tumour with a diameter from 10 mm up to 20 mm, T2+= any 
tumour with a diameter larger than 20 mm. There is no transition between low-grade DCIS, 
intermediate-grade DCIS and high-grade DCIS.  
Following onset, breast cancer in a pre-clinical stage can progress to the next pre-clinical 
stage (dependent on the duration of the previous state), or become clinically detected. In 
addition, the DCIS stages may also regress to normal.(24, 25) Screening is superimposed on 
this life history. 
The transition probabilities, duration of tumour stages, and test sensitivities were calibrated 
using data from the Dutch population and Dutch breast cancer screening from 1975 to 2010 
on breast cancer incidence by stage, age, and detection mode. The Dutch nationwide 
breast-cancer screening program has invited all women aged 50-69 since 1990 and women 
aged 50-75 since 1998 biennially for a mammographic screening examination, free of 
charge. The attendance rate is approximately 80%.(26)  
We chose to look at model-outcomes for the years 2000-2009 because there was a steady 
state situation in these years, more than 10 years after the start of the screening program. 
We evaluated the following output: incidence rate by detection mode (screen detected or 
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clinically detected), age, and year of diagnosis. The model compares women in the situation 
with screening, to the same women in the situation without screening; if a woman has a 
screen-detected cancer, but would not have had a diagnosis in the situation without 
screening, this case is regarded as overdiagnosed (Figure 2). 
 
Figure 2. Screening affecting three women differently. The first box is the life history of a 
woman who has an onset of breast cancer, is diagnosed clinically, and dies of breast cancer. 
The second box is the life history of a woman who also has an onset of breast cancer, but 
who dies of other causes before this would be detected. The third box is the life history of a 
woman who has an onset of breast cancer, but also a spontaneous regression, this woman 
would not have been diagnosed without screening. The fourth box indicates the situation 
for these three women had screening been introduced. The woman in the first box no 
longer dies from breast cancer; the other two women do not benefit from screening, they 
have been overdiagnosed. 
The estimates and definitions of overdiagnosis vary widely among international 
publications. (4) To minimize confusion we used the definitions of overdiagnosis which were 
deemed most useful by an independent review panel in the UK; from a population 
perspective: The proportion of all cancers ever diagnosed in women of the screening age 
and over (50-100 years) that are overdiagnosed; and from an individual perspective: The 
proportion of all cancers ever diagnosed in women of the screening age (50-75 years) that 
are overdiagnosed.(27)  
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ASSUMPTIONS ON NATURAL BEHAVIOUR OF DCIS 
In the original model a 2% regression rate, a 11% progression rate, and a 5% clinical 
detection rate was assumed for all DCIS, resulting in a proper fit of incidence.(28) Little is 
known about the natural history of DCIS without treatment. Small studies were published, 
indicating a progression rate of 1 in 2 to 1 in 3 for low-grade DCIS, 1 in 3 for intermediate-
grade DCIS and 2 in 3 in high-grade DCIS.(29, 30) Progression rate may differ from the rate 
assumed in the original model. In the new model we assumed that intermediate-grade DCIS 
has the same transition probabilities as all DCIS had in the original model. We lowered the 
regression rate to 1% for high-grade DCIS, and increased the regression rate to 4% for low-
grade DCIS, based on the findings of Sanders et al.(30) The probability for a DCIS to be 
clinically detected was assumed independent of grade. The probability of progression: 16% 
for low-grade DCIS, 31% for intermediate-grade DCIS, and 53% for high-grade DCIS, was 
estimated by correcting the probabilities of low-grade DCIS and high-grade DCIS by the 
progression found in literature.(29, 30) Adjusting the progression rate and therefore the 
duration of the state, influences all successive states, because the progression of each 
successive state is dependent on the duration of the previous state. High-grade invasive 
breast cancer follows high-grade DCIS and low-grade invasive breast cancer follows low-
grade DCIS. We calibrated DCIS incidence rate to observed data for the period 1990-2010. 
Parameters are summarized in table 2. 
  
Table 2. Model parameters, sources and estimates.  
Parameter Estimate Source 
        
 
Incidence of breast cancer prior to 
screening 
  
51.61 / 100,000 women Dutch cancer 
registry 
 
Current incidence of breast cancer 
  
85.33 / 100,000 women 
Dutch cancer 
registry 
        
Grade distribution of DCIS low grade DCIS 16.4% - 18.8% PALGA (this study) 
  
intermediate grade 
DCIS 27.2% - 31.6%   
  high grade DCIS 52.0% - 54.0 %   
        
Progression rate low grade DCIS 16% Sanders (2005) 
  
intermediate grade 
DCIS 31%   
  high grade DCIS 53%   
        
Regression rate low grade DCIS 4% 
Collins (2005), 
Sanders (2005) 
  
intermediate grade 
DCIS 2%   
  high grade DCIS 1%   
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RESULTS 
PATIENTS/DISTRIBUTION OF DCIS GRADE 
Patient characteristics are summarised in table 3. There was no significant difference in the 
distribution of grades between the DCIS detected by mass-screening and the DCIS not 
detected by mass-screening (from the interval group); 16.4-18.8% were low-grade, 27.2-
31.6% were intermediate-grade, and 52.0-54.0% were high-grade (Table 4).  
Univariate analysis of the group, not detected by mass-screening, showed that DCIS grade 
has an inverse linear association with 5-year age group (p-value=0.015), and with age as a 
linear variable (p-value=0.018). Year of diagnosis did not contribute in this group (Table 5). 
Overall the year of diagnosis was a significant independent variable (p-value=0.02).  
ESTIMATING OVERDIAGNOSIS 
The distribution of DCIS grade was included in the model and the new model was calibrated 
estimating dwell times and probabilities of transition on incidence data from the Cancer 
Registry and grade distribution from our study (Figure 3).  
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Figure 3. Low-grade DCIS, intermediate-grade DCIS and high-grade DCIS per 100,000 women 
aged 50-60. DCIS: Ductal Carcinoma In Situ. MISCAN: Predicted rates by the model. 
Observed: The number of DCIS as calculated when applying DCIS-grade distribution to the 
data on total DCIS incidence from the Dutch Cancer Registry. 
Overdiagnosis estimates from the model were, from the population perspective; 60% of 
low-grade DCIS, 56% of intermediate-grade DCIS, 45% of high-grade DCIS. Overall (invasive 
disease and DCIS) overdiagnosis rate from the population perspective was 8%. 
Overdiagnosis estimates from the individual perspective were; 61% of low-grade DCIS, 57% 
of intermediate-grade DCIS, 45% of high-grade DCIS. When stratified by age group, the 
younger women had a much lower overdiagnosis rate when being diagnosed with a high-
grade DCIS, varying from 21% in age group 50-55 to 29% in age group 55-60, up to 66% in 
age group 70-75 (Table 6). 
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Table 3. Descriptive statistics of the DCIS cases reviewed. ‘Known at mass-screening’ are all women who were listed in the database of the 
screening organisations, with a positive or a negative screen, ‘Not known at mass-screening’ are all women who were not mentioned in the 
screening organisation’s database. N.a.: Not applicable.  
  Known at mass-screening   Not known at mass-screening   P-value 
  N %   N %     
Patients 4.075     8.226       
Exclusions 2.382 58%   5.687 69%     
Inclusions 1.693 42%   2.539 31%     
                
Year diagnosis               
2007 429 25%   865 34%   <0·001 
2008 583 34%   806 32%     
2009 681 40%   868 34%     
                
Age group               
<49 0 0%   651 26%   <0·001 
49-75 1.690 100%   1.686 66%     
>75 3 0%   202 8%     
                
Screen result               
Positive screen 1.430     n.a.       
No positive screen 263     n.a.       
                
  Mean     Mean       
Age 60·8     56·3     <0·001 
                
  
Table 4. Distribution of different DCIS grades by screening status and age group. The p-values indicate the significance of the difference of 
these distributions between screening status. DCIS: Ductal Carcinoma In Situ. Low-grade DCIS: DCIS with a low malignant potential. 
Intermediate-grade DCIS: DCIS with an intermediate malignant potential. High-grade DCIS: DCIS with a high malignant potential. 
        Detected at mass-screening   Screen negative   
P-
value   
        N %   N %       
  Age group                     
  <49     0     0         
    Low-grade DCIS   0 n.a.   0 n.a.       
    
Intermediate-grade 
DCIS   0 n.a.   0 n.a.       
    High-grade DCIS   0 n.a.   0 n.a.       
                        
  49-75     1,429     261         
    Low-grade DCIS   234 16.4%   49 18.8%   
 
  
    
Intermediate-grade 
DCIS   452 31.6%   71 27.2%    0.579   
    High-grade DCIS   743 52.0%   141 54.0%       
                        
  >75     1     2         
    Low-grade DCIS   0 0.0%   0 0.0%   
 
  
    
Intermediate-grade 
DCIS   0 0.0%   2 100.0%    0.297   
    High-grade DCIS   1 100.0%   0 0.0%       
                        
                        
  
Table 5. Distribution of different DCIS grades by year and screening status. The p-values indicate the significance of the difference of these 
distributions between screening status. DCIS: Ductal Carcinoma In Situ. Low-grade DCIS: DCIS with a low malignant potential. Intermediate-
grade DCIS: DCIS with an intermediate malignant potential. High-grade DCIS: DCIS with a high malignant potential. 
                    
      Detected at mass-screening   Screen negative   
P-
value 
      N %   N %     
Year                   
2007     410     19       
                    
  Low-grade DCIS   59 14.4%   3 15.8%     
  Intermediate-grade DCIS   109 26.6%   2 10.5%   0.083 
  High-grade DCIS   242 59.0%   14 73.7%     
                    
2008     525     58       
                    
  Low-grade DCIS   91 17.3%   11 19.0%     
  Intermediate-grade DCIS   167 31.8%   15 25.9%   0.827 
  High-grade DCIS   267 50.9%   32 55.2%     
                    
2009     495     186       
                    
  Low-grade DCIS   84 17.0%   35 18.8%     
  Intermediate-grade DCIS   176 35.6%   56 30.1%   0.651 
  High-grade DCIS   235 47.5%   95 51.1%     
                    
  
Table 6. Overdiagnosis estimates by two different definitions. Population perspective: The proportion of all cancers ever diagnosed in women 
of the screening age and over (50-100 years) that are overdiagnosed. Individual perspective: The proportion of all cancers ever diagnosed in 
women of the screening age (50-75 years) that are overdiagnosed. DCIS: Ductal Carcinoma In Situ. Low-grade DCIS: DCIS with a low malignant 
potential. Intermediate-grade DCIS: DCIS with an intermediate malignant potential. High-grade DCIS: DCIS with a high malignant potential. 
 
  Low-grade DCIS Intermediate-grade DCIS High-grade DCIS 
        
        
Population perspective 60% 56% 45% 
        
        
Individual perspective 61% 57% 45% 
        
Individual perspective by age group 
      
      
50-55 58% 46% 21% 
55-60 62% 55% 29% 
60-65 66% 64% 50% 
65-70 49% 52% 61% 
70-75 54% 58% 66% 
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DISCUSSION 
This is the largest study on the distribution of DCIS grade and the first modelling study to 
estimate overdiagnosis rate by DCIS grade. The distribution of grades in DCIS is dependent 
on age, but not on mass-screening status. This is in accordance with earlier studies on grade 
distribution. The overall distribution is also consistent with these studies (Table 4).(6, 14-16, 
18, 19, 31) 
The incidence rate of DCIS has increased rapidly over recent years. DCIS is unequivocally 
associated with mammography screening. Approximately one third of the cases in the 
database were detected by mass-screening, which corresponds to the overall distribution of 
breast cancers detected by mass-screening (both in situ and invasive) of all breast cancers in 
the Dutch population, and to the findings of Shin et al.(32) However, in our study, when 
linking Dutch pathology reports to the records of the screening organisations, most DCIS 
were not known at mass-screening organisations. This can partly be explained by the fact 
that one of the nine organisations, that were responsible for screening at the time, did not 
deliver data to be linked to the PALGA database. This organisation represents approximately 
15% of all screened women annually. Secondly, we do not know how the diagnoses not 
detected by mass-screening were established. Given the age distribution and the fact that 
DCIS is generally not palpable, we assume that the majority of these cases are diagnosed 
through screening outside the mass-screening program. 
As expected, and in line with previous studies, we found more low-grade DCIS in older 
women.(33) In general, more aggressive cancers are diagnosed earlier in life. Those that 
remain for detection at an older age are more likely to be less aggressive.(34) 
In the Netherlands, a transition to screening with digital mammography was made between 
2005 and 2010. In 2010, the detection rate of DCIS in mass-screening increased 
substantially, probably as a result of the introduction of digital mammography screening. 
Currently, it is not yet clear whether this is a prevalence effect or a lasting effect. We 
studied the years 2007, 2008 and 2009; thus, an increasing proportion of the DCIS we 
considered have been found with digital screening. We have no knowledge which DCIS were 
detected by digital mammography or film screen mammography. Also the DCIS detected 
outside the mass-screening program are equally likely to have been detected with digital 
mammography. We did not find a difference in grade distribution in screen detected DCIS 
over this period; therefore it seems unlikely that digital screening will have significantly 
altered the grade distribution, which is also in accordance with the findings of Bluekens et 
al.(19) 
We have found that grade distribution for DCIS in the years 2007, 2008 and 2009, was 
inversely related to age, but we have no information on historical development of this 
distribution. For our study, we assumed the distribution to be stable over time. 
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Considerable controversy exists on whether DCIS is the ideal stage of the disease for early 
detection, or whether the detection of DCIS represents overdiagnosis, and, consequently, 
overtreatment. However, agreement exists that it is essential to determine which individual 
diagnosis is overdiagnosis and which is not. Central to this discussion is the natural 
behaviour of DCIS. Now that we have specified grade of DCIS in the microsimulation model, 
we can estimate overdiagnosis more accurately. Only 16.4% of detected by mass-screening 
DCIS are low-grade, 60% respectively 61% of which are overdiagnosed, depending on the 
definition of overdiagnosis. We found that 50.9% of all detected by mass-screening DCIS are 
high-grade, and therefore have a high risk of progression. In these cases we are bound to 
find aggressive cancer earlier and to prevent fast-growing invasive cancer, but even so, 45% 
of these cases are overdiagnosed, independent on the definition of overdiagnosis. For 
younger women (age 50-60) with a high-grade DCIS however, overdiagnosis estimates vary 
between 21% and 29% from an individual perspective, therefore for these women screening 
is most protective.  
We found an increasing amount of overdiagnosis in older women with high-grade DCIS, this 
is the result of a longer dwell time in the model in high-grade DCIS in women over 60. This 
dwell time was calibrated by the model. A disease with a longer dwell time is more likely to 
be detected by screening. The longer dwell time of high grade DCIS in older women 
correlates to the findings of Weigel et al., who found a higher detection rate of high grade 
DCIS in older women.(33)  
Our overdiagnosis estimates make a general decision on treatment from a population based 
approach a very difficult one for women with DCIS. We estimate that 60% of these women 
would be overtreated if they undergo treatment for this disease, of which they would never 
have been aware in the absence of screening. On the other hand, they are diagnosed with 
an entity that carries a specific risk for progression to an invasive and potentially lethal 
disease and will therefore lean towards treatment, rather than active surveillance. If this 
entity would be named differently this might be perceived differently.(35) DCIS can also be 
regarded as a risk factor like lobular carcinoma in situ. One can question whether the 
increased risk in DCIS as compared to LCIS, justifies the current practice of invasive 
treatments.  
Specific estimates for overdiagnosis rate by grade will become increasingly important. These 
estimates may change when the treatment for DCIS can be even more customised according 
to grade.(36) To our knowledge a trial to compare treatment of DCIS to active surveillance is 
planned.(37) 
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LIMITATIONS OF THE STUDY 
We did not review grading or examined interobserver variation between pathologists, 
because this was beyond the scope of our study. PALGA and the Dutch association of 
pathologists will be conducting a study to evaluate the interobserver variation in the near 
future. We believe our study to be a proper representation of the current Dutch situation. 
There is no reason to suspect that DCIS not detected by mass-screening represents a 
different patient group than DCIS detected by mass-screening, and for that reason for both 
groups the same dilemma with regard to a possible interobserver variation exists.  
Assumptions on behaviour of DCIS were done on older studies. Advances have been made 
in the evaluation of biopsies. Currently more sampling is done and pathologists are more 
aware of the possible findings in DCIS, this could influence the assumptions on behaviour of 
DCIS if the studies on which they are based were repeated now. 
CONCLUSION 
DCIS grade is almost equally distributed across the screened population in the breast cancer 
screening program and the population not subjected to/participating in mass-screening.  
DCIS has been divided into three grades, each constituting a unique entity with its own 
natural history. We found that the distribution of these grades is not dependent on mass-
screening status, but is dependent on age. When taking the different grades into account, 
overdiagnosis rates of breast cancer in mass-screening are 60% for low-grade DCIS and 45% 
for high-grade DCIS from a population perspective, and 61% and 45% respectively from an 
individual perspective. When taking the younger ages and high-grade into account 
overdiagnosis rate from an individual perspective is 21-29%.  
These figures underline the necessity of large randomised trials for watchful waiting in low-
grade DCIS, whether these are detected in a mass-screening program or not. 
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ABSTRACT 
The incidence of breast cancer in Norway has fluctuated in the last three decades. This is 
partly explained by the use of hormone replacement therapy (HRT) and mammography 
screening, overdiagnosis has been suggested as well. The Norwegian Breast Cancer 
Screening Programme (NBCSP) was gradually implemented between 1996 and 2005. We 
calibrated our microsimulation model to Norwegian Cancer Registration data. The model 
takes mammography use, in the NBCSP and outside the programme, and HRT use into 
account. We obtained a proper fit of breast cancer incidence in recent years, when 
assuming an increase in the background risk for breast cancer and estimated overdiagnosis. 
We estimated a 2% overdiagnosis rate as a fraction of all cancers diagnosed in women aged 
50-100, and a 3% overdiagnosis rate as a fraction of all cancers diagnosed in women aged 
50-70, i.e. the screening age. If all of the increased incidence would be the result of the 
detection of slow growing tumours, these estimates were 7% and 11%, respectively. Besides 
mammography and HRT use, additional risk factors have contributed to the sudden increase 
in breast cancer incidence in Norway. Overdiagnosis estimates due to screening were within 
the range of international plausible estimates.  
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INTRODUCTION 
Breast cancer incidence in Norway rose sharply in the mid-1990s for women aged 50-69 
years old; from 193 per 100,000 women in 1995 to 262 per 100,000 women in 1997 (1). The 
Norwegian Breast Cancer Screening Programme (NBCSP) was introduced in Norway 
between 1996 and 2005 (2). The rapid increase in breast cancer incidence for women aged 
50-69 started in 1995, prior to the introduction of the NBCSP. Two possible causes for this 
increase have been described before: First, many women were already screened outside the 
NBCSP, in the period 1983-1996 (3); second, many women used hormone replacement 
therapy (HRT) in those days (4-7), which is associated with an increased risk of breast cancer 
(8, 9). Recent studies on breast cancer incidence in Norway found that the use of 
mammography and HRT alone is not enough to explain the steep increase in breast cancer 
incidence in Norway (10, 11). 
Mammography screening impacts breast cancer incidence because women are diagnosed 
earlier, so breast cancer incidence in the screening age increases temporarily, but breast 
cancer incidence after the screening age will decrease. Also screening will lead to diagnoses 
of breast cancer in women who would never have had a diagnosis in the situation without 
screening (12). These women are overdiagnosed. Since it is not known which women are 
overdiagnosed, all women with a diagnosis of breast cancer will be treated. Thus 
overdiagnosis is directly related to overtreatment. Overdiagnosis is one of the major harms 
of screening, and the main topic of controversy regarding mass mammography screening 
(10, 13-19). Overdiagnosis rates in Norway have been estimated to range from 10-50% (14, 
15, 17). This variation is mainly attributable to different methods to estimate overdiagnosis 
(20) and definitions (12). We use the definitions the UK Independent Review Panel deemed 
most useful, to allow for maximal comparability (21). 
The aim of our study is to assess the trends in breast cancer incidence and overdiagnosis in 
Norway. First, we evaluated trends in overall breast cancer incidence rate, and ductal 
carcinoma in situ (DCIS) incidence rate, as provided by the Norwegian Cancer Registry, with 
joinpoint analysis (22). Second, we calibrated our MIcro-simulation SCreening ANalysis 
(MISCAN) model to the Norwegian data. Finally we used the model to evaluate the NBCSP 
and HRT and estimate the amount of overdiagnosis.  
  
98  
MATERIALS AND METHODS 
JOINPOINT ANALYSIS 
We evaluated trends in invasive breast cancer incidence rate for women aged 50-70 years 
from 1970 to 2009; DCIS incidence rate for women aged 50-70 years from 1993 to 2009; 
mammography use from 1995 to 2005; and HRT-use from 1986 to 2008. We performed a 
joinpoint analysis, using the tool provided on the Surveillance research website of the 
National Cancer Institute (23, 24). Incidence data were provided by the Cancer Registry of 
Norway. Figures for mammography use were taken from Lynge et al (3). HRT use was 
extracted from the Norwegian Prescription Database (25). 
THE MISCAN MODEL 
The MISCAN-model is a micro-simulation model designed for the evaluation of screening. In 
MISCAN, individual life histories are simulated, and the consequences of introducing a 
screening programme are assessed.  
The model is a semi-Markov model using Monte Carlo simulation. The model simulates a 
large number of individual life histories; together these life histories form a population. Year 
of birth, cause of death (breast cancer death or death from other causes), and time of death 
are included in the life history. Some individuals have an onset of breast cancer and develop 
a pre-clinical DCIS. After the onset of disease, the pre-clinical DCIS may regress back to 
normal, progress to consecutive stages of pre-clinical invasive cancer, or become clinically 
detected (26). The natural history of breast cancer in the model is shown in Figure 1. Age-
dependent dwell times represent the average amount of time between transitions from one 
stage to the subsequent stage. In each stage there is an age-dependent probability that the 
cancer will be clinically detected. Once the disease is detected, an age and stage dependent 
survival is assigned. The model determines the cause of death by taking the first of the two 
options from the life history: death from breast cancer or death from other causes. 
Screening is superimposed on the life histories. Screening changes the course of the life 
histories by changing the time of diagnosis and the time and cause of death. The model 
generates two life histories for each individual: one for the situation without screening and 
one for the situation with screening.  
Originally, the model was calibrated to the Dutch situation (12, 26). Survival after clinical 
diagnoses and the improvement of prognosis after detection by screening were modelled 
using several international sources (27, 28).  
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Figure 1. Graphic presentation of the transitions in the MISCAN model. DCIS; ductal 
carcinoma in situ, T1A; invasive breast cancer with a diameter of 1-5 mm., T1B; invasive 
breast cancer with a diameter of 6-10 mm.,T1c; invasive breast cancer with a diameter of 
11-20mm., T2+; invasive breast cancer with a diameter greater than 21 mm. Every woman 
has a probability of having an onset of breast cancer. This may be a DCIS or a T1A tumour. 
From DCIS she may regress back to not having breast cancer, be clinically or screen-detected 
or progress to T1A. The possibility of regression exists only in the DCIS state. 
MODEL ADJUSTMENTS TO THE NORWEGIAN SITUATION 
Observed data on breast cancer incidence, stage distribution, detection mode, and 
attendance rate of the NBCSP were provided by the Cancer Registry Norway.  
The Norwegian population was modelled by calibrating the birth table to fit the population 
composition in 2005 and by replacing the Dutch life table with the Norwegian life table (29). 
We calibrated the model by fitting the onset rate by age and the stage specific dwell times 
against the observed incidence rate for the period 1970-1990 (before the wide-spread use 
of mammography).  
Opportunistic screening was included based on the data published by Lynge et al, she found 
an increased use of mammography from the early 1980’s up to approximately 130,000 
women examined in 2003.(3) The total number of mammographies in the model was 
calibrated to the total number of mammographies in the paper . HRT use was implemented 
as a relative risk for different birth cohorts in individual calendar years (Table 1)(11). The 
frequency of HRT use was estimated using data from the Norwegian Prescription Database. 
We used a relative risk of 2.2 of onset of breast cancer for women using HRT, found in 
previous studies (8, 11).  
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Table 1 (next page): Relative risk factors used to model increased risk for breast cancer for 
the whole female population as a result of hormone replacement therapy (HRT). In model 2 
an additional relative risk was added to increase the incidence in later years. Note: relative 
risks in Model 3 are the same as in Model 1. 
  
  Model 1 Model 2 
Birth 
cohort 
1960-
1970 
1950-
1960 
1940-
1950 
1930-
1940 
1920-
1930 
1910-
1920 
1900-
1910 
1890-
1900 
1960-
1970 
1950-
1960 
1940-
1950 
1930-
1940 
1920-
1930 
1910-
1920 
1900-
1910 
1890-
1900 
Age group 30-46 30-56 37-66 47-76 57-86 67-96 77-99 87-99 30-46 30-56 37-66 47-76 57-86 67-96 77-99 87-99 
Year                                 
1987     1.01 1.01 1.03 1.02 1.02 1.02     1.01 1.01 1.03 1.02 1.02 1.02 
1988     1.01 1.07 1.04 1.02 1.02 1.02     1.01 1.07 1.04 1.02 1.02 1.02 
1989     1.01 1.08 1.04 1.02 1.03 1.03     1.01 1.08 1.04 1.02 1.03 1.03 
1990   1.01 1.09 1.05 1.03 1.03 1.03     1.01 1.09 1.05 1.03 1.03 1.03   
1991   1.02 1.12 1.06 1.03 1.04 1.04     1.02 1.12 1.06 1.03 1.04 1.04   
1992   1.02 1.15 1.08 1.04 1.05 1.05     1.02 1.15 1.08 1.04 1.05 1.05   
1993   1.03 1.20 1.12 1.06 1.06 1.06     1.03 1.20 1.12 1.06 1.06 1.06   
1994   1.04 1.27 1.16 1.07 1.08 1.08     1.04 1.27 1.16 1.07 1.08 1.08   
1995   1.05 1.29 1.19 1.08 1.09 1.08     1.05 1.29 1.19 1.08 1.09 1.08   
1996   1.05 1.31 1.22 1.10 1.10 1.09     1.05 1.31 1.22 1.10 1.10 1.09   
1997   1.06 1.33 1.25 1.11 1.11 1.10     1.75 1.75 1.75 1.75 1.75 1.10   
1998   1.06 1.35 1.28 1.12 1.12 1.11     1.75 1.75 1.75 1.75 1.75 1.11   
1999   1.07 1.35 1.29 1.13 1.13 1.11     1.75 1.75 1.75 1.75 1.75 1.11   
2000 1.06 1.31 1.27 1.12 1.12 1.10     1.75 1.75 1.75 1.75 1.75 1.75     
2001 1.06 1.31 1.27 1.13 1.11 1.10     1.75 1.75 1.75 1.75 1.75 1.75     
2002 1.05 1.27 1.24 1.12 1.10 1.08     1.75 1.75 1.75 1.75 1.75 1.75     
2003 1.04 1.19 1.17 1.09 1.07 1.06     1.75 1.75 1.75 1.75 1.75 1.75     
2004 1.03 1.16 1.14 1.08 1.06 1.05     1.75 1.75 1.75 1.75 1.75 1.75     
2005 1.03 1.13 1.12 1.07 1.05 1.04     1.75 1.75 1.75 1.75 1.75 1.75     
2006 1.02 1.11 1.11 1.06 1.05 1.04     1.75 1.75 1.75 1.75 1.75 1.75     
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Incidence rate after the implementation of screening was calibrated, adjusting the 
parameters age specific hazard (of having an onset of breast cancer), stage specific test 
sensitivity, the probability of having an onset by age and the incidence of breast cancer. To 
calibrate these parameters we used data on breast cancer incidence by age after the 
introduction of screening (1990-2009), disease stage, and detection mode. To reach the 
observed increase breast cancer incidence, we increased the background incidence for all 
women under the age of 87 in the years 1997 to 2006 with a relative risk of 1.75. The factor 
1.75 is comparable to the cohort effect used by Weedon-Fekjaer in his study.   
Mean estimated dwell times are shown in table 2.  
Table 2. Dwell time in years by patient age and preclinical disease stage in model 2. 
  DCIS T1A T1B T1C T2+ 
Age           
0 2.1 0.0 0.1 0.2 0.3 
20 2.1 0.0 0.2 0.4 0.4 
30 2.1 0.1 0.2 0.5 0.5 
40 2.1 0.1 0.3 0.6 0.7 
45 2.1 0.1 0.3 0.7 0.8 
50 2.1 0.1 0.4 0.8 0.9 
55 2.1 0.1 0.4 1.0 1.1 
60 2.1 0.1 0.5 1.2 1.3 
65 2.1 0.2 0.7 1.5 1.6 
100 2.1 0.2 0.7 1.5 1.6 
            
            
 
In sensitivity analysis we also included the outcomes of the model if we would not increase 
the background risk, and calibrate the dwell time of DCIS to the observed data on breast 
cancer incidence after the introduction of screening (1990-2009), disease stage, and 
detection mode. Dwell times in this model were 25.0 years for DCIS, 0.01 year for T1a 
tumours, 0.1 year for T1b tumours, 0.6 years for T1c tumours and 0.6 years for T2+ tumours.  
A long dwell time simulates the existence of a large pool of dormant breast cancer. 
Screening will then mostly detect indolent cancers, and thus create overdiagnosis.  
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OUTPUT MEASURES  
Our analysis was performed on runs that simulated a population of 10 million women for all 
three models. Rates were calculated per 100,000 women years. We calculated breast cancer 
incidence with screening, and breast cancer incidence without screening, per 5 year age 
group for the years 1970-2008.  
CALCULATING OVERDIAGNOSIS 
In accordance with the UK Independent Review Panel we defined two measures of 
overdiagnosis: overdiagnosis from a population perspective and overdiagnosis from an 
individual perspective.  
Overdiagnosis from a population perspective = (excess-deficit)/all diagnoses in women 
exposed to screening aged 50-100. 
Overdiagnosis from an individual perspective = (excess-deficit)/all diagnoses in women 
exposed to screening aged 50-70. 
A population, which is exposed to screening, initially has a higher breast cancer incidence 
compared to a population not exposed to screening (due to earlier diagnoses). These extra 
diagnoses are called the excess. After the upper age limit of screening is reached, the 
exposed population initially has a lower breast cancer incidence (breast cancers that were 
detected in the screening ages, do not occur after screening). The difference between the 
amount of diagnoses in the entire population (aged 0-100) exposed to screening and the 
number of diagnoses in the entire population (aged 0-100) not exposed to screening is 
called the deficit. The total number of overdiagnosed cancers in a population is the 
difference between excess and deficit.  
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RESULTS 
JOINPOINT ANALYSIS 
Mammography use in Norway increased steeply from 1983 to 2002, although subtle, 
significant changes in annual percentage change were seen in 1985 and 1991. More 
evidently the use of mammography reached a climax in 2002, after which it gradually 
declines (Figure 2a). HRT use was increasing steadily between 1990 and 1994, after which 
the increase became less steep. In 2000 a turning point can be seen, after which the use of 
HRT rapidly declines (Figure 2b).  
A 
 
B 
 
Figure 2. A: Mammography use (both in the NBCSP and opportunistic screening) per 
100,000 women of all ages. B: HRT use in defined daily doses (DDD) per 1,000 women of all 
ages. 
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Invasive breast cancer was steadily increasing from 1970 to 1995 with 1% per year. From 
1995 to 1997 there was a much steeper increase of 13% per year, and after 1997 the 
increase attenuated to 2.5% per year. The maximum incidence was reached in 2003, after 
which incidence has been declining with 1.9% per year (Figure 3a). DCIS was increasing 
rapidly from 1995 to 1997 with 29.5% per year, after which the increase attenuated to 3.3% 
per year (Figure 3b).  
A 
 
B 
 
Figure 3. A: Breast cancer incidence rate (invasive cancers only) per 100,000 women aged 
50-70. B: DCIS incidence rate per 100,000 women aged 50-70. 
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MODEL OUTPUT 
When assuming an increased background risk the model adequately reproduced the 
observed breast cancer incidence data. If a stable background risk is assumed, the model 
underestimates breast cancer incidence in Norway in the years 1997-2009. If we assume a 
long dwell time for DCIS, incidence rates peak at first introduction of mammography use, 
but after that incidence rates drop rapidly, and incidence is underestimated in the years 
1997-2009 (Figure 4).  
 
Figure 4. Breast cancer incidence rate/ 100,000 women aged 50-75. The calibrated model to 
Norwegian demographics, mammography use and HRT use; with increased background risk; 
model calibrated to Norwegian demographics, mammography use and HRT use, without 
increased background risk; calibrated model to Norwegian demographics, mammography 
use and HRT use, without increased background risk, but with very long dwell times for 
DCIS. 
When comparing the output for the situation with screening and without screening, we 
found an estimated overdiagnosis rate for the years 2014-2023 for all invited women aged 
50-100 years (population estimate) of 2% in our best model. For all invited women aged 50-
70 (individual estimate) in 2014-2023 this rate was 3%.  
The model with long dwell times estimates the highest level of overdiagnosis, because it 
assumes a large pool of dormant tumours to be detected by screening, which would never 
have led to breast cancer death or even invasive disease in the absence of screening. In this 
model estimated overdiagnosis rate for the years 2014-2023 for all invited women aged 50-
100 years (population estimate) was 7%. For all invited women aged 50-70 (individual 
estimate) in 2014-2023 this rate was 11%. Overdiagnosis estimates per model are given in 
Table 3. Overdiagnosis estimates decrease with a longer follow up, because this allows for 
the full deficit in the years after screening to manifest. 
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Table 3 (next page): Outcomes per model. Based on a simulated population of 10,000,000 
women. Excess-deficit is the difference of all breast cancer diagnoses (invasive and DCIS) for 
all ages with screening minus all breast cancer diagnoses (invasive and DCIS) for all ages 
without screening (diagnoses with screening in ages 50-100 and 50-70). The overdiagnosis 
estimates follow by dividing excess-deficit by the second and third columns. 
  
  Excess - Deficit per 100,000 
women of all ages 
Breast cancer diagnosis with 
screening in ages 50-100 per 
100,000 women 
Breast cancer diagnosis with 
screening in ages 50-70 per 
100,000 women 
Overdiagnosis estimate on a 
population level  
Overdiagnosis estimate on an 
individual level  
  Model 1  Model 2 Model 3 Model 1  Model 2 Model 3 Model 1  Model 2 Model 3 Model 1  Model 2 Model 3 Model 1  Model 2 Model 3 
2000 5.17 7.44 10.00 90.89 103.70 93.59 50.52 58.27 51.38 5.7% 7.2% 10.7% 10.2% 12.8% 19.5% 
2001 11.69 14.03 20.27 95.76 110.81 102.57 55.38 65.86 60.64 12.2% 12.7% 19.8% 21.1% 21.3% 33.4% 
2002 10.20 12.98 19.50 95.65 112.72 102.44 55.99 66.69 61.79 10.7% 11.5% 19.0% 18.2% 19.5% 31.5% 
2003 7.95 10.02 16.20 93.34 110.20 99.09 53.26 64.34 59.19 8.5% 9.1% 16.3% 14.9% 15.6% 27.4% 
2004 5.72 7.36 12.67 90.07 109.05 95.97 51.66 63.12 56.02 6.4% 6.7% 13.2% 11.1% 11.7% 22.6% 
2005 4.65 5.08 10.85 89.85 107.38 94.61 52.36 62.26 55.86 5.2% 4.7% 11.5% 8.9% 8.2% 19.4% 
2006 2.87 3.17 7.94 87.33 106.07 90.53 50.26 60.97 52.94 3.3% 3.0% 8.8% 5.7% 5.2% 15.0% 
2007 1.23 2.34 7.68 84.34 103.48 88.44 48.73 59.39 51.55 1.5% 2.3% 8.7% 2.5% 3.9% 14.9% 
2008 3.23 3.23 8.42 85.98 104.11 89.68 50.84 61.19 53.24 3.8% 3.1% 9.4% 6.3% 5.3% 15.8% 
2009 2.96 3.62 6.81 85.87 103.66 88.15 50.49 61.03 52.54 3.5% 3.5% 7.7% 5.9% 5.9% 13.0% 
2010 3.41 3.09 7.11 85.29 103.23 88.55 51.52 61.66 54.25 4.0% 3.0% 8.0% 6.6% 5.0% 13.1% 
2011 1.39 2.90 7.24 87.67 106.91 88.32 53.40 65.07 54.47 1.6% 2.7% 8.2% 2.6% 4.5% 13.3% 
2012 3.27 2.94 7.37 87.74 104.84 90.30 53.80 63.61 55.87 3.7% 2.8% 8.2% 6.1% 4.6% 13.2% 
2013 1.97 1.99 5.80 89.00 105.55 91.39 54.97 65.44 56.30 2.2% 1.9% 6.3% 3.6% 3.0% 10.3% 
2014 0.66 2.80 6.30 89.36 107.05 93.25 53.84 65.24 56.79 0.7% 2.6% 6.8% 1.2% 4.3% 11.1% 
2015 2.21 1.87 5.95 92.11 111.10 95.73 56.54 67.93 58.80 2.4% 1.7% 6.2% 3.9% 2.7% 10.1% 
2016 1.80 2.61 7.67 96.26 114.15 97.49 58.96 70.20 59.53 1.9% 2.3% 7.9% 3.1% 3.7% 12.9% 
2017 3.32 3.88 6.77 96.45 116.40 99.44 59.39 70.27 61.78 3.4% 3.3% 6.8% 5.6% 5.5% 11.0% 
2018 2.39 4.02 8.22 98.02 118.91 100.83 60.56 72.99 62.06 2.4% 3.4% 8.2% 3.9% 5.5% 13.3% 
2019 1.35 0.55 5.88 100.36 120.79 103.21 59.81 72.42 62.80 1.3% 0.5% 5.7% 2.2% 0.8% 9.4% 
2020 1.53 0.55 6.15 101.58 125.38 105.74 61.97 75.53 64.38 1.5% 0.4% 5.8% 2.5% 0.7% 9.6% 
2021 2.28 3.73 7.70 104.89 125.02 107.24 63.55 77.10 66.08 2.2% 3.0% 7.2% 3.6% 4.8% 11.7% 
2022 3.07 2.47 7.07 108.83 130.04 108.68 65.18 77.02 65.82 2.8% 1.9% 6.5% 4.7% 3.2% 10.7% 
2023 1.23 2.37 5.33 106.60 131.56 112.41 63.45 79.41 66.37 1.2% 1.8% 4.7% 1.9% 3.0% 8.0% 
2014-2023 19.8 24.85 67.04 994.46 1200.42 1024.01 603.26 728.1005 624.42 2% 2% 7% 3% 3% 11% 
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DISCUSSION 
In this study, we confirmed that the steep increase in breast cancer incidence cannot be 
explained by mammography use and HRT use alone. We explained the additional increase 
with a relative risk of 1.75 for women aged 87 and younger in the years 1997-2006. 
The increase in breast cancer incidence in 1994 occurred three years after the introduction 
of mammography, and was therefore probably the cumulative result of increased HRT use 
and increasing mammography use. The relative decline in 1997 coincided with a relative 
decline of DCIS. Since this is a condition strongly associated with mammography, it seems 
likely that this change is the result of the fact that by then many women have had a 
prevalence screening; the increase in incidence as a result of detection of prevalent tumours 
was decreasing. The rapid decrease in 2003 coincided with the stabilization of 
mammography use, and followed three years after the rapid decrease in the use of HRT, and 
thus was most likely a combined result of these factors.  
In order to fit our model to the data we increased the background risk, similar to the cohort 
effect used by Weedon-Fekjaer(11). This is also in line with the findings of Duffy et al. who 
found that not all increase in incidence could be explained by extrapolating an age-specific 
period effect model or an age-adjusted common period effect based on data prior to the 
introduction to screening, to the years after the introduction of screening, and that this 
excess incidence could not be attributed to screening alone (10). The problem with 
calibrating the relative risk to the empirical incidence is that we deny the possibility that all 
of this increase could be due to overdiagnosis. Therefore we included the analysis with the 
model with long dwell times, which aims to attribute the excess incidence to overdiagnosis. 
This model however does not fit the data as well, and the relative risk is externally validated 
by the findings of Weedon-Fekjaer, who found a similar cohort effect.(11) They found an 
increase in risk from 0.74 to 1.25, a factor 1.7, which  correlates nicely to our RR of 1.75.  
A possible explanation for the unaccounted increase in incidence may be that Norwegian 
women may have a larger additional risk of breast cancer due to HRT use. This could be the 
result of differences in doses, combinations of hormones in preparations, and duration of 
use (8, 11). We used a relative risk of 2.2, which is among the highest in literature, and still 
could not fully explain the increase in incidence.  
Miscellaneous factors may be responsible. A possible association has been suggested 
between breast cancer and age at menarche, age at first birth, physical activity, alcohol, and 
general change in life style factors. Number of children may play a role, however fertility 
rates in Norway have been stable and the rate of childlessness at the age of 45 is relatively 
low (30). Also refraining from breast feeding has been suggested, however lactation is very 
common in Norway(31). Tall women may also be at greater risk, Norwegians are among the 
tallest people of the world (32). 
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In light of this discussion it would be interesting to look at the histopathological 
characteristics of breast cancers detected by screening, vs breast cancers detected outside 
the screening programme. A previous study showed a more favourable stage-distribution 
among participants in the NBCSP. This indicates early detection on one hand, but may also 
be the result of the detection of slow growing tumours with low malignant potential (33). 
If we do not assume an increased background risk, our model is comparable to the study of 
Falk et al (14). They showed that the estimated incidence rate ratio due to screening is 
approximately 1.86 for prevalence mammography (women attending screening have an 
incidence rate of 1.86 times that of women who do not attend screening). The incidence 
rate ratio was 1.46-1.69 for incidence mammography and 0.60-0.92 for women aged 70-80 
(after the end of screening has been reached). We compared the impact of HRT and 
mammography, based on literature, to the background incidence, which is an extrapolation 
of trends in the years 1970-1990. The overdiagnosis estimate from this model was low for 
the period 2014-2023. The estimates in the early 2000s corresponded to the estimate made 
by Falk et al. (11-21%, results not shown). 
When we attributed all excess increase in incidence to the detection of prevalent, slow 
growing tumours (assuming no regression of invasive disease), this provided a poorer fit to 
the incidence data, but it also provided the highest estimate of overdiagnosis rate. The 
results stated in the report of the Research Council of Norway indicated their overdiagnosis 
estimates to be within this range. (34) (34) (34) (34) 
Our overdiagnosis estimates in the early 2000s were in line with earlier estimates published 
for the same time periods (14, 17). These estimates were between 10 and 25%. Our 
overdiagnosis estimates for later years were much lower and emphasised the need for 
sufficient follow-up before calculating overdiagnosis, to allow the complete occurrence of 
the deficit (12).  
CONCLUSION 
The increase in breast cancer incidence in Norway cannot be fully explained by 
mammography screening and HRT use. We calculated models to estimate the impact of an 
increased back ground incidence and a large impact of screening. We estimate 
overdiagnosis rates at 2-3%, with a maximum estimation of 7-11% for the period 2014-2023. 
It will be very interesting to see what will happen to breast cancer incidence in the 
upcoming years, as we move further from the massive use of HRT and have a prolonged 
steady state screening programme in place. 
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ABSTRACT 
The Norwegian Breast Cancer Screening Programme (NBCSP) has a nation-wide coverage 
since 2005. All women aged 50-69 years are invited biennially for mammography screening. 
We evaluated breast cancer mortality reduction and performed a cost-effectiveness 
analysis, using our microsimulation model, calibrated to most recent data. The 
microsimulation model allows for the comparison of mortality and costs between a 
(hypothetical) situation without screening and a situation with screening. Breast cancer 
incidence in Norway had a steep increase in the early 1990s. We calibrated the model to 
simulate this increase and included recent costs for screening, diagnosis and treatment of 
breast cancer and travel and productivity loss.We estimate a 16% breast cancer mortality 
reduction for a cohort of women, invited to screening, followed over their complete 
lifetime. Cost-effectiveness is estimated at NOK 112,162 per QALY gained, when taking only 
direct medical costs into account (the cost of the buses, examinations, and invitations). We 
used a 3.5% annual discount rate. Cost-effectiveness estimates are substantially below the 
threshold of NOK 1,926,366 as recommended by the WHO guidelines. For the Norwegian 
population, which has been gradually exposed to screening, breast cancer mortality 
reduction for women exposed to screening is increasing and is estimated to rise to 
approximately 30% in 2020 for women aged 55-80 years. The NBCSP is a highly cost-
effective measure to reduce breast cancer specific mortality. We estimate a breast cancer 
specific mortality reduction of 16 to 30%, at the cost of 112,162 NOK per QALY gained. 
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INTRODUCTION 
The Norwegian Breast Cancer Screening Program (NBCSP) was initiated in 1996 and 
gradually expanded to provide nation-wide coverage in 2005.(1) All women aged 50-69 
years, based on the Central Population Register, are invited every other year for 
mammography screening. Breast cancer incidence increased in the early 1990s, as a result 
of screening, the use of hormone replacement therapy and increasing back ground risk.(2, 3)  
The cost-effectiveness of the Norwegian screening program and the achievable breast 
cancer mortality reduction was reported by Norum and Wang et al. in 1999 and 2001 
respectively.(4, 5) Norum used an estimated 30% reduction in breast cancer deaths at the 
cost of £8,561 (12,971 USD at the exchange rate in 2000) per life year saved. Wang 
calculated several scenarios at different positive predictive values of the program. At a 
maximum estimated breast cancer mortality reduction of 20%, the costs were 5,622 USD 
per life year saved, and at a maximum estimated mortality reduction of 40% the costs were 
2,813 USD per life year saved.  
The use of mass screening programs for breast cancer has been under debate since 2001, 
when the Cochrane collaboration first published a systematic review on the topic.(6) Kalager 
investigated the mortality reduction, by comparing historical groups, based on the 
staggered implementation of the NBCSP. They found a mortality reduction of only 10%. (7, 
8) The focus of the debate is on the estimated breast cancer mortality reduction and the 
estimated overdiagnosis rate. These estimates vary greatly depending on the analysis 
chosen to correct for lead time and historical bias, the minimal amount of follow up to allow 
for full dwell time, and the definition of denominator and numerator(9-11). Historical bias 
occurs when incidence rates rise, independent of screening, due to increases in background 
incidence. Recently the Research Council of Norway reviewed the literature and had several 
analyses conducted on breast cancer mortality reduction. They found estimates between 7 
and 30%. They concluded based on the quality of the studies that a mortality reduction of 
20-30% is a reasonable estimate.(12)  
In 2008, the Research Council of Norway set up a project to evaluate the NBCSP. “The 
objective of the research-based evaluation was to investigate whether the NBCSP fulfils its 
intentions and purpose to estimate.”(12) This study was done as a part of this project. The 
council concluded that “The estimates indicate that the Norwegian program performs on 
average at the level that could be expected from the majority of previous reviews of the 
mammography screening trials.” This is in line with the conclusions of the International 
Agency for Research on Cancer, as published in their handbook.(13)  
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The aim of the study is to estimate the breast cancer mortality reduction due to screening 
and to calculate cost-effectiveness in the NBCSP. We established trends in breast cancer 
mortality, using joinpoint analysis, and simulated the NBCSP using microsimulation to 
estimate expected mortality reduction as a result of screening, and calculate cost-
effectiveness by QALY gained for women invited to screening, using direct and indirect costs 
of screening and treatment. 
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MATERIALS AND METHODS 
JOINPOINT ANALYSIS 
Data on breast cancer mortality were obtained from Nordcan.(14) Breast cancer mortality 
was given as a crude rate and calculated by year. We evaluated breast cancer mortality 
trends with joinpoint analysis, with the tool provided on the Surveillance research website 
of the National Cancer Institute.(15) We analysed breast cancer mortality in women aged 
55-80 and 0-100 years in the years 1984-2011, and allowed for a maximal of 5 joinpoints. 
MODEL DESCRIPTION 
The MIcro-simulation SCreening ANalysis (MISCAN) model simulates a female population by 
simulating individual life histories from birth to death.(16-18) The age-composition of the 
study population was determined by calibrating the model with the birth table and life table 
from Statistics Norway from 2005. Each woman has a probability of an onset of breast 
cancer, based on incidence rate, which we obtained from the Cancer Registry of Norway. 
The first transition from disease free to preclinical disease is dependent on the onset. Each 
preclinical disease stage has two possibilities: the disease can be clinically detected or the 
disease can have a transition from the first preclinical disease state to the next preclinical 
disease state. Preclinical ductal carcinoma in situ (DCIS) can also regress back to normal. 
Progression of breast cancer is modelled in a pseudo Markov transition model (Figure 1). In 
the model any woman can only develop breast cancer once in her life history. Treatment is 
implemented in the model based on data from the Dutch screening organisations and the 
Eindhoven Cancer Registry.(19, 20) Early detection has an improved prognosis and therefore 
reduced mortality. Breast cancer mortality is stage-dependent and based on the data from 
the Swedish breast cancer screening trials.(21, 22) Screening is superimposed on the natural 
history. Data from the Cancer Registry of Norway on coverage and attendance, by age (we 
used five year age groups), year (1990-2010), and stage for the whole country were used to 
model screening attendance by age and year. 
We performed two runs; one population run, based on the Norwegian composition of the 
population in 2005 (used to estimate current and future breast cancer mortality reduction in 
the population), and a cohort run, based on an imaginary cohort of 10,000,000 women all 
born in 1955, with complete follow-up to 2055. The model assumes all women die at the 
age of 100 years at the latest. In the cohort run we only included the NBCSP, and not 
opportunistic screening for the cost-effectiveness analysis. All output used in the cost-
effectiveness analysis is from the cohort run. 
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Figure 1. Graphic presentation of the transitions in the MISCAN model. DCIS; ductal 
carcinoma in situ, T1A; invasive breast cancer with a diameter of 1-5 mm., T1B; invasive 
breast cancer with a diameter of 6-10 mm.,T1c; invasive breast cancer with a diameter of 
11-20mm., T2+; invasive breast cancer with a diameter greater than 21 mm. Every woman 
has a chance of having an onset of breast cancer. This may be a DCIS or a T1A tumour. From 
DCIS she may regress back to not having breast cancer, be clinically or screen-detected or 
progress to T1A. The possibility of regression exists only in the DCIS state. 
We performed two runs; one population run, based on the Norwegian composition of the 
population in 2005 (used to estimate current and future breast cancer mortality reduction in 
the population), and a cohort run, based on an imaginary cohort of 10,000,000 women all 
born in 1955, with complete follow-up to 2055. The model assumes all women die at the 
age of 100 years at the latest. In the cohort run we only included the NBCSP, and not 
opportunistic screening for the cost-effectiveness analysis. All output used in the cost-
effectiveness analysis is from the cohort run. 
ADDITIONAL DATA 
Screening outside the NBCSP was included based on the data published by Lynge et al, 
which took place between 1983 and 2008.(23) HRT-use was implemented as an additional 
risk. The frequency of HRT use was estimated using data from the Norwegian Prescription 
Database by ten year age group from 1987 to 2006, from the Norwegian Institute of Public 
Health.(24) We used a relative risk of 2.2 to have an onset of breast cancer for HRT-users, 
the relative risk found in previous studies. (3) 
Observed incidence rates were higher than the estimates made by the model based on 
mammography use and HRT-use alone. To allow for the steep increase in breast cancer 
incidence in Norway we added an additional risk factor of 1.75 in the years 1997-2010 for all 
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women aged 30-100. The additional risk factor creates more onsets and thereby increases 
breast cancer incidence. This is similar to the effect of HRT-use, but stronger on a population 
level. A detailed description of the model can be found in a previous paper, which is in 
press. (25) 
BREAST CANCER MORTALITY REDUCTION 
We compared the observed breast cancer mortality to the estimated mortality rate in the 
model (Figure 2). To calculate mortality reduction we compared mortality rate in the 
situation with screening to the mortality rate without screening. We estimated the expected 
breast cancer mortality reduction from 2014 to 2034. 
The survival rate after treatment was modelled on international sources and the Swedish 
randomized controlled trials. Details are described in the article of de Gelder et al. (20) 
COSTS AND EFFECTS  
Direct medical costs including costs of screening, diagnostics and treatment were used in 
this analysis. The direct non-medical costs of screening are the costs for travel for screening 
and follow-up examination, and the indirect costs are the costs as a result of productivity 
loss (societal perspective). All of these costs were obtained from the University of Oslo.(26)  
The cost of screening was calculated by multiplying the number of visits with the average 
screening costs. The average costs per woman attending screening are 812 NOK (83.72 
Euro), when only taking direct medical costs into account, or 1,262 NOK (130.11 Euro) when 
also taking direct non-medical costs and indirect costs (productivity loss) into account. (26) 
The number of false positives was calculated using the positive predictive value of 
screening. This is 12.5% in Norway in the years 1996-2005; for every screen detected cancer, 
8 women were evaluated after a recall.(27)  
To calculate the cost of a diagnosis for a woman who has not been screened we calculated 
the number of women examined per diagnosis. Positive predictive value of a diagnostic 
mammography is 59%.  
(28) We used the number of false positives as a measure for the number of women 
undergoing a diagnostic procedure following a diagnostic mammography. The detection 
rate for symptomatic women is 10.3/1,000 examinations.(29) 
The costs for treatment according to stage were provided by the University of Oslo.(30) The 
costs are shown in Table 1. The initial costs are the costs in the first 6 months since 
diagnosis. If a woman survives she will have continuous care up to 10.5 years after 
diagnosis. If she dies of breast cancer she will have six months of terminal costs. If she dies 
of other causes within 10 years since diagnosis, she will have continuous care up to her 
death.Treatment costs were given by disease stage: DCIS, TNM I, TNM II, TNM III, and TNM 
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IV; and in three time frames: initial treatment, for the first six months since a diagnosis; 
continuous care, from the seventh month up to ten years and six months since diagnosis; 
and terminal care, the last six months prior to death from breast cancer. The probability of 
receiving a certain treatment was based on data from the Norwegian Cancer Register. 
 
Table 1. Estimated costs for treatment by disease stage and period.(30) 
Initial costs for first 12 months following diagnosis: 
  DCIS TNM1 TNM2 TNM3  TNM4 
            
Mean: 70,642.63 106,868.50 214,542.19 263,548.04 247,895.15 
95% CI: 65,000-77,000 102,000-111,000 
205,000-
224,000 
232,000-
294,000 
200,000-
301,000 
SE: 3 2.3 4.8 16 26 
            
Continuous care per two months following the first 12 months after diagnosis: 
  DCIS TNM1 TNM2 TNM3  TNM4 
            
Mean: 1,034.52 1,643.52 3,125.05 4,347.90 9,111.90 
95% CI: 837-1,240 1,481-1,814 2,862-3,389 3,022-5,849 6,945-11,539 
SE: 102 84 133 721 1.158 
            
Terminal costs (last 6 months before death): 
  DCIS TNM1      TNM2     TNM3       TNM4 
            
Mean: 174,504.20 133,712.30 168,846.80 138,925.30 182,511.20 
95% CI: 124,000-234,000 
106,000-
161,000 
153,000-
186,000 
97,000-
181,000 
142,000-
226,000 
SE: 28 14 9 21 21 
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Women who died of breast cancer within six months since their diagnosis were assumed to 
only have terminal costs. Women who died of breast cancer between 6 months and ten 
years since their diagnosis were assumed to have initial costs, some continuous care costs, 
and terminal costs. Women who died of breast cancer after 10.5 years were assumed to 
have initial costs, all continuous care costs, and terminal costs.  
We assumed that women who died from other causes did not receive terminal breast 
cancer care. If these women died within the first six months since their diagnosis, we 
calculated the cost of treatment for the time they were alive since their diagnosis. The 
treatment costs for a woman who died from other causes after six months since diagnosis 
was calculated by six months of initial care and continuous care for the time they were alive 
in the period of continuous care.  
Because we had costs per timeframe, we used model output on cause of death, number of 
deaths in the first six months after diagnosis, between six months and 10.5 years after 
diagnosis, and after 10.5 years after diagnosis. We also used number of diagnosis per stage, 
the lifeyears in each timeframe and number of visits. 
The effect of screening was estimated by calculating the life years gained (LYG). We 
calculated quality adjusted life years (QALYs) by adjusting life years with utilities, such as 
described by Haes et al.(31) We adjusted for the screening, diagnostic phase, therapy, 
disease free survival, terminal illness and palliative care. Based on the data from the 
Norwegian Cancer Registry we calculated the probability of a certain event by disease stage, 
and multiplied the number of life years in every disease stage with the probability and the 
utility. The summarized utility loss and quality adjustment are in table 2 (Table 2). From left 
to right the columns list the utility loss based on the publication of Haes, the number of 
events per 100,000 women years in the situation without screening, and in the situation 
with screening, the difference between these two situations, the average duration 
associated with an event, the resulting qualitity of life adjustment, the total of life years 
gained in the situation with screening, the total loss of quality of life, and finally the quality 
of life adjusted life years gained. Costs and effects were calculated for a cohort of 10 million 
women born in 1955 and followed until death. Both effects and costs were discounted at 
3.5% per year to take time preference into account (NICE).(32) The cost-effectiveness ratio 
(CER), costs per QALY compared to a situation without screening, was calculated. 
  
Table 2. Utilities and quality adjustment. LY: life years, QALY: quality adjusted life year. 
Health stage 
Utility 
loss 
No 
screening Screening Difference 
Duration 
§ 
Quality 
adjustment 
LY 
gained 
Quality of life 
lost 
QALY 
gained 
Per 100,000 women aged 50 years 
in 2005 with complete follow-up:                   
Screening 0.01   586,555 586,555 0.0962 67.68       
Diagnostic phase  0.11 14,025 14,157 132 0.0192 1.33       
Initial surgery 0.13 9,913 10,000 87 0.1667 1.92       
Initial radiotherapy 0.20 6,815 6,797 -18 0.1667 -0.60       
Initial chemotherapy 0.28 2,367 2,134 -233 0.5000 -32.93       
Initial hormonal therapy 0.18 4,098 3,760 -338 2.0000 -121.80       
                    
Terminal illness 0.71 6,002 5,611 -391 0.0833 -23.18       
                    
Palliative therapy + chemotherapy 0.47 1,554 1,358 -196 0.3333 -30.70       
Palliative therapy + radiotherapy 0.42 4,156 3,861 -296 0.0833 -10.32       
Palliative therapy + surgical therapy 0.38 5,973 5,582 -391 0.0962 -14.40       
Palliative therapy + hormonal 
therapy 0.34 2,646 2,346 -300 1.1667 -118.05       
              6,390.00 304.95 6,085.05 
In life years:                   
Disease free 2m-1y mastectomy 0.16 84 78 -6 0.8333 -0.80       
Disease free 2m-1y breast 
conserving 0.09 149 139 -10 0.8333 -0.72       
In life years:                   
Disease free >1y mastectomy 0.05 49,674 53,309 3,636 1.0000 192.68       
Disease free >1y breast conserving 0.04 90,056 99,927 9,871 1.0000 394.83       
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RESULTS 
JOINPOINT ANALYSIS 
Crude breast cancer mortality rate for women aged 55-80 rose steadily from 1981 to 1995. 
In 1995 a significant difference in the annual percent change was found, when breast cancer 
mortality rates began to drop, coinciding with the start of breast cancer screening, but five 
years after opportunistic screening came up. For the age group 0 to 100 breast cancer 
mortality was already declining from 1984, in 1994 a significant percentage change was 
seen, and from 1994 breast cancer mortality decreased more rapidly (Figure 2). 
 
Figure 2. Joinpoint analysis and MISCAN model estimate of breast cancer specific mortality 
rate per 100,000 women aged 0-100 and 55-80. 
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MORTALITY 
Based on a population run (i.e. a realistic representation of the population of Norway, 
gradually exposed to screening) of women aged 55-80 in the years 2014-2034. Because we 
anticipate that mortality will decrease up to 2022 we chose a long follow-up. 2014 was 
chosen because the program had been nation-wide from 2004, so in 2014 it had been in 
place for 10 years, and there was a steady situation. Breast cancer mortality reduction was 
expected to increase up to the year 2022. The reduction was maximally 30%, compared to a 
situation without screening. The model underestimates the total mortality reduction (Figure 
2). 
COST-EFFECTIVENESS ANALYSIS 
Results are given per 100,000 women (Table 3). Our model showed a life-time breast cancer 
mortality reduction of 16% for the entire cohort, with a number needed to screen of 1,470 
(total number of screens divided by breast cancer deaths prevented). We estimated 399 
breast cancer deaths prevented, with approximately 10 deaths prevented annually in the 
age group 49-100, with a maximum number of 20 deaths prevented in the year 2027 when 
the cohort is 72 years. The number of QALYs gained was 6,085 /100,000, the number of life-
years gained was 6,390, there was a loss of 5% when calculating QALYs from life-years.  
The costs per QALY gained are given for two calculations: only including the direct medical 
costs of screening (NOK 812); and including all direct medical, non-medical and indirect 
costs of screening (NOK 1,262). Cost effectiveness was NOK 112,162 for only direct medical 
costs and NOK 189,557 for all costs. 
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Table 3. Effects, costs and breast cancer mortality reduction per 100,000 women, aged 49 in 
2004, with complete follow-up (to 2055), with screening in the NBCSP. QALY: quality 
adjusted life years. Only the incremental costs/QALY gained are given with a 3.5% annual 
discount. NOK: Norwegian Krones. 
  Without screening With screening 
 
    
Screening tests/100,000 - 586,555 
      
Health effects      
Cancer diagnosed  9,968 10,062 
Screen detected cancers - 2,323 
False positives 16,945 31,743 
Breast cancer deaths  2,425 2,026 
QALY gained  - 6,085 
      
Mortality reduction - 16% 
Number needed to screen - 1,470 
      
Costs (in NOK x1,000)     
Direct medical costs of screening - 476,283 
Total costs of screening - 740,232 
Diagnosis 77,214 119,937 
Treatment 2,515,048 2,324,794 
Total costs  based on direct medical costs of 
screening 
2,592,263 2,921,013 
Total costs  based on total costs of screening   3,184,963 
      
Incremental costs based on direct medical costs of 
screening 
- 328,750,348 
Incremental costs based on total costs of screening   592,700,098 
      
Cost-effectiveness     
      
Direct medical costs of screening     
Incremental costs/QALY gained, discounted in NOK   112,162 
      
Total costs of screening     
Incremental costs/QALY gained, discounted in NOK   189,557 
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DISCUSSION 
The NBCSP is cost-effective even when taking direct non-medical and indirect costs of 
screening into account, assuming a threshold for cost-effectiveness of 3 times the gross 
domestic product (GDP) per capita (WHO guideline).(33) The GDP per capita in Norway was 
USD 99,636 in 2013 (The World Bank).(34) The exchange rate from USD to NOK on 
02/10/2014 was 6.44468. The cost-effectiveness threshold thus is 99,636 x 6.44468 x 3 = 
1,926,366 NOK. 
The costs of screening in Norway are relatively high compared to other countries; this is 
probably due to the fact that it is a geographically vast country with a relatively small 
population. The country has a very high welfare level, which results in a high cost-
effectiveness threshold. A recent report in the NEJM advocated the use of a threshold of 
100,000 USD (NOK 644,680).(35) Therefore, the NBCSP is also cost-effective when using this 
threshold. This analysis predicts that breast cancer screening reduces breast cancer 
mortality at a cost-effective price.  
With regards to costs of the program in terms of overdiagnosis, the independent UK review 
found an estimate of overdiagnosis of 11% acceptable, we found 2-3% overdiagnosis in a 
separate analysis.(12, 36)  
Norum found a lower estimate of cost-effectiveness of NOK 89,325 (calculated from the 
published £8,561 with the current exchange rate of 10.4339).(4) At the time of their analysis 
no data on breast cancer mortality reduction was available and they assumed a breast 
cancer mortality reduction of 30%, accordant with the aim of the Norwegian Mammography 
Project. The results are difficult to compare, since they discounted by 5% per year and they 
did not adjust for quality of life.(4) 
The cost-effectiveness analysis of Wang estimated much lower costs per life-year gained 
(NOK 24,167, calculated from the published USD 3,750 with the current exchange rate). 
These costs did not include treatment costs and did not adjust for quality of life.(5) They 
discounted with 4.5% per year.(1)  
Cost-effectiveness is not the only argument to implement or continue a screening 
programme. There is a need for public support based on proper information on harms and 
benefits. We estimated breast cancer mortality reduction of up to 30% and an acceptable 
overdiagnosis rate.(12)  
Crude breast cancer mortality rate of women of all ages had a sharp decline in 1994, which 
cannot be satisfactorily explained by mammography use. The drop in mortality reduction is 
too soon after the introduction of mammography outside the NBCSP and too large, given 
the fact that also opportunistic screening has gradually increased, to be the result of 
opportunistic screening. This decline is probably the result of adjuvant therapy and 
improvements in overall survival rates, possibly enhanced by the “re-organization of the 
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breast cancer health care system”.(37) In the second half of the 1980s and the first half of 
the 1990s combined multi-agent chemotherapy and Tamoxifen were being used more 
frequently.(38) Treatment effects are included in our model. The fact that breast cancer 
mortality keeps decreasing despite increases in incidence, indicates that over the years 
following the sharp decline multiple factors have contributed to this decrease. 
We found an estimated maximal mortality reduction in 2022 of 30% increasing breast 
cancer mortality rate for the Norwegian population, gradually having been exposed to 
screening. This is in line with the estimated breast cancer mortality reduction of 
approximately 28% found by Weedon-Fekjaer.(39) In the model we used the estimated 
effects of screening and treatment to establish mortality reduction. In reality mortality 
reduction is even greater. Because we do not know what causes the greater reduction in 
mortality we used a conservative estimate of mortality reduction based on screen effects 
and treatment effects. 
The analysis is based on the outcomes of the MISCAN model. There are some limitations to 
the model. First the model assumes an increased background risk for breast cancer, which 
cannot be fully explained.(2, 3, 12) Second we performed analysis on a cohort run. The 
benefits of a cohort run is that all women in the model are the same age, and that follow up 
for the entire population is complete. The drawback of a cohort run is that it may 
overestimate the effects of a program, because in an actual population not all women are 
exposed to screening at the same age, and follow up is never complete for all women at the 
same time.  
Another limitation of the study is that the data on utilities is from a period when treatment 
was different from now. Recent figures are not readily available.  
In conclusion, we estimate a breast cancer mortality reduction of 16% in women aged 55-80 
years, with a projected maximal reduction in 2022 of 30%. The NBCSP is cost-effective in 
preventing breast cancer specific mortality. 
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CHAPTER 7: 
GENERAL DISCUSSION  
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RESEARCH QUESTIONS AND OUTLINE OF THIS THESIS: 
THE DETECTION OF DCIS SEEMS TO BE ASSOCIATED WITH A HIGHER 
RISK OF OVERDIAGNOSIS. WHAT IS THE IMPACT OF THE TRANSITION TO 
DIGITAL MAMMOGRAPHY ON THE AMOUNT OF DCIS DIAGNOSED WITH 
SCREENING (CHAPTER 2)? 
We found that during and after the transition of the Dutch breast cancer screening program 
from film screen mammography to digital mammography, the program had a higher 
detection level. Significantly more DCIS and very small tumors were found with digital 
mammography.  
An earlier modeling study showed that digital mammography screening would further 
reduce breast cancer mortality by 4.4%, at a 21% increased overdiagnosis rate.(1) 
To put these results in an international perspective: In 2015 the International Breast Cancer 
Screening Network (IBCSN) published a paper reporting performance indicators of 15 
different regions, data were collected between 2004 and 2008.(2) The Netherlands has a 
low detection rate compared to Norway and Denmark, but at the same time an average 
detection rate when compared to the overall rate of the 15 regions that had provided data 
to the report. The proportion of DCIS in the Dutch program is significantly higher than the 
average of the regions in the report, but lower than the percentage of DCIS in Norway 
(Table 1). Recall rate was not mentioned in the report. 
We also compared detection rate, recall rate and percentage of DCIS in the Dutch program 
to data from the United Kingdom, as provided in the NHS evaluation report.(3) In the United 
Kingdom 90% of all screening units had a full field digital mammography set in 2009. The 
detection rate in the UK program in 2009, for women aged 45-74, was also higher than it 
was in the Netherlands. Recall rate was 8.2/1,000 screens in 2009 in women aged 45-74, 
compared to an average of 5.9/1,000 screens in women aged 50-74 in the Netherlands 
between 2004 and 2010 with digital mammography.  
The detection rate is not only dependent on the sensitivity of the screening program, but on 
the background incidence of breast cancer as well. In countries with a higher incidence of 
breast cancer, the program will detect more breast cancer.  
The Dutch program managed to achieve an average detection rate even with relatively low 
recall rates. The Dutch program detects an average amount of DCIS.  
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Table 1. Detection rate (DR) per 1,000 screens and proportion of DCIS in percentages in the 
Netherlands, compared to results in the Danish, Norwegian and UK program. IBCSN: 
International Breast Cancer Screening Network, NHS: National Health Services. 
  DR 95% CI % DCIS 95% CI 
IBCSN     
Denmark 7.13 (6.70 ; 7.57) 13.20% (11.14% ; 15.27%) 
Norway 5.27 (5.13 ; 5.42) 17.82% (16.76% ; 18.87%) 
Overall (IBCSN 
2015) 4.90 (4.85 ; 4.95) 15.24% (14.87% ; 15.62%) 
NHS evaluation 
report     
United Kingdom 8.17 (8.05 ; 8.30) 20.00% (19.39% ; 20.61%) 
The Netherlands 4.90 (4.73 ; 5.06) 16.39% (15.16% ; 17.61%) 
OVERDIAGNOSIS IS A WELL DEBATED ISSUE IN BREAST CANCER 
SCREENING, BUT NOT IN SCREENING FOR CERVICAL CANCER SCREENING. 
IS THERE OVERDIAGNOSIS IN CERVICAL CANCER SCREENING, AND HOW 
DOES THIS RELATE TO THE OVERDIAGNOSIS RATE IN BREAST CANCER 
SCREENING (CHAPTER 3)? 
We calculated estimates for overdiagnosis rate in cervical cancer screening and in breast 
cancer screening and found that the cervical cancer screening also yields quite some 
overdiagnosis. In breast cancer screening the detection of pre-invasive disease (DCIS) adds 
to the incidence of breast cancer. In cervical cancer screening the detection of pre-invasive 
disease (CIN) is not counted in the incidence of cervical cancer. Both DCIS and CIN warrant 
treatment. The treatment of pre-invasive disease aims to prevent the occurrence of 
advanced disease and cancer related mortality. 
In breast cancer screening DCIS constitutes an early phase of breast cancer. Not all DCIS will 
progress to invasive disease within a woman’s lifetime. The mortality rate from breast 
cancer in women with DCIS is low.(4) Treatment of DCIS however is extensive and includes 
(partial) mastectomy and sometimes radiation therapy. The burden of overdiagnosis in 
breast cancer is considered substantial.  
In the cervical cancer screening program CIN is practically the only disease detected with 
screening.(5) In cervical cancer, pre-invasive disease is not considered a cancer diagnosis. 
The detection and elimination of pre-invasive disease prevents the occurrence of cancer at a 
later stage in life. One could argue that this is a late form of primary prevention. Even in the 
setting of cervical cancer screening however, some women will be diagnosed and treated 
unnecessarily. Some of the CIN lesions detected at population-based screening would have 
never developed into cervical cancer, and never become clinically apparent in the woman’s 
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lifetime. The treatment for CIN is not very invasive and the occurrence of complications is 
rare. However, treatment for CIN may be associated with preterm delivery, low birth 
weight, caesarean section and preterm rupture of the membranes in future pregnancies.(6) 
Because the number of lesions detected and treated is substantial, 5,037 screen detected 
CIN/ 100,000 women, this still constitutes a substantial burden.  
WHAT IS THE IMPACT OF DCIS ON OVERDIAGNOSIS ESTIMATES IN 
BREAST CANCER SCREENING (CHAPTER 4)? 
We found that the distribution of DCIS differentiation grades does not differ between 
screened women and women who had never attended population-based screening. The 
majority of DCIS (50.9%) is high grade. The overdiagnosis rate of DCIS by grade on a 
population level varies from 60% in low-grade DCIS, to 56% in intermediate-grade DCIS, and 
45% in high-grade DCIS. The overdiagnosis rate of DCIS by grade on an individual level varies 
from 61% in low-grade DCIS, to 57% in intermediate-grade DCIS, and 45% in high-grade 
DCIS.  
The impact of detecting more DCIS with new screening strategies; i.e. digital mammography, 
and in the future possibly tomosynthesis, on overdiagnosis is significant. The best way to 
address this expected increase would be to tailor the treatment of DCIS to expected natural 
behavior. New strategies to predict natural behavior will include genetic profiling.  
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IS THE NORWEGIAN BREAST CANCER SCREENING PROGRAM 
GENERATING OVERDIAGNOSIS, AND AT WHAT LEVEL (CHAPTER 5)? 
We found that breast cancer incidence in Norway has been erratic. Many factors have been 
identified that influence breast cancer incidence, mostly hormone replacement therapy 
(HRT) and the increased use of mammography screening. These factors together, 
mammography use and HRT use, cannot satisfactorily explain the erratic course of breast 
cancer incidence in Norway. We were able to replicate the increase by increasing the 
background incidence with an increased relative risk, applicable to all women in the 
population under age 87, of 1.75, in the model. The added relative risk correlates nicely to 
the work of Weedon-Fekjaer et al. who found a similar relative risk in the cohort effect, 
increasing the RR from 0.74 to 1.25 (a factor of 1.7) to fit his age-period-cohort model to the 
observed data.(7) The difficulties in explaining the erratic course of breast cancer incidence 
have also already been pointed out by Duffy et al.(8)  
The cause of this large increase in background incidence remains unknown. Some argue that 
all of this increase must be the result of overdiagnosis in the NBCSP.(9) Our model has 
always been able to predict incidence rates of breast cancer very well in the Netherlands 
and also in other countries (Germany, Spain, US).(10-12) Therefore we have confidence in 
our disease model. We assume that the disease process from onset is the same in 
Norwegian women with breast cancer as in Dutch women with breast cancer. The earliest 
steep increase in breast cancer incidence occurred in 1995, prior to the introduction of 
screening. Therefore it is more plausible that the rate of onset is higher, than that the 
increase is incidence would be attributable to overdiagnosis.  
We estimate an overdiagnosis rate of 2% from a population perspective (number of excess 
diagnoses in a situation with screening divided by the total number of diagnoses in a 
situation with screening (screendetected and clinically detected) in women aged 50 to 100), 
and 3% from an individual perspective (number of excess diagnoses in a situation with 
screening divided by the total number of diagnoses in a situation with screening 
(screendetected and clinically detected) in women aged 50 to 75). This corresponds with 
overdiagnosis estimates in different countries, and is well within the range of what is 
deemed acceptable internationally.(13) 
The breast cancer mortality reduction caused by the NBCSP will increase in coming years, up 
to 105 breast cancer deaths prevented annually among women aged 55-80 in 2030. In 
accordance to the findings of Marmot et al. we found that a follow-up period of at least 10 -
15 years is necessary to appreciate the full impact of the screening on breast cancer 
mortality (Figure 1).(13) 
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Figure 1. Estimated breast cancer mortality reductions in Norway in 2010 to 2030 per 
100,000 women aged 55-80 invited to screening.  
IS THE NBCSP EFFECTIVE IN REDUCING BREAST CANCER MORTALITY 
DESPITE THE OCCURRENCE OF OVERDIAGNOSIS (CHAPTER 6)? 
We found that the NBCSP is highly cost-effective. The program achieved a breast cancer 
mortality reduction of 16% in a cohort of women aged 49 in 2004, with complete follow-up. 
The number of screen examinations necessary to prevent one breast cancer death (number 
needed to screen, NNS) is 1,470. The incremental costs per QALY gained is 112,162 NOK 
(11,884 EUR) for direct medical costs of screening, or 189,557 NOK (20,084 EUR) for direct 
medical and indirect costs of the screening. 
If we would assume that the increased breast cancer incidence in Norway is the result of 
overdiagnosis, the impact of a screening program would be less favorable. We can model 
this situation by assuming a high prevalence of slow growing tumors, or of tumors with a 
high potential for regression. If there is a large pool of dormant disease with little clinical 
significance, the detection of this disease will yield more overdiagnosis, without reducing 
breast cancer mortality.  
We modeled this situation by increasing the time of progression between onset of DCIS to 
early pre-clinical invasive disease (Table 3). Because the possibility of progression to the 
next stage is dependent on the probability of progression of the previous state, this will 
increase the time to progression between subsequent disease states as well. Now the model 
will predict a large amount of overdiagnosis and less prevented deaths per screen. We can 
use this model to calculate the most conservative estimate of the cost-effectiveness of the 
NBCSP (Table 4). 
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Table 3. Average duration of the stages (in years) for women aged 50 years in the model 
with the added relative risk and in the model with the exceptionally long dwell times. 
  
High relative 
risk 
Long dwell 
time 
DCIS 2.09 25.00 
T1a 0.09 0.01 
T1b 0.37 0.07 
T1c 0.82 0.76 
T2+ 0.89 0.65 
 
This scenario does not fit the observed incidence data as well as our added relative risk 
model, and is only provided for the purpose of a conservative estimate (Figure 2). Even in 
this scenario, the program is cost-effective considering the WHO guidelines (threshold 
1,926,366 NOK).  
  
142 
 
A 
 
B 
 
Figure 2: Breast cancer incidence rate/ 100,000 women aged 50-75 in Norway. A) Model 
with added relative risk, B) Model with extended dwell times to mimic a maximal amount of 
overdiagnosis.  
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Table 4. Effects, costs and breast cancer mortality reduction per 100,000 women, aged 49 in 
2004, with complete follow-up (to 2055), with screening only in the NBCSP, in a scenario 
where we ascribed most of the increase in breast cancer incidence to overdiagnosis. QALY: 
quality adjusted life years. Only the incremental costs/QALY gained are given with a 3.5% 
annual discount. 
  Without 
screening 
With 
screening 
Screening tests -         439,142  
      
Health effects      
Cancer diagnosed  4,249 4,933 
Screen detected cancers - 2,018 
False positives 7,224 21,097 
Breast cancer deaths  785 641 
QALY gained  - 1,120 
      
Mortality reduction - 18% 
Number needed to screen - 3,042 
      
Costs (in NOK x1000)     
Direct medical costs of screening - 356,583 
Total costs of screening - 554,197 
Diagnosis 32,916 74,681 
Treatment 1,046,853 1,015,458 
Total costs based on direct medical costs of 
screening 1,079,769        1,446,722  
Total costs based on total costs of screening   1,644,336 
      
Incremental costs based on direct medical costs of 
screening - 366,953,096 
Incremental costs based on total costs of screening   564,566,996 
Cost-effectiveness     
      
Direct medical costs of screening     
Incremental costs/QALY gained, discounted in NOK   327,637 
      
Total costs of screening     
Incremental costs/QALY gained, discounted in NOK   504,078 
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GENERAL DISCUSSION 
METHODOLOGY 
Many objections have been raised to modelling studies, arguing that the assumptions do 
not hold, or are not communicated transparently enough.(14) 
Modelling studies can compare hypothetical situations. This comparison is necessary in the 
evaluation of breast cancer screening, because screening is so widely adopted. There are no 
identical populations available that are not exposed to population-based screening. 
Comparisons have been made between historical groups, comparing the situation prior to 
the introduction of breast cancer screening to the current situation with breast cancer 
screening.(15) The disadvantage of this approach is the introduction of bias, caused by the 
fact that other circumstances have also changed in time (i.e. incidence, treatment, 
awareness, overall survival). Another way to address the problem is by comparing different 
countries that have introduced population-based screening at a different time.(16) In this 
comparison bias can occur because different countries have different overall health policies 
and overall survival rates. Also, in countries surrounded by countries that have a population-
based screening program in place, women are bound to have abundant opportunistic 
screening.  
The MISCAN model was first developed in 1985.(17) Since then the model has repeatedly 
been recalibrated with the latest available data, provided by the Netherlands Evaluation of 
the Breast cancer screening program Team (NETB) and the Dutch cancer registry. These 
calibration processes have always been reported and documented.(1, 18) Predictions made 
by the model in 1995 on breast cancer incidence rates in 2010 closely resemble the 
observed breast cancer incidence rate observed in 2010.(19) The assumptions made in 
modeling the disease process and the impact of screening have been extensively 
documented.(1) This documentation has been so precise that independent researchers have 
been able to closely replicate the results by recreating the model from the descriptions.(20) 
The details of the current MISCAN model can be found in appendix 1. 
The evidence derived from modeling studies can never compete with data provided by 
randomized controlled trials. The data provided by such trials however are incorporated in 
the model. Modeling studies provide us with a validated, reliable insight on the current 
performance of the breast cancer screening program, allow us to continually monitor if the 
screening program is still effective, and can translate screening trial results to different 
settings or screening protocols. Another advantage of a model is the ability to model 
complete follow-up. 
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DIGITAL MAMMOGRAPHY UPDATE 
Some time has passed since the evaluation of the transition from film screen to digital 
screen mammography in chapter 2. We compared our results from the years 2004-2010 to 
the now complete data from 2013. 
In the period 2010-2013, in women who were screened for the first time (aged 49-74), recall 
rate increased to 6.3%. This resulted in a high detection rate in these women of 8.5/1,000 
women screened. But the positive predictive value (PPV) remained low at 13.5% (Table 4). 
In women who were screened at a subsequent visit, within 2.5 years since their last visit 
(timely subsequent screen), recall rate remains low at 2.0%, with a detection rate of 
8.5/1,000 women screened, resulting in a PPV of 32.3% (Table 5 and 6).  
The proportion of DCIS in all detected malignancies is high in first screens with 31%, which is 
higher than it was in 2004-2010 (25%). Among malignancies detected at timely subsequent 
screens the proportion of DCIS is unchanged at 21%.  
Table 5. Recall rate, detection rate, and positive predictive value of the Dutch screening 
program in 2013 and in 2004-2010 in women screened for the first time. PPV: positive 
predictive value.  
  2004-2010 2013 
  
Point 
estimate 95% CI 
Point 
estimate 95% CI 
Recall rate (%) 2.8 (2.70 ; 2.80) 6.3 (6.28 ; 6.37) 
Detection Rate  
(per 1,000 women screened) 
5.2 (4.99 ; 5.41) 8.5 (8.39 ; 8.70) 
PPV (%) 20.8 (20.03 ; 21.52) 13.5 (13.45 ; 13.57) 
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Table 6. Recall rate, detection rate, and positive predictive value of the Dutch screening 
program in 2013 and in 2004-2010 in women with a timely subsequent screening (within 2.5 
years since the previous screening). PPV: positive predictive value.  
  2004-2010 2013 
  Point estimate 95% CI 
Point 
estimate 95% CI 
Recall rate (%) 1.7 (1.72 ; 1.77) 2.0 (1.97 ; 2.02) 
Detection Rate  
(per 1,000 women 
screened) 
6.2 (6.07 ; 6.37) 6.5 (6.31 ; 6.58) 
PPV (%) 
32.5  (34.73 ; 
36.14) 32.3 (32.20 ; 32.36) 
 
The recall rates and detection rates vary among different groups of reading radiologists. An 
analysis of the period 2008-2011 showed that even though there were reading groups that 
differed significantly from the national average for every parameter (recall rate, detection 
rate and PPV), both positively and negatively, there was only one reading group of the 16 
groups that performed significantly worse on all parameters than the national average.(21)  
Recall decisions are based on the score in the Breast Imaging Reporting and Data System (BI-
RADS) classification system. Every examination is read by two different radiologists. If there 
is a difference in BI-RADS code, the two readers can confer with one and other to reach 
consensus, or call in a third party for arbitration. The radiologists that reports the latest BI-
RADS code, decides.  
There are seven different BI-RADS codes: 0: there is a lesion, further investigation necessary 
to determine probability of malignancy; 1: normal; 2: benign finding; 3: probably benign 
finding, re-evaluate after 6 months, 4: lesion, suspected malignancy, not typical for 
malignancy, 5: probable malignancy, 6: histologically proven malignancy. For obvious 
reasons BI-RADS 3 and 6 are not applicable in the screening situation. 
The outcome of screening in terms of BI-RADS were; 52.7% of all recalls are the result of a 
BI-RADS 0. The PPV of a recall based on a BI-RADS 0 is 11.5%. The amount of recalls based 
on BI-RADS 0 increased in the years 2010-2013 from 43.9% in 2010 to 56.4% in 2013. On the 
other hand, the amount of recalls based on BI-RADS 4 decreased in this period from 49.2% 
to 37.5%. The percentage of DCIS in women recalled for a BI-RADS 0 decreased from 11.5% 
in 2010 to 8.2% in 2013, when small invasive carcinoma with negative lymph nodes in these 
women increased from 61.1% to 65.8%.(22) 
So radiologists have found more lesions that warrant further investigation, rather than 
lesions that are probably malignant, but at the same time these lesions were more often 
invasive carcinomas.  
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BREAST CANCER INCIDENCE IN NORWAY FROM AN INTERNATIONAL 
PERSPECTIVE 
Because the situation in Norway appears exceptional in terms of breast cancer incidence 
increase, we compared the observed data from Norway in the years 1990-2013 to Dutch 
data from 1990-2013, Finnish data from 1989 -2013, and Swedish data from 1989-2013. 
Invasive breast cancer incidence in 2003 did not differ much, the most remarkable was the 
increase of breast cancer incidence. In the Netherlands invasive breast cancer incidence in 
women aged 50-70 years old rose from 228 /100,000 women in 1990 to 309 /100,000 
women in 2003.(23) In Norway invasive breast cancer incidence in 1990 was only 158 
/100,00 women, yet rapidly increased up to 298 /100,000 women in 2003 (Figure 3).(24) 
The increase in invasive breast cancer incidence was therefore twice as high. After 2003, 
there was some decline in invasive breast cancer incidence in women aged 50-70 years in 
Norway. At the same time the invasive breast cancer incidence in the Netherlands kept 
increasing. This may be explained by the reduction in the number of breast cancers caused 
by the reduced use of HRT in Norway.  
Invasive breast cancer incidence in Finland rose from 213 /100,000 women in 1989 to 297 
/100,000 women in 2003, but kept increasing up to 336 /100,000 women in 2013.(24)  
Invasive breast cancer incidence in Sweden started at the same level in as the Netherlands 
in 1989 with 236 invasive breast cancers/ 100,000 women, reached 305 /100,000 women in 
2003 and remained steadily around 300 /100,000 women up to 2013 (Figure 3). Therefore, 
the increase in Norway is still by far the highest.(24) 
One could argue that breast cancer registration in the early years was incomplete. This 
would explain a rather low breast cancer incidence in the years prior to 1990 and the rapid 
catch up in the years after that. It cannot explain the decrease in breast cancer incidence 
since 2003 however. Moreover the Norwegian Cancer Registry has a reported 100% 
coverage of incident cases for the entire period.  
We know that the use of HRT in Norway has been exceptionally high in the 1990’s.(25, 26) 
After publication of the Million Women study however, HRT use rapidly declined. Although 
some decline in breast cancer incidence can be seen from 2006, it does not return to the 
situation prior to the massive HRT intake. The incidence rate after 2003 is approximately 
270 /100,000, in comparison to 160 /100,000 in the early 1990’s. 
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Figure 3. Invasive breast cancer incidence per 100,000 women aged 50-70 in The 
Netherlands, Norway, Finland and Sweden from 1989 to 2013. 
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BREAST CANCER MORTALITY AFTER THE INTRODUCTION OF SCREENING 
In the Netherlands breast cancer mortality in women aged 55-80 has been decreasing 
steadily since 1990. This coincides with the start of population-based mammography 
screening. However, we cannot attribute this reduction to screening alone, given the fact 
that we expect mortality reduction to take effect after at least five years of follow-up. In 
Norway a similar pattern can be seen; breast cancer mortality reduced gradually after 1997, 
which is too early to be fully attributable to screening alone (Figure 4). The decrease in 
breast cancer mortality in both countries is probably the combined effect of early detection 
and advances in adjuvant treatment regimens.(18)  
 
  
Figure 4. Breast cancer mortality rate per 100,000 women aged 55-80 in the Netherlands 
and Norway.   
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DCIS, REDUCING THE IMPACT OF OVERDIAGNOSIS 
More and more diagnoses are DCIS. The mortality rate from breast cancer after DCIS is very 
low.(4) A recent analysis of the 10- and 20-year mortality from DCIS based on 108,196 
women with DCIS from the Surveillance, Epidemiology, and End Results (SEER) database 
from the United States, showed that the 10-year breast cancer specific mortality rate after a 
diagnosis of DCIS was 1.1%. The 20-year breast cancer specific mortality rate after a 
diagnosis of DCIS was 3.3%. 
A large proportion of DCIS represents overdiagnosis. This is a problem, both from an 
individual point of view; women will suffer unnecessary treatment and anxiety, and from a 
population point of view; resources allocated to medical care are being wasted.  
The solution to this problem is not to stop looking for DCIS. The solution should be to be 
able to discriminate between those DCIS that will progress to aggressive invasive disease 
and those DCIS that will remain dormant, or even regress back to normal. More and more 
diagnostic tools are becoming available in an attempt to predict natural behavior. In the 
near future a new study will be conducted to include biomarkers in the determination of 
low-risk and high-risk DCIS. 
Individualized policies towards treatment need to be developed based on the expected 
natural behavior of each DCIS. In order to develop such strategies, two large trials have 
been set up in recent years.  
The LORIS trial, funded by the National Health Services (NHS), in the United Kingdom aims to 
randomize women aged 46 and older, with screen-detected or incidental calcifications on 
mammography, that constitute a histologically proven non-high grade DCIS on core biopsy, 
vacuum assisted core biopsy, or surgical biopsy, into a follow-up arm, with annual 
mammography for 10 years, and a surgery arm, followed by annual mammography for 10 
years.(27) Inclusion appears to be difficult because patients do not like to be randomized for 
surgery or no surgery.(28) 
The second trial is the LOw Risk DCIS (LORD) trial, a European trial, funded by the European 
Organization for Research and Treatment of Cancer (EORTC). It aims to randomize “women 
aged 45 and older with asymptomatic, pure and low-grade DCIS based on vacuum assisted 
biopsies of calcifications only, detected by population-based population-based screening or 
opportunistic screening mammography” into standard care (usually surgery), followed by 
annual mammography for 10 years, and active surveillance, which consists of annual 
mammography for 10 years.(29)  
Other initiatives include a trial by Hwang et al., to be set up in the near future in the United 
States, in response to recent findings in the trend in treatment of DCIS in the US.(30) 
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One of the reasons why it is so very hard to include women in a watchful waiting trial for 
low-grade DCIS could be that women prefer surgery because DCIS is considered an early 
form of cancer. It seems contradictory to diagnose someone with cancer, and not treat 
them. Some experts have already argued that it might be beneficiary to change the name of 
DCIS, to avoid the word “cancer”.  
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FUTURE DIRECTIONS 
TOMOSYNTHESIS 
New imaging strategies in breast cancer imaging include tomosynthesis. Tomosynthesis uses 
a machine comparable to mammography to obtain not just one image of the breast, but 
several images, each at a slightly different angle between X-ray source and detector. This 
produces a stack of images, through which the radiographer can scroll. The technique allows 
to discriminate between real masses and over-projection. The images can be combined to 
produce a C-view image, on which calcifications are better appreciated.  
As of this moment tomosynthesis is only used in a clinical setting, but because the machine 
uses approximately the same amount of radiation as a normal mammogram does, it is being 
considered to replace traditional mammography in a screening setting. Two trials have been 
conducted to assess the feasibility of tomosynthesis in a screening situation. They found 
that the use of tomosynthesis in combination with 2D imaging improves breast cancer 
detection and has the potential to reduce false positive recalls.(31, 32) The costs of storing 
the extra amount of images associated with tomosynthesis is dependent on the degree of 
image compression allowed, these costs would be added to the €65,- per examination in the 
current situation (preliminary report of the NETB 2016). 
Tomosynthesis is estimated to have a higher sensitivity for both masses and calcifications. 
Therefore implementation of tomosynthesis in a screening setting would increase early 
diagnosis at the cost of more overdiagnosis. How much breast cancer mortality reduction 
can be obtained and at the cost of what amount of overdiagnosis needs to be calculated.  
RISK STRATIFICATION 
In search of an individualized approach to breast cancer screening, two trials are being 
conducted to stratify women with a different risk of having breast cancer in different 
screening strategies.  
The first trial is the DENSE trial, in which women in the breast cancer screening program 
with extremely dense breasts (ACR 4) and a negative mammogram are randomized in either 
the standard care arm (no additional mammography), or in the arm in which they undergo 
additional MR examination with dynamic MRI with gadolinium based contrast medium for 
three screening rounds. The aim is to evaluate the value of additional MRI in women with 
dense breasts. Dense breasts are associated with a lower sensitivity of mammography, and 
a higher risk of developing breast cancer.(33) 
The second trial is the PRISMA trial, where participants of the breast cancer screening 
program are asked to fill out an online questionnaire, for permission to measure breast 
density on the mammogram, and for a blood sample. The aim is to determine risk factors, 
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that increase the probability of developing breast cancer and to design screening strategies 
based on these risk factors.(34) 
CO-MORBIDITY 
Women with a high co-morbidity may benefit from a less stringent screening strategy, as 
their mortality is determined by their co-morbidity rather than a small screen-detected 
breast cancer. Women who have very little or no co-morbidity may benefit from breast 
cancer screening despite advanced age. In order to be able to tailor screening strategies to 
co-morbidity, women with high co-morbidity need to be identified and strategies need to be 
evaluated, for example by using the MISCAN model.  
CONCLUSIONS 
The transition to digital mammography has increased breast cancer detection level, mostly 
of DCIS and small invasive disease.  
The cervical cancer screening program yields even more overdiagnosis than the breast 
cancer screening program, but less invasive treatment is warranted.  
DCIS grade distribution does not differ between screened women and women who never 
attended population-based screening. Higher grade DCIS has a lower overdiagnosis 
estimate. The contribution of DCIS to the overdiagnosis estimate is high.  
Breast cancer incidence in Norway is erratic, and cannot be fully explained by the use of HRT 
and mammography alone. Overdiagnosis estimates of the NBCSP are low, and well within 
international limits. 
Breast cancer screening is a safe and cost-effective way to prevent breast cancer deaths in 
Norway.  
Overdiagnosis in breast cancer screening occurs, but the occurrence does not outweigh the 
benefits of population-based screening. 
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RECOMMENDATIONS FOR FURTHER RESEARCH 
The changes in breast cancer in Norway, which cannot be fully explained by current 
knowledge about risk factors, warrant further investigation. It would be interesting to know 
some more characteristics of the tumors, and if these characteristics have changed over 
time, along with the incidence changes.  
Further and more specific risk stratification of DCIS and small invasive tumors is needed to 
adequately predict natural behavior and necessary treatment. Better individual 
management of DCIS and small invasive tumors can lower the impact of overtreatment and 
further research should be aimed at the least invasive treatment strategies with favorable 
outcome for these patients.  
To decrease overtreatment and reduce the amount of invasive diagnostic tests, we need to 
be able to determine malignancy and grade on imaging alone, without the need of invasive 
biopsies for BI-RADS IV lesions. Current practice for calcifications is to do a vacuum assisted 
biopsy, often leading to a diagnosis of DCIS. If it were possible to definitely determine low-
grade DCIS on imaging alone, and if it would have been proven safe to manage this with a 
watchful waiting policy, then an overdiagnosed low-grade DCIS would be of much less 
impact. To obtain this amount of certainty about diagnosis and grade on imaging alone, 
research would have to be done on tomosynthesis imaging, ultrasound imaging and MRI, to 
determine imaging characteristics only seen in low-grade DCIS.  
With increased life expectancy the upper age limit of screening might have to be re-
evaluated. Any endeavor in this direction needs to be accompanied with a more 
personalized approach. Not all women over 75 are the same. Some are in the prime of their 
life, some have extensive co-morbidity. For those expecting to live to be over 100 years old, 
screening may add a significant amount of life-years. The implications of expanding the 
program need to be calculated, so that cost-effectiveness can be assessed.  
Already much work has been done on the implications of lowering the age-limit of 
population-based screening.(35) Despite arguments that this could be cost-effective, it has 
not been implemented yet. A pilot program to objectively observe the effects of lowering 
the age-limit is necessary to gain insight in the actual implications.  
Population-based screening for breast cancer is here to stay, and for good reasons. The 
challenge will be to adequately address the occurrence and consequences of the generated 
overdiagnosis by tailoring treatment and follow-up regimes to the personal needs of 
patients.  
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SUMMARY 
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CHAPTER 1 
Breast cancer has been around for a long time. Thanks to the efforts of patients and doctors, 
most people became aware of the risk of breast cancer, and the treatment and detection 
has taken flight. Breast cancer develops in the glandular tissue of the breast or in the 
milkducts. There are five stages of breast cancer. The earliest stage is ductal carcinoma in 
situ (DCIS). In DCIS malignant cells are present in the breast, but they have not yet grown 
out of the normal bounds. At the next stage, invasive breast cancer, there is growth beyond 
the normal limits and thus also risk of metastases. Metastases in breast cancer go first to 
the sentinel node, a lymph node in the armpit on the same side. 
Screening aims to detect breast cancer as early as possible so that the cancer is still 
treatable and has not spread. In the Netherlands, all women aged 50 to 74 years are invited 
every other year for screening. Screening is done by taking two X-rays of each breast 
(mammogram). These mammograms are examined by two radiologists and the GP and the 
patient receive a letter with the results. If there is an anomaly which requires further 
examination, patients are referred to the hospital. Women can also be referred because it is 
not possible to make a judgment based on the screening mammograms. 
In Norway screening started then years later. All women from 50 to 70 years are invited 
every other year for mammography. Women are referred to the hospital to see if there is an 
abnormality. 
Screening prevents breast cancer mortality, this has been shown by the first trials from 
Sweden. Since then several studies were conducted to evaluate whether screening is 
functioning properly. There are also research groups that believe that mortality reduction is 
moderate and that screening has many disadvantages. The main disadvantage of screening 
is overdiagnosis. Overdiagnosis occurs when a woman has a breast cancer diagnosis, as a 
result of the screening, that she would have never gotten in the absence of screening. This 
does not mean that she does not have breast cancer, that would be a false-positive 
diagnosis. It means she has a diagnosis of a disease which would never have become 
clinically apparent. 
In this thesis, I examined the impact of overdiagnosis. Overdiagnosis is most common in 
DCIS. I have therefore looked at whether more DCIS is found with digital screening. I also 
looked at the various forms of DCIS and what the impact is on overdiagnosis. I compared the 
breast cancer screening program with the program for cervical cancer screening, because in 
cervical cancer screening the discussion on overdiagnosis is very different. I also evaluated 
the situation in Norway, where the program is implemented more recently, and where the 
incidence of breast cancer has taken a very different course in recent decades than in the 
Netherlands. 
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CHAPTER 2 
In Chapter 2, I looked at the transition of the program of screening with analogue X-ray 
photos, printed on film, to digital X-ray photos evaluated on a computer screen. Digital 
screening found more DCIS. Initially, more women were recalled, but after everyone got 
used to the new photos, recall rates are again similar to recall rates prior to the transition. 
CHAPTER 3 
In Chapter 3, I compared the breast cancer screening with cervical cancer screening. The 
cervical screening program is older than the breast cancer screening. The cervical cancer 
screening detects precancerous cervical lesions (CIN), which are not yet considered to be 
cancer. The treatment of CIN prevents the development of cervical cancer. In cervical cancer 
there is also overdiagnosis. Some of the women who had a diagnosis of CIN, would have 
never have developed cervical cancer. This is because some of the CIN can be cleared by the 
body itself. Overdiagnosis of cervical cancer can result in an unnecessary loop excision or 
cone biopsy. These are not very invasive procedures, but a subsequent pregnancy can have 
rare but serious complications. Overdiagnosis in breast cancer can result in an unnecessary 
partial or complete mastectomy. A partial mastectomy treatment includes radiotherapy. 
Altogether invasive treatments. The frequency of diagnosis of cervical cancer is higher in 
than in breast cancer, but the consequences smaller. 
CHAPTER 4 
In Chapter 4, I looked at the differentiation grade of DCIS. The degree of differentiation tells 
us something about the degree of malignancy. In this chapter I express malignancy grade in 
low grade, intermediate grade, or high grade. The distribution of these grades is the same 
for DCIS detected by screening and for DCIS that are not detected by screening. 18% is low-
grade, 31% intermediate grade, and 51% high grade. With our micro-simulation model I 
have calculated the degree of overdiagnosis per grade. High grade DCIS has less 
overdiagnosis than low-grade DCIS. 
CHAPTER 5 
In Chapter 5, I looked at the incidence of breast cancer in Norway. The screening program in 
Norway was gradually introduced between 1996 and 2005. The incidence of breast cancer in 
women 50-54 started to rise dramatically in 1995. This cannot be explained by the 
screening. Many women in Norway have used hormone replacement therapy (HRT) for 
menopausal symptoms in the 90s. In 2000, it became clear that this greatly increases the 
risk of breast cancer. In the model, I examined whether I can explain the increase in 
incidence with the use of HRT. I found that the expected increase in breast cancer incidence 
as a result of HRT use is not enough to explain the increased breast cancer incidence. I have 
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insufficient explanation for the increase in incidence. Other research groups had the same 
problem. I have solved this by adding a risk factor in the model for women. With this I could 
model the incidence rise. This solution is very similar to that of another group, which made 
use of a cohort-effect. If I look at overdiagnosis, the estimates are in line with previous 
estimates and are not higher than in other European countries. 
CHAPTER 6 
In chapter 6, I used the model described in chapter 5 to calculate the cost-effectiveness of 
the program. The cost-effectiveness of a program indicates how much it costs to maintain 
an additional year of life, after correction for decrease in the quality of life. 
The cost is the cost of the screening program, but also the cost of treatment. Because you 
have to treat more cancer when screening for breast cancer, these costs may be higher. 
Because the treatment can be done at an earlier stage, the costs may be lower. 
The quality of life is temporarily decreased by screening, mostly due to uncertainty about 
the outcome. Quality of life also decreases when receiving a breast cancer diagnosis and 
additional treatments, this often takes longer. The extent to which the quality of life is 
diminished is expressed in utilities. The utilities are multiplied by the duration of this period 
in order to get a factor by which the years of life are less in quality. 
The Norwegian breast cancer screening program prevents 16% breast cancer mortality. This 
will cost 189.557 NOK per year of life adjusted for quality of life gained (QALY gained). The 
threshold for cost effectiveness of a program is either 20,000 to 30,000 GBP, or three times 
the gross national product. In Norway that threshold would be NOK 1,926,366. The program 
is a cost-effective measure to reduce breast cancer specific mortality. 
CHAPTER 7 
In chapter 7, I answer the research questions described in Chapter 1. Digital screening 
detects more DCIS, thus there is a higher risk of overdiagnosis. The transition to digital 
screening did not lead to more referrals. Cervical screening also provides a substantial 
amount of diagnosis, but with less impact. The distribution of low grade, intermediate 
grade, and high grade DCIS is the same for DCIS detected at screening, as for DCIS detected 
outside of screening. Of high grade DCIS fewer cases represent overdiagnosis than of low 
grade DCIS. In Norway, the incidence of breast cancer increased dramatically in the 90s. The 
use of HRT and mammography cannot explain this increase sufficiently. The percentage of 
overdiagnosis in Norway is similar to other countries. The Norwegian breast cancer 
screening program is cost effective.   
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What are the results of digital screening after the study period described in chapter 2? In 
the years following the study in Chapter 1, the referral rate of women who have their first 
screening examination increased from 2.8% to 6.3%. For women with a follow-up screening 
referral rate remained about the same at 1.7% in 2004-2010 and 2.0% in 2013. 
Is the increase in breast cancer incidence in Norway unlike that in any of the other 
Scandinavian countries? In Finland and Sweden the incidence of breast cancer increased 
considerably, but nowhere as strong as in Norway. 
A good number of DCIS is overdiagnosis. The possible increase in overtreatment as result of 
the detection of more DCIS must be addressed. Two trials are currently set up to randomize 
between surgery and watchful waiting for low grade DCIS. The problem with these trials is 
that not many women want to wait. Another strategy is to further identify tumors with a 
high malignant potential and those with a low malignant potential by histological 
characteristics. 
In the future tomosynthesis will play a greater role. Tomosynthesis takes a small series of 
photos instead of taking just one picture of the breast, always from a slightly different angle. 
The result is a set of photos in which you can scroll through the breast. This technique 
avoids false-positive results which can occur when overprojection of breast creates a 
composite picture suggestive of a mass or distorsion. The sensitivity for architecture 
disturbances and small tumors is higher. The tomosynthesis may be performed at 
approximately the same dose of radiation as a conventional mammography. This means 
that it may also be used for screening. The implications of the use of tomosynthesis for 
screening will have to be studied extensively, both for the results of the program, as well as 
for the cost of evaluating and storing the photo-sets. 
Individualized screening and treatment strategies based on personal characteristics and risk 
factors avoids unnecessary screening and treatment. A young woman with severe 
comorbidity will have little benefit from the early detection of DCIS, while an elderly woman 
without any comorbidity may have many years of life to gain in preventing breast cancer 
mortality. Risk factors may help to determine screening strategy. 
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HOOFDSTUK 1 
Borstkanker bestaat al heel lang. Mede dankzij de inspanningen van patiënten zijn de 
meeste mensen zich bewust van het risico op borstkanker en heeft de behandeling en 
detectie een vlucht genomen. Borstkanker ontstaat in het klierweefsel van de borst of in de 
melkweg-gangetjes. Er zijn vijf stadia van borstkanker. Het vroegste stadium is het ductaal 
carcinoom in situ (DCIS). Hierbij zijn er kwaadaardige cellen aanwezig in de borst, maar die 
zijn nog niet doorgegroeid buiten de normale begrenzingen. Bij het volgende stadium, het 
invasieve mammacarcinoom, is er doorgroei door de normale begrenzingen en hiermee ook 
kans op uitzaaiingen. Uitzaaiingen gaan bij borstkanker het eerst naar de schildwachtklier, 
een lymfklier in de oksel aan dezelfde kant.  
Screening is erop gericht om borstkanker in een zo vroeg mogelijk stadium te detecteren, 
zodat de kanker nog goed behandelbaar is en nog niet is uitgezaaid. In Nederland worden 
alle vrouwen van 50 tot en met 74 jaar om het jaar uitgenodigd voor de screening. 
Screening gebeurt door twee foto’s van elke borst te maken (mammogram). Deze foto’s 
worden door twee radiologen beoordeeld en indien er een afwijking te zien is die nader 
onderzoek behoeft, krijgen de huisarts en de patiënte een brief met de uitslag. Na 
verwijzing naar het ziekenhuis volgt dan nader onderzoek. Vrouwen kunnen ook verwezen 
worden omdat het niet mogelijk is om een uitspraak te doen op basis van de foto’s van de 
screening. 
In Noorwegen zijn ze tien jaar later begonnen met screening. Alle vrouwen van 50 tot en 
met 70 jaar oud worden om het jaar uitgenodigd om foto’s te laten maken. Ook hier geldt 
dat vrouwen naar het ziekenhuis worden verwezen als er een afwijking te zien is. 
Dat screening op borstkanker sterfte voorkomt is gebleken uit de eerste tests die gedaan 
zijn in Zweden. Sindsdien zijn er meerdere studies verricht om te evalueren of de screening 
naar behoren functioneert. Er zijn ook onderzoeksgroepen die van mening zijn dat er niet 
zoveel sterfte voorkomen wordt en dat de screening vooral veel nadelen heeft. Het 
belangrijkste nadeel van screening is overdiagnose. Overdiagnose komt voor als een vrouw 
een diagnose borstkanker krijgt, als gevolg van de screening, die zij in het geval dat er 
helemaal geen screening aangeboden zou worden, nooit zou hebben gekregen. Het is dus 
niet zo dat zij geen borstkanker heeft, dat zij ten onrechte die diagnose heeft gekregen. Het 
is een diagnose van een ziekte waar zij nooit ziek van zou zijn geworden. 
In dit proefschrift heb ik onderzocht wat de impact van overdiagnose nou eigenlijk is. 
Overdiagnose komt vooral voor bij DCIS. Daarom heb ik gekeken of er meer DCIS wordt 
gevonden met digitale screening. Ik heb ook gekeken naar de verschillende vormen van DCIS 
en wat de impact daarvan is op overdiagnose. Ik heb het borstkankerscreeningsprogramma 
vergeleken met het programma voor de screening op baarmoederhalskanker, omdat daar 
de discussie over overdiagnose heel anders is. En ik heb gekeken naar de situatie in 
Noorwegen, waar het programma korter geleden geïmplementeerd is, en waar het 
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voorkomen van borstkanker in de afgelopen decennia heel anders is verlopen dan in 
Nederland. 
HOOFDSTUK 2 
In hoofdstuk 2 heb ik gekeken naar de overgang van het programma van screening met 
analoge foto’s naar het screenen met digitale foto’s. Bij het screenen met digitale foto’s 
worden er meer DCIS gevonden. Aanvankelijk werden er veel meer vrouwen verwezen, 
maar nadat iedereen aan de nieuwe foto’s gewend was, zijn die cijfers weer vergelijkbaar 
met de cijfers van voor de overgang.  
HOOFDSTUK 3 
In hoofdstuk 3 heb ik de borstkankerscreening vergeleken met de 
baarmoederhalskankerscreening. De screening op baarmoederhalskanker is ouder dan de 
borstkankerscreening. De baarmoederhalskankerscreening detecteert voorstadia van 
baarmoederhalskanker (CIN), die nog niet als kanker worden beschouwd. De behandeling 
van zo’n voorstadium voorkomt het ontstaan van baarmoederhalskanker. Ook bij deze 
screening komt overdiagnose voor. Een deel van de vrouwen waarbij een CIN wordt 
gevonden, zou nooit baarmoederhalskanker ontwikkeld hebben. Dat komt omdat een deel 
van de CIN door het lichaam zelf opgeruimd worden. Overdiagnose bij 
baarmoederhalskanker betekent een onnodige lis-excisie of conisatie. Dit zijn op zichzelf 
weinig invasieve ingrepen, maar bij een eventuele zwangerschap kunnen er zeldzame, maar 
ernstige, complicaties optreden. Bij de borstkankerscreening betekent een overdiagnose 
een onnodige borstoperatie waarbij de gehele, of een deel van de borst verwijderd worden. 
Bij een gedeeltelijke verwijdering volgt dan ook nog radiotherapie. Al met al ingrijpende 
behandelingen. De frequentie van overdiagnose is hoger bij baarmoederhalskanker dan bij 
borstkanker, maar de gevolgen geringer.  
HOOFDSTUK 4 
In hoofdstuk 4 heb ik gekeken naar de differentiatiegraad van DCIS. De differentiatiegraad 
zegt iets over de mate van kwaadaardigheid. In dit hoofdstuk druk ik de kwaadaardigheid uit 
in laaggradig, gemiddeld, of hooggradig. De verdeling tussen deze graden is gelijk voor DCIS 
die door screening zijn gedetecteerd als voor DCIS die niet door screening zijn gedetecteerd. 
18% is laaggradig, 31% gemiddeld en 51% is hooggradig. Met ons microsimulatiemodel heb 
ik de mate van overdiagnose uitgerekend per graad. Hooggradig DCIS heeft minder 
overdiagnose dan laaggradig DCIS.  
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HOOFDSTUK 5 
In hoofdstuk 5 heb ik gekeken naar de incidentie (het voorkomen) van borstkanker in 
Noorwegen. Het screeningsprogramma in Noorwegen is geleidelijk geïntroduceerd tussen 
1996 en 2005. In 1995 begon de incidentie van borstkanker bij vrouwen van 50-54 al 
dramatisch te stijgen. Dit kan niet verklaard worden door de screening. Veel vrouwen in 
Noorwegen hebben in de jaren 90 hormoon vervangende therapie (HRT) gebruikt voor 
overgangsklachten. In 2000 werd duidelijk dat dit een sterk verhoogd risico op borstkanker 
geeft. Met het model kijk ik de of de stijging in incidentie te verklaren is door het gebruik 
van HRT. Dit bleek niet het geval te zijn. Het gebruik van HRT geeft onvoldoende verklaring 
voor de incidentiestijging. Andere onderzoeksgroepen hadden ditzelfde probleem. Dit is 
opgelost door in het model een risicofactor toe te kennen aan vrouwen van een bepaalde 
leeftijdsgroep. Hiermee is de incidentiestijging wel te modelleren. Deze oplossing lijkt erg op 
die van een andere groep, die gebruik maakte van een cohort-effect. Met betrekking tot 
overdiagnose, liggen de schattingen in lijn met eerdere schattingen en zijn niet hoger dan in 
andere Europese landen. 
HOOFDSTUK 6 
In hoofdstuk 6 gebruik ik het model uit hoofdstuk 5 om de kosten-effectiviteit van het 
programma te berekenen. De kosten-effectiviteit van een programma geeft aan hoeveel het 
kost om een extra levensjaar te behouden, na correctie voor afname van de kwaliteit van 
leven. 
De kosten zijn de kosten van het screeningsprogramma, maar ook de kosten voor 
behandeling. Omdat je meer borstkanker moet behandelen als je screent op borstkanker, 
zijn deze kosten mogelijk hoger. Omdat de behandeling in een vroeger stadium kan 
plaatsvinden, zijn de kosten mogelijk lager.  
De kwaliteit van leven neemt af door de screening, meestal als gevolg van onzekerheid over 
de uitslag, dit duurt maar kort. De kwaliteit van leven neemt ook af door de diagnose 
borstkanker en de bijkomende behandelingen, dit duurt vaak langer. De mate waarin de 
kwaliteit van leven afneemt wordt uitgedrukt in utiliteiten. De utiliteiten worden 
vermenigvuldigd met de duur hiervan om een factor te krijgen waarmee de levensjaren 
minder zijn in kwaliteit. 
Het Noorse borstkanker screeningsprogramma voorkomt 16% borstkankersterfte. Dit kost 
189,557 NOK per voor kwaliteit van leven gecorrigeerd levensjaar. De drempel om een 
programma kosteneffectief te kunnen noemen is ofwel 20,000 tot 30,000 GBP of 3 maal het 
bruto nationaal product, in Noorwegen zou die drempel 1,926,366 NOK zijn. Het 
programma is dus kosteneffectief. 
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HOOFDSTUK 7 
In hoofdstuk 7 geef ik antwoord op de in hoofdstuk 1 beschreven onderzoeksvragen. 
Digitale screening detecteert meer DCIS, daarmee is er een hogere kans op overdiagnose. 
Digitale screening leidt niet tot meer verwijzingen. Screening op baarmoederhalskanker 
levert ook een aanzienlijk aandeel overdiagnose, maar met minder consequenties. De 
verdeling van laaggradige, gemiddelde en hooggradige DCIS is gelijk voor DCIS gedetecteerd 
bij de screening, als voor DCIS gedetecteerd buiten de screening. Hooggradige DCIS geeft 
minder overdiagnose dan laaggradige DCIS. In Noorwegen is de incidentie van borstkanker 
in de jaren 90 dramatisch gestegen. Het gebruik van mammografie en HRT kunnen deze 
stijging onvoldoende verklaren. Het percentage overdiagnose in Noorwegen is vergelijkbaar 
met andere landen. Het Noorse borstkanker screeningsprogramma is kosteneffectief.  
Hoe zit het nou met de digitale screening van 2010 tot 2013? In de jaren na de studie uit 
hoofdstuk 1 is het verwijscijfer van vrouwen die voor het eerst naar de screening komen 
gestegen van 2.8% naar 6.3%, voor vrouwen met een vervolgscreening is het ongeveer gelijk 
gebleven met 1.7% in 2004-2010 en 2.0% in 2013.  
Is de incidentiestijging in Noorwegen anders dan in andere Scandinavische landen? Ook in 
Finland en Zweden steeg de incidentie van borstkanker flink, maar nergens zo sterk als in 
Noorwegen. 
Een flink aantal DCIS is overdiagnose. Om te voorkomen dat veel vrouwen overbehandeld 
blijven worden moet de behandeling van DCIS kritisch bekeken worden. Er lopen twee trials 
waarin gekeken wordt of het mogelijk is om bij vrouwen met een laaggradig DCIS niet direct 
te behandelen, maar regelmatig de borsten te controleren met mammografie. Het lastige 
van deze trials is dat niet veel vrouwen daar voor voelen. Een andere strategie is om nader 
in kaart te brengen wat nou de histologisch kenmerken zijn van tumoren die langzaam 
groeien en wat de kenmerken zijn van tumoren die juist heel snel groeien.  
In de toekomst zal tomosynthese een grotere rol gaan spelen. Tomosynthese maakt in 
plaats van 1 foto van de borst een kleine serie foto’s, steeds vanuit een klein beetje andere 
hoek. Het resultaat is een set foto’s waarmee je door de borst heen kunt bladeren. Deze 
techniek voorkomt fout-positieve uitslagen doordat borstklierweefsel op de foto over elkaar 
heen projecteert. Ook is de sensitiviteit voor architectuurverstoringen en kleine tumoren 
hoger. De tomosynthese kan verricht worden met ongeveer dezelfde dosis straling als een 
gewone foto. Dat betekent dat het ook inzetbaar is voor de screening. De implicaties van 
het gebruik van tomosynthese voor screening zullen uitgebreid onderzocht moeten worden, 
zowel voor de uitkomsten van het programma, als voor de kosten van beoordelen en 
opslaan van de foto-sets. 
Individualisering van screenings-strategieën en behandeling op basis van persoonlijke 
kenmerken en risicofactoren voorkomt onnodige screening en behandeling. Een jonge 
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vrouw met ernstige co-morbiditeit zal weinig baat hebben bij de vroege detectie van een 
DCIS, terwijl een oudere vrouw zonder enige co-morbiditeit juist veel levensjaren zou 
kunnen winnen bij het voorkomen van borstkankersterfte. Risicofactoren kunnen helpen 
om screeningsstrategie te bepalen.  
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INTRODUCTION 
This is a description of the MIcrosimulation SCreening ANalysis (MISCAN) model. The 
MISCAN model is a microsimulation model developed in 1985 to assess the harms and 
benefits of mass screening programs.  
This description is specifically written for the MISCAN breast model, which is used to 
evaluate the Dutch Breast cancer screening program. In the past the model has been 
adapted to other countries.  
MISCAN is a microsimulation model; it models individual life histories for all women in a 
given population.  
The Dutch model is calibrated on Dutch demographic data to simulate a female population 
with the same number of women of a certain age as seen in the Dutch population. To tailor 
the model to a different country (population) we use demographic data of the country of 
interest.  
The natural history of breast cancer is implemented next. We model onset of breast cancer 
and progression of the disease, as well as clinical detection (detection because of 
symptoms). For each woman in the population a time of death is modelled. This death can 
be the result of breast cancer or of other causes. Demographics and natural history 
determine the population composition and breast cancer incidence in the modeled 
population at any given time.  
Screening is superimposed on these individual life histories. The gradual implementation 
and current attendance rate are modelled. Test sensitivity is put in the model to match 
program sensitivity.  
In figure 1 the life history of a woman with breast cancer is depicted for two situations: the 
first without screening and the second with screening.  
The model predicts:  
1. Birth, based on the life table; 
2. Onset of breast cancer, based on incidence data;  
3. Disease progression onto clinical detection, based on data on stage distribution;  
4. Death as a result of breast cancer. The model had also predicted a time of death of 
other causes.  
In this case, in a situation without screening, death as a result of breast cancer came first. 
Screening advanced the breast cancer detection. The disease is now detected at an earlier 
stage, and the patient could be treated in time. Her breast cancer death was averted and 
the model now predicted a death of other causes based on the life table. She has gained 
life-years as a result of screening. 
175  
 
Figure 1. Life history affected by screening. 
At the end the model can predict outcomes for the modelled population, these include, but 
are not limited to; life years; number of breast cancer diagnoses by stage, age of detection 
and year of detection; death by age, year and by cause of death, breast cancer or other; 
number of screens; number of invitations. All output can be generated for a situation with 
screening and for a situation without screening. 
 
Figure 2. Graphic depiction of the input and output.   
Life-years gained
Birth Onset of breast cancer Screen detected Other cause death
Birth Onset of breast cancer Clinically detected Breast cancer death
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DEMOGRAPHIC DATA 
Using demographic data from Statistics Netherlands we calibrate the population in the 
model to a population composition in a given year, by comparing the outcomes of the 
model with observed data. The calibration yields a birth table. Life table data from Statistics 
Netherlands are used to estimate all-cause mortality.(1) 
The population is divided into several cohorts in order to allow for gradual implementation 
of screening. A given cohort has its own birth table and its own exposure to screening. Table 
1 shows the distribution of births per calendar year for a cohort born between 1928 and 
1989.  
For each woman, a time of death from other causes (i.e. causes other than breast cancer) is 
generated; this time of death is independent of the breast cancer disease model. In the 
model, a woman’s lifetime cannot exceed 100 years. The time of death from other causes is 
generated using a life table for women from Statistics Netherlands (Table 2). 
Table 1. Birth table used in the MISCAN model for the cohort born between 1928 and 1989. 
Year Cumulative 
probability of birth 
in year 
1928 0 
1929 0.0063222 
1934 0.069544 
1939 0.13414 
1944 0.20286 
1949 0.29219 
1954 0.38428 
1959 0.48048 
1964 0.58081 
1969 0.68389 
1974 0.77872 
1979 0.85569 
1984 0.92716 
1989 1 
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Table 2. Life table used in the MISCAN model. 
Age Cumulative 
probability 
of death 
0 0 
5 0 
10 0 
15 0 
20 0 
25 0.0016 
30 0.0034 
35 0.006 
40 0.0093 
45 0.0141 
50 0.0221 
55 0.0348 
60 0.0555 
65 0.087 
70 0.1364 
75 0.2161 
80 0.3424 
85 0.526 
90 0.7335 
95 0.8962 
99.9 0.9734 
100 1 
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NATURAL HISTORY 
Some of the women develop breast cancer. The probability of developing breast cancer is 
based on data on breast cancer incidence, growth rate, and probability of detection. To 
account for the increasing background incidence of breast cancer in the Netherlands, the 
model applies a 1.4% annual percentage change to the onset rate since 1975.(2, 3)  
After having an onset women have preclinical DCIS. Four different things can happen with a 
preclinical DCIS: it can progress to preclinical invasive breast cancer; it can regress back to 
normal; it may become clinically detected; or (in the presence of screening) it may become 
screen-detected. All transitions through the successive disease stages are modeled using a 
semi-Markov process (Figure 3).  
 
 
Figure 3. Schematic drawing of progression of breast cancer through the different disease 
stages.  
The following disease stages are modelled: preclinical-, clinical- or screendetected- ; DCIS, 
T1a, Ta1b, T1c and T2+; each with and without lymph node involvement. 
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After onset, the course of the disease is modeled by : 
1. The probability of progression  
a. Immediate progression 
b. Progression after dwell time 
c. Regression (only modeled for DCIS) 
d. Clinical detection 
2. The time spend in a certain disease stage (dwell time) 
 
Table 3. Probability of progression manner by disease stage. 
Disease 
stage 
Age Clinically 
detected 
Immediate 
progression 
Progression after dwell 
time 
Regression 
DCIS 0 6% 76% 15% 3% 
 34 6% 76% 15% 3% 
 79 3% 92% 4% 1% 
 100 3% 92% 4% 1% 
      
T1a 0 2%  98%  
 35 2%  98%  
 80 1%  99%  
 100 1%  99%  
      
T1b 0 9%  91%  
 35 9%  91%  
 80 4%  96%  
 100 3%  97%  
      
T1c 0 42%  58%  
 35 42%  58%  
 80 31%  69%  
 100 26%  74%  
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Progression is modeled by the probability of each disease stage to transition to the next 
stage and the respective dwell time. A correlation between the dwell time of the first stage 
of the disease and the subsequent stage of disease is modeled. Dwell times have a Weibull 
distribution and are age- and stage dependent.  
Table 4. Mean dwell times used in MISCAN, in years by disease stage. 
 Mean dwell time for a 45 year old woman 
(years) 
DCIS 2.1 
T1A 0.1 
T1B 0.3 
T1C 0.7 
T2+ 0.8 
  
Data on incidence prior to the introduction of screening is used to calibrate onset rate, 
incidence, and age specific hazard ratios for the onset. These data were provided by the 
Eindhoven Cancer Registry from 1975-1990(4).  
The incidence of breast cancer after the implementation of screening, both clinically 
detected and screen detected, are based on data from 1990-2008 from the Cancer Registry 
Netherlands(5). Incidence is specified by age, calendar year, tumor stage, and screening 
round (first/subsequent). 
TREATMENT  
Any screen detected or clinical disease stage transits directly to one of the four treated 
states: no adjuvant therapy (all patients receive standard care, which includes surgery and 
possibly radiotherapy); chemotherapy; hormonal therapy; or a combination of 
chemotherapy and hormone therapy. A woman in a treated state can die, either of breast 
cancer or from other causes.  
The probability for a certain treatment is dependent on disease stage, age calendar year, 
and detection mode. From 1975-1990 this is based on data from the Eindhoven Cancer 
Registry, and no combined use of hormone and chemotherapy was assumed prior to 1990. 
The duration of treatment with Tamoxifen was assumed to be 5 years, and this treatment 
was assumed to only be administered to women with a estrogen receptor positive breast 
cancer. The data on treatment after 1990 was provided by the Dutch screening organization 
and is specified by age, tumor stage, detection mode (screendetected or clinically detected), 
and calendar year.    
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SCREENING 
The gradual implementation of mass screening is mimicked using strata. The population is 
distributed into different strata of a certain magnitude. Each stratum is exposed to an 
invitation to screening at a given time, in such a way that replicates the roll out. This 
strategy is also used to model the extension of the program to include the women aged 70-
74. At the end of roll out 100% of the women aged 50-74 are invited to screening, some 
since 1990 and some since later years.  
The specific sensitivity for every test by age, disease stage, and calendar year, is calibrated 
to data on breast cancer incidence in the presence of screening (Table 5). Sensitivity in the 
model is for analogous mammography screening. Sensitivity is assumed to be 25% less in 
women under the age of 50. 
Table 5. Mean test sensitivity by stage. 
 Mean test sensitivity 
DCIS 77% 
T1A 52% 
T1B 62% 
T1C 90% 
T2+ 95% 
 
The effects of screening on survival depend on a stage shift, which occurs due to early 
detection. Survival is dependent on treatment and disease stage (see also the chapter 
survival below).  
  
182  
SURVIVAL 
All-cause mortality is determined by the life table. All women die at age 100 at the latest. 
Breast cancer survival is stage dependent. Survival rates per stage and treatment choice 
were modeled using international sources.(6-10)  
The long-term relative survival by different treatments was previously published by de 
Gelder et al.(2). Relative survival is modelled by age, disease stage, and type of treatment 
(Tables 6 through 9). Tables are repeated here for the purpose of completeness.  
Table 6. Relative survival by disease stage and age for women not receiving adjuvant 
treatment.  
 DCIS T1aN- T1aN+ T1bN- T1bN+ T1cN- T1cN+ T2+N- T2+N+ 
<30 1 0.761 0.510 0.696 0.408 0.557 0.236 0.310 0.056 
40 1 0.798 0.575 0.741 0.481 0.628 0.310 0.386 0.102 
50 1 0.815 0.605 0.762 0.512 0.646 0.341 0.418 0.118 
60 1 0.796 0.568 0.738 0.472 0.612 0.298 0.375 0.089 
70 1 0.737 0.476 0.667 0.376 0.524 0.213 0.282 0.052 
≥80 1 0.678 0.383 0.597 0.279 0.435 0.128 0.189 0.016 
 
Table 7. Relative survival by disease stage and age for women receiving hormonal adjuvant 
treatment. 
 DCIS T1aN- T1aN+ T1bN- T1bN+ T1cN- T1cN+ T2+N- T2+N+ 
<30 1 0.854 0.701 0.814 0.639 0.730 0.534 0.579 0.424 
40 1 0.865 0.714 0.826 0.650 0.743 0.533 0.585 0.388 
50 1 0.860 0.699 0.819 0.629 0.731 0.499 0.558 0.330 
60 1 0.856 0.696 0.815 0.628 0.727 0.505 0.559 0.357 
70 1 0.832 0.666 0.788 0.601 0.696 0.497 0.541 0.394 
≥80 1 0.797 0.612 0.746 0.546 0.644 0.451 0.489 0.380 
 
Table 8. Relative survival by disease stage and age for women receiving adjuvant 
chemotherapy treatment. 
 DCIS T1aN- T1aN+ T1bN- T1bN+ T1cN- T1cN+ T2+N- T2+N+ 
<30 1 0.831 0.652 0.784 0.580 0.686 0.458 0.510 0.329 
40 1 0.858 0.700 0.817 0.634 0.731 0.513 0.567 0.366 
50 1 0.855 0.691 0.814 0.619 0.723 0.486 0.546 0.314 
60 1 0.820 0.620 0.769 0.535 0.659 0.382 0.450 0.198 
70 1 0.767 0.535 0.705 0.446 0.578 0.301 0.363 0.157 
≥80 1 0.720 0.464 0.649 0.373 0.509 0.241 0.294 0.144 
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Table 9. Relative survival by disease stage and age for women receiving both adjuvant 
chemotherapy and adjuvant hormonal treatment. 
 DCIS T1aN- T1aN+ T1bN- T1bN+ T1cN- T1cN+ T2+N- T2+N+ 
<30 1 0.905 0.806 0.879 0.765 0.824 0.697 0.726 0.626 
40 1 0.912 0.814 0.887 0.772 0.833 0.697 0.730 0.602 
50 1 0.890 0.765 0.859 0.711 0.790 0.611 0.655 0.481 
60 1 0.872 0.729 0.835 0.669 0.757 0.559 0.608 0.428 
70 1 0.851 0.702 0.811 0.645 0.730 0.552 0.592 0.461 
≥80 1 0.820 0.654 0.774 0.596 0.683 0.511 0.545 0.448 
 
CALIBRATION OF THE MODEL 
Based on the observed data the model optimizes set parameters to meet the observed data 
in the model output. MISCAN uses the Nelder and Mead simplex (“Amoeba”) multivariate 
minimization routine, which has been adapted for optimizing random functions. The model 
will be run repeatedly, and the simulation run is compared to the counts in the 
observations. The total deviance is the sum of the individual deviances. A convergence 
criterion is set by a Kendall Tau test. The required significance level of the test can be 
specified. An example of the results of calibration is shown in Figure 4.  
 
Figure 4. Example of the result of calibration. Model fit for DCIS in women aged 50-60 years. 
The model output is compared to the observed data.  
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